

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07K		A2	(11) International Publication Number: WO 93/18054
			(43) International Publication Date: 16 September 1993 (16.09.93)
(21) International Application Number: PCT/EP93/00517 (22) International Filing Date: 8 March 1993 (08.03.93) (30) Priority data: 92400598.6 6 March 1992 (06.03.92) EP (34) Countries for which the regional or international application was filed: GB et al.		(74) Agents: GUTMANN, Ernest et al.; Ernest Gutmann-Yves Plasseraud S.A., 67, boulevard Haussmann, F-75008 Pa- ris (FR). (81) Designated States: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, NZ, PL, PT, RO, RU, SD, SK, UA, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG).	
(71) Applicant (for all designated States except US): N.V. IN- NOGENETICS S.A. [BE/BE]; Industriepark Zwijna- arde 7, Box 4, B-9052 Ghent (BE). (72) Inventor; and (75) Inventor/Applicant (for US only) : DE LEYS, Robert [US/ BE]; Diepekanten 20, B-1850 Grimbergen (BE).		Published Without international search report and to be republished upon receipt of that report.	
(54) Title: PROCESS FOR THE DETERMINATION OF PEPTIDES CORRESPONDING TO IMMUNOLOGICALLY IM- PORTANT EPITOPES AND THEIR USE IN A PROCESS FOR DETERMINATION OF ANTIBODIES OR BI- OTINYLATED PEPTIDES CORRESPONDING TO IMMUNOLOGICALLY IMPORTANT EPITOPES, A PRO- CESS FOR PREPARING THEM AND COMPOSITIONS CONTAINING THEM			
(57) Abstract The technical problem underlying the present invention is to provide peptides corresponding to immunologically import- ant epitopes on bacterial and viral proteins, as well as the use of said peptides in diagnostic or immunogenic compositions. The invention relates to a process for the <i>in vitro</i> determination of antibodies, wherein the peptides used are biotinylated, particularly in the form of complexes of streptavidin-biotinylated peptides or of avidin-biotinylated peptides.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

PROCESS FOR THE DETERMINATION OF PEPTIDES CORRESPONDING TO IMMUNOLOGICALLY IMPORTANT EPITOPES AND THEIR USE IN A PROCESS FOR DETERMINATION OF ANTIBODIES OR BIOTINYLATED PEPTIDES CORRESPONDING TO IMMUNOLOGICALLY IMPORTANT EPITOPES, A PROCESS FOR PREPARING THEM AND COMPOSITIONS CONTAINING THEM

The technical problem underlying the present invention is to provide peptides corresponding to immunologically important epitopes on bacterial and viral proteins, as well as the use of said peptides in diagnostic or immunogenic compositions.

Recent developments in genetic engineering as well as the chemistry of solid phase peptide synthesis have led to the increasingly wider use of synthetic peptides in biochemistry and immunology. Protein sequences which become available as a result of molecular cloning techniques can be synthesized chemically in large quantities for structural, functional, and immunological studies. Peptides corresponding to immunologically important epitopes found on viral and bacterial proteins have also proven to be highly specific reagents which can be used for antibody detection and the diagnosis of infection.

Despite the many advantages synthetic peptides offer, there are a number of disadvantages associated with their use. Because of their relatively short size (generally less than 50 amino acids in length), their structure may fluctuate between many different conformations in the absence of the stabilizing influence of intramolecular interactions present in the full-length protein. Furthermore, the small size of these peptides means that their chemical properties and solubilities will frequently be quite different from those of the full-length protein and that the contribution of individual amino acids in the peptide sequence toward determining the overall chemical properties of the peptide will be proportionally greater.

Many immunological assays require that the antigen used for antibody detection be immobilized on a solid support. Most enzyme-linked immunosorbent assays (ELISA) make use of polystyrene as the solid phase. Many proteins can be stably adsorbed to the solid phase and present sequences which are accessible for subsequent interactions with antibodies. Because of their small size, direct adsorption of peptides to the solid phase frequently gives rise to unsatisfactory results for any of a number of reasons.

Firstly, the peptide may not possess the correct overall charge or amino acid composition which would enable the peptide to bind to the solid phase. Secondly, the same amino acid residues which are required for binding to the

solid phase may also be required for antibody recognition and therefore not available for antibody binding. Thirdly, the peptide may become fixed in an unfavorable conformation upon binding to the solid phase which renders it unrecognizable to antibody molecules. In many cases, it is neither possible nor necessary to distinguish between these possibilities. Binding to the solid phase can be increased and made less sensitive to the specific chemical properties of a peptide by first coupling the peptide to a large carrier molecule. Typically, the carrier molecule is a protein.

While the amount of peptide bound to the solid phase, albeit indirectly, can in some cases be increased by this method, this approach suffers from the fact that the linkage between the peptide and the carrier protein frequently involves the side chains of internal trifunctional amino acids whose integrity may be indispensable for recognition by antibodies. The binding avidity of antisera for the internally modified peptide is frequently very much reduced relative to the unmodified peptide or the native protein.

The production of antisera to synthetic peptides also requires in most cases that the peptide be coupled to a carrier. Again, the coupling reaction between an internal trifunctional amino acid of the peptide and the carrier is likely to alter the immunogenic properties of the peptide.

There exist many methods for performing coupling reactions and most of the procedures in current use are discussed in detail in Van Regenmortel, M.H.V., Briand, J.P., Muller, S., and Plaué, S.; *Laboratory Techniques in Biochemistry and Molecular Biology*, vol. 19, *Synthetic Polypeptides as Antigens*, Elsevier Press, Amsterdam, New York, Oxford, 1988. In addition to these procedures, unprotected peptides can also be biotinylated using commercially available reagents such as N-hydroxysuccinimidobiotin or biotinamidocaproate N-hydroxysuccinimide ester. Many of these reagents are discussed in Billingsley, M.L., Pennypacker, K.R., Hoover, C.G., and Kincaid, R.L., *Biotechniques* (1987) 5(1):22-31. Biotinylated peptides are capable of being bound by the proteins streptavidin and avidin, two proteins which exhibit extraordinarily high affinity binding to biotin.

In certain instances, it is possible to selectively couple biotin to an unprotected peptide or an unprotected peptide to a carrier. This may be accomplished by synthesizing the peptide with an additional trifunctional amino acid added to one of the ends which is capable of participating in the coupling reaction. This approach will only be successful, however, as long as this amino acid is not a critical residue in the immunogenic sequence of

interest and as long as the coupling agent chosen is sufficiently selective. No single technique is applicable to all unprotected peptides regardless of their amino acid composition.

The etiological agent responsible for non-A, non-B hepatitis has been identified and termed hepatitis C virus (HCV). Patent application EP-A-0 318 216 discloses sequences corresponding to approximately 80% of the viral genome. The availability of these sequences rapidly led to the elucidation of the remainder of the coding sequences, particularly those located in the 5' end of the genome (Okamoto; J. Exp. Med. 60, 167-177, 1990). The HCV genome is a linear, positive-stranded RNA molecule with a length of approximately 9400 nucleotides. With the exception of rather short untranslated regions at the termini, the genome consists of one large, uninterrupted, open reading frame encoding a polyprotein of approximately 3000 amino acids. This polyprotein has been shown to be cleaved co-translationally into individual viral structural and non-structural (NS) regions. The structural protein region is further divided into capsid (Core) and envelope (E1 and E2) proteins. The NS regions are divided into NS-1 to NS-5 regions.

A number of independent patent applications have employed a variety of strategies to determine the locations of diagnostically important amino acid sequences and many of these studies have led to the identification of similar regions of the HCV polyprotein.

The NS4 region has mainly been studied in EP-A-0 318 216, EP-A-0 442 394, US-5,106,726, EP-A-0 489 986, EP-A-0 484 787, and EP-A-0 445 801. Unfortunately only 70% of HCV-infected individuals produce antibodies to NS4, neither the synthetic nor recombinant proteins containing sequences from this region are adequate for identifying all infected serum samples. The nucleocapsid or Core region has been studied in patent applications EP-A-0 442 394, US-5,106,726, EP-A-0 489 986, EP-A-0 445 801, EP-A-0 451 891 and EP-A-0 479 376. It was found that these peptides often used as mixtures, were more frequently recognized by antibodies (85-90%) in sera from chronically infected individuals than were the peptides derived from NS4. The NS5 region was studied in patent applications EP-A-0 489 986 and EP-A-0 468 527. Depending on the serum panel used, more than 60% of NANB hepatitis can be shown to contain antibodies directed against these peptides. The NS3 region was also studied in patent application EP-A-0 468 527. All available evidence suggests that the most dominant epitope of NS3 are discontinuous in nature and cannot be adequately represented by synthetic peptides. The E1 region which is potentially interesting as a region from the outer surface of the virus particles (possible immunogenic epitopes) was

studied in both patent applications EP-A-0 468 527 and EP-A-0 507 615. The E2/NS1 region was studied for the same reason as E1. Comparisons of this region from different HCV variants elucidated that this protein contains variable region which are reminiscent of the HIV V3 loop region of gp120 envelope protein. Four peptides were found in EP-A-0 468 527 which were shown to contain relatively infrequently recognized epitopes. Finally, the NS2 region of HCV was analyzed in EP-A-0 486 527. However, the diagnostic value of this region is not clear yet. Virtually all patent applications concerning diagnostically useful synthetic peptides for antibody detection describe preferred combinations of peptides. Most of these include peptides from the HCV core protein and NS4. In some cases, peptides from NS5 (EP-A-0 489 968 and EP-A-0 468 527), and E1 and E2/NS1 are included (EP-A-0 507 615 and EP-A-0 468 527).

Different patent applications have addressed the problem of finding diagnostically useful epitopes of human immunodeficiency virus (HIV). An important immunodominant region containing cyclic HIV-1 and HIV-2 peptides was found in patent application EP-A-0 326 490. In EP-A-0 379 949, this region was asserted to be even more reactive with HIV-specific antibodies in case a biotin molecule was coupled to these cyclic HIV peptides. SU - A - 161 22 64 also describes the use of a biotinylated peptide in a solid phase immunoassay for the detection of HIV antibodies.

Other applications have looked for useful HIV epitopes in the hypervariable V3 loop region of gp120 (such as EP-A-0 448 095 and EP-A-0 438 332).

US Patent number 4,833,071 provides peptide compositions for detection of HTLV I antibodies.

Deciding whether or not an epitope is diagnostically useful is not always straightforward and depends to an extent on the specific configuration of the test into which it is incorporated. It should be ideally an immunodominant epitope which is recognized by a large percentage of true positive sera or should be able to complement other antigens in the test to increase the detection rate. Epitopes which are not frequently recognized may or may not be diagnostically useful depending on the contribution they make towards increasing the detection rate of antibodies in true positive sera and the extent to which incorporation of these epitopes has an adverse effect on the sensitivity of the test due to dilution of other stronger epitopes.

Peptides can thus be used to identify regions of proteins which are specifically recognized by antibodies produced as a result of infection or immunization. In general, there are two strategies which can be followed. One of these strategies has been described by Geysen, H.M.,

Meloan, R.H., and Barteling, S.J.; Proc. Natl. Acad. Sci. USA (1984) 81:3998-4002. This approach involves the synthesis of a large series of short, overlapping peptides on polyethylene rods derivatized with a noncleavable linker such that the entire length of the protein or protein fragment of interest is represented.

The rods are incubated with antisera and antibody binding is detected using an anti-immunoglobulin: enzyme conjugate. A positive reaction immediately identifies the location and sequence of epitopes present in the protein sequence. This technique has the advantage that all peptides are uniformly linked to the solid support through their carboxy-terminus. While this method allows for very accurate mapping of linear epitopes, the length of the peptides which can be reliably synthesized on the rods is limited. This may sometimes present problems if the length of the epitope exceeds the length of the peptides synthesized.

A second approach to epitope mapping involves the synthesis of larger peptides, generally between fifteen and thirty amino acids in length, along the sequence of the protein to be analyzed. Consecutive peptides may be contiguous but are preferably overlapping. Following cleavage, the evaluation of antibody binding to the individual peptides is assessed and the approximate positions of the epitopes can be identified. An example of this approach is given in Neurath, A.R., Strick, N., and Lee, E.S.Y.; J. Gen. Virol. (1990) 71:85-95. This approach has the advantage that longer peptides can be synthesized which presumably more closely resemble the homologous sequence in the native protein and which offer better targets for antibody binding. The disadvantage of this approach is that each peptide is chemically unique and that the conditions under which each peptide can be optimally coated onto a solid phase for immunological evaluation may vary widely in terms of such factors as pH, ionic strength, and buffer composition. The quantity of peptide which can be adsorbed onto the solid phase is also an uncontrolled factor which is unique for each peptide.

The main purpose of the present invention is to provide modified peptides corresponding to immunologically useful epitopes with said modified peptides having superior immunological properties over non-modified versions of these peptides.

Another aim of the present invention is to provide modified peptides corresponding to immunologically useful epitopes which could not be identified through classical epitope mapping techniques.

Another aim of the present invention is to provide a process for the in vitro determination of antibodies using said peptides, with said process being easy to perform and amenable to standardization.

Another aim of the invention is to provide a process for the determination of peptides corresponding to immunologically important epitopes on bacterial and viral proteins.

Another aim of the invention is to provide a method for preparing protein sequences used in any of said methods.

Another aim of the invention is to provide a method for preparing protein sequence which can be used in a process for the determination of their epitopes or in an in vitro method for the determination of antibodies.

Another aim of the invention is to provide intermediary compounds useful for the preparation of peptides used in the above-mentioned methods.

Another aim of the present invention is also to provide compositions containing peptides determined to correspond to immunologically important epitopes on proteins for diagnostic purposes.


Another aim of the present invention is also to provide compositions containing peptides determined to correspond to immunologically important epitopes on proteins for vaccine purposes.

According to the present invention, a series of biotinylated peptides representing immunologically important regions of viral proteins have been identified and prepared by solid phase peptide synthesis. These peptides have been identified to be very useful for (i) the detection of antibodies to HCV, and/or HIV, and/or HTLV-I or II. In some preferred arrangements, these peptides were also found or are at least expected, to be useful in stimulating the production of antibodies to HCV, and/or HIV, and/or HTLV-I or II in healthy animals such as BALB/C mice, and in a vaccine composition to prevent HCV and/or HIV, and/or HTLV-I or II infection.

As demonstrated in the Examples section of the present invention, the use of biotinylated peptides also allows the determination of immunologically important epitopes within a previously determined protein sequence. The determination of immunologically important epitopes using non-biotinylated peptides, which are covalently coupled to the solid phase, often fails to localize these epitopes. Especially in case of localization of structural epitopes,

the use of biotinylated peptides seems to be quite successful.

(1) According to the present invention, a peptide composition useful for the detection of antibodies to HCV, and/or HIV, and/or HTLV-I or II comprise peptides corresponding to immunologically important epitopes being of the structure:



where

- [amino acids]_n is meant to designate the length of the peptide chain where n is the number of residues, being an integer from about 4 to about 50, preferably less than about 35, more preferably less than about 30, and advantageously from about 4 to about 25;

- B represents biotin;

- X represents a biotinylated compound which is incorporated during the synthetic process;

- Y represents a covalent bond or one or more chemical entities which singly or together form a linker arm separating the amino acids of the peptide proper from the biotinyl moiety B or X, the function of which is to minimize steric hindrance which may interfere with the binding of the biotinyl moiety B or X to avidin or streptavidin, wherein Y is not a covalent bond, it is advantageously at least one chemical entity and may consist of as many as 30 chemical entities but will consist most frequently of 1 to 10 chemical entities, which may be identical or different, more preferably glycine residues, β -alanine, 4-aminobutyric acid, 5-aminovaleric acid, or 6-aminohexanoic acid;

- B and X being enclosed in parentheses to indicate that the presence of biotin or a biotinylated compound in these positions is optional, the only stipulation being that B or X be present in at least one of the positions shown;

- A, when present, as indicated by parentheses, represents (an) amino acid(s), an amino group, or a chemical modification of the amino terminus of the peptide chain;

- Z represents (an) amino acid(s), an OH-group, an NH₂-group, or a linkage involving either of these two chemical groups wherein the amino acids are selectively chosen to be immunodominant epitopes which are recognized by a large percentage of true positive sera or are able to complement other antigens in the test to increase the detection rate and B interacts with the selected amino acids to produce a compound with greater diagnostic sensitivity.

The peptide composition comprises at least one and preferably a combination of two, three, four or more biotinylated peptides chosen from the following sequences:

1. Human immunodeficiency Virus type 1 Envelope Peptides:

a. gp41

1. gp41, isolate HTLV-IIIB

(A)-(B)-(X)-Y-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Ile-Cys-Y-(X)-Z

2.

(A)-(B)-(X)-Y-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-Cys-Thr-Thr-Ala-Val-Pro-Trp-Asn-Ala-Ser-Y-(X)-Z

3.

(A)-(B)-(X)-Y-Glu-Arg-Tyr-Leu-Lys-Asp-Gln-Gln-Leu-Leu-Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-Y-(X)-Z

4.

(A)-(B)-(X)-Y-Leu-Gln-Ala-Arg-Ile-Leu-Ala-Val-Glu-Arg-Tyr-Leu-Lys-Asp-Gln-Gln-Leu-Y-(X)-Z

5. gp41, isolate Ant70

(A)-(B)-(X)-Y-Leu-Trp-Gly-Cys-Lys-Gly-Lys-Leu-Val-Cys-Y-(X)-Z

6. gp41, isolate ELI

(A)-(B)-(X)-Y-Asp-Gln-Gln-Leu-Leu-Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-His-Ile-Cys-Thr-Thr-Asn-Val-Pro-Trp-Asn-Y-(X)-Z

b. gp 120

1. Partial V3 loop sequence, consensus

(A)-(B)-(X)-Y-Asn-Asn-Thr-Arg-Lys-Ser-Ile-His-Ile-Gly-Pro-Gly-Arg-Ala-Phe-Tyr-Thr-Thr-Gly-Glu-Ile-Ile-Gly-Y-(X)-Z

1.a. Complete V3 loop sequence, consensus

(A)-(B)-(X)-Y-Cys-Thr-Arg-Pro-Asn-Asn-Asn-Thr-Arg-Lys-Ser-Ile-His-Ile-Gly-Pro-Gly-Arg-Ala-Phe-Tyr-Thr-Thr-Gly-Glu-Ile-Ile-Gly-Asp-Ile-Arg-Gln-Ala-His-Cys-Y-(X)-Z

2. Partial V3 loop sequence, isolate HIV-1 SF2

(A)-(B)-(X)-Y-Asn-Asn-Thr-Arg-Lys-Ser-Ile-Tyr-Ile-Gly-Pro-Gly-Arg-Ala-Phe-His-Thr-Thr-Gly-Arg-Ile-Ile-Gly-Y-(X)-Z

3. Partial V3 loop sequence, isolate HIV-1 SC

(A)-(B)-(X)-Y-Asn-Asn-Thr-Thr-Arg-Ser-Ile-His-Ile-Gly-Pro-Gly-Arg-Ala-Phe-Tyr-Ala-Thr-Gly-Asp-Ile-Ile-Gly-Y-(X)-Z

4. Partial V3 loop sequence, isolate HIV-1 MN

(A)-(B)-(X)-Y-Tyr-Asn-Lys-Arg-Lys-Arg-Ile-His-Ile-Gly-Pro-Gly-Arg-Ala-Phe-Tyr-Thr-Thr-Lys-Asn-Ile-Ile-Gly-Y-(X)-Z

5. Partial V3 loop sequence, isolate HIV-1 RF
(A)-(B)-(X)-Y-Asn-Asn-Thr-Arg-Lys-Ser-Ile-Thr-Lys-Gly-
Pro-Gly-Arg-Val-Ile-Tyr-Ala-Thr-Gly-Gln-Ile-Ile-Gly-Y-
(X)-Z

6. Partial V3 loop sequence, isolate HIV-1 mal
(A)-(B)-(X)-Y-Asn-Asn-Thr-Arg-Arg-Gly-Ile-His-Phe-Gly-
Pro-Gly-Gln-Ala-Leu-Tyr-Thr-Thr-Gly-Ile-Val-Gly-Y-
(X)-Z

7. Partial V3 loop sequence, isolate HTLV-IIIB
(A)-(B)-(X)-Y-Asn-Asn-Thr-Arg-Lys-Ser-Ile-Arg-Ile-Gln-
Arg-Gly-Pro-Gly-Arg-Ala-Phe-Val-Thr-Ile-Gly-Lys-Ile-
Gly-Y-(X)-Z

8. Partial V3 loop sequence, isolate HIV-1 ELI
(A)-(B)-(X)-Y-Gln-Asn-Thr-Arg-Gln-Arg-Thr-Pro-Ile-Gly-
Leu-Gly-Gln-Ser-Leu-Tyr-Thr-Thr-Arg-Ser-Arg-Ser-Y-(X)-Z

9. Partial V3 loop sequence, isolate ANT70
(A)-(B)-(X)-Y-Gln-Ile-Asp-Ile-Gln-Glu-Met-Arg-Ile-Gly-
Pro-Met-Ala-Trp-Tyr-Ser-Met-Gly-Ile-Gly-Gly-Y-(X)-Z

10. Partial V3 loop sequence, Brazilian isolate,
Peptide V3-368
(A)-(B)-(X)-Y-Asn-Asn-Thr-Arg-Arg-Gly-Ile-His-Met-Gly-Trp-
Gly-Arg-Thr-Phe-Tyr-Ala-Thr-Gly-Glu-Ile-Ile-Gly-Y-(X)-Z

11. Carboxy-terminus, HIV-1 gp120
(A)-(B)-(X)-Y-Arg-Asp-Asn-Trp-Arg-Ser-Glu-Leu-Tyr-Lys-
Tyr-Lys-Val-Val-Lys-Ile-Glu-Pro-Leu-Gly-Val-Ala-Pro-
Thr-Lys-Ala-Lys-Arg-Arg-Val-Val-Gln-Arg-Glu-Lys-
Arg-Y-(X)-Z

2. Human immunodeficiency Virus type 2 Envelope Peptide
a. gp41, isolate HIV-2 rod
(A)-(B)-(X)-Y-Ser-Trp-Gly-Cys-Ala-Phe-Arg-Gln-Val-Cys-
Y-(X)-Z

b.
(A)-(B)-(X)-Y-Lys-Tyr-Leu-Gln-Asp-Gln-Ala-Arg-Leu-Asn-
Ser-Trp-Gly-Cys-Ala-Phe-Arg-Gln-Val-Cys-Y-(X)-Z

c. gp120, isolate HIV-2 NIHZ
(A)-(B)-(X)-Y-Asn-Lys-Thr-Val-Leu-Pro-Ile-Thr-Phe-Met-
Ser-Gly-Phe-Lys-Phe-His-Ser-Gln-Pro-Val-Ile-Asn-Lys-Y-
(X)-Z

d. Partial V3 loop sequence, Peptide V3-GB12
(A)-(B)-(X)-Y-Asn-Lys-Thr-Val-Val-Pro-Ile-Thr-Leu-Met-Ser-
Gly-Leu-Val-Phe-His-Ser-Gln-Pro-Ile-Asn-Lys-Y-(X)-Z

e. Partial V3 loop sequence, Peptide V3-239

(A)-(B)-(X)-Y-Asn-Lys-Thr-Val-Leu-Pro-Val-Thr-Ile-Met-Ser-Gly-
Leu-Val-Phe-His-Ser-Gln-Pro-Ile-Asn-Asp-Y-(X)-Z

3. Chimpanzee immunodeficiency Virus

a. gp41

(A)-(B)-(X)-Y-Leu-Trp-Gly-Cys-Ser-Gly-Lys-Ala-Val-Cys-Y-(X)-Z

4. Simian immunodeficiency Virus

a. Transmembrane protein, isolate SIVagm(TY01)

(A)-(B)-(X)-Y-Ser-Trp-Gly-Cys-Ala-Trp-Lys-Gln-Val-Cys-Y-(X)-Z.

b. Transmembrane protein, isolate SIVmnd

(A)-(B)-(X)-Y-Gln-Trp-Gly-Cys-Ser-Trp-Ala-Gln-Val-Cys-Y-(X)-Z

5. HTLV-I and HTLV-II Virus

Peptide I-gp46-3

(A)-(B)-(X)-Y-Val-Leu-Tyr-Ser-Pro-Asn-Val-Ser-Val-Pro-Ser-Ser-Ser-Ser-Thr-Leu-Leu-Tyr-Pro-Ser-Leu-Ala-Y-(X)-Z
Peptide I-gp46-5

(A)-(B)-(X)-Y-Tyr-Thr-Cys-Ile-Val-Cys-Ile-Asp-Arg-Ala-Ser-Leu-Ser-Thr-Trp-His-Val-Leu-Tyr-Ser-Pro-Y-(X)-Z

Peptide I-gp46-4

(A)-(B)-(X)-Y-Asn-Ser-Leu-Ile-Leu-Pro-Pro-Phe-Ser-Leu-Ser-Pro-Val-Pro-Thr-Leu-Gly-Ser-Arg-Ser-Arg-Arg-Y-(X)-Z

Peptide I-gp46-6

(A)-(B)-(X)-Y-Asp-Ala-Pro-Gly-Tyr-Asp-Pro-Ile-Trp-Phe-Leu-Asn-Thr-Glu-Pro-Ser-Gln-Leu-Pro-Pro-Thr-Ala-Pro-Pro-Leu-Leu-Pro-His-Ser-Asn-Leu-Asp-His-Ile-Leu-Glu-Y-(X)-Z

Peptide I-p21-2

(A)-(B)-(X)-Y-Gln-Tyr-Ala-Ala-Gln-Asn-Arg-Arg-Gly-Leu-Asp-Leu-Leu-Phe-Trp-Glu-Gln-Gly-Gly-Leu-Cys-Lys-Ala-Leu-Gln-Glu-Gln-Cys-Arg-Phe-Pro-Y-(X)-Z

Peptide I-p19

(A)-(B)-(X)-Y-Pro-Pro-Pro-Pro-Ser-Ser-Pro-Thr-His-Asp-Pro-Pro-Asp-Ser-Asp-Pro-Gln-Ile-Pro-Pro-Pro-Tyr-Val-Glu-Pro-Thr-Ala-Pro-Gln-Val-Leu-Y-(X)-Z

Peptide II-gp52-1

(A)-(B)-(X)-Y-Lys-Lys-Pro-Asn-Arg-Gln-Gly-Leu-Gly-Tyr-Tyr-Ser-Pro-Ser-Tyr-Asn-Asp-Pro-Y-(X)-Z

Peptide II-gp52-2

(A)-(B)-(X)-Y-Asp-Ala-Pro-Gly-Tyr-Asp-Pro-Leu-Trp-Phe-Ile-Thr-Ser-Glu-Pro-Thr-Gln-Pro-Pro-Pro-Thr-Ser-Pro-Pro-Leu-Val-His-Asp-Ser-Asp-Leu-Glu-His-Val-Leu-Thr-Y-(X)-Z

Peptide II-gp52-3:

(A)-(B)-(X)-Y-Tyr-Ser-Cys-Met-Val-Cys-Val-Asp-Arg-Ser-Ser-Leu-Ser-Ser-Trp-His-Val-Leu-Tyr-Thr-Pro-Asn-Ile-Ser-Ile-Pro-Gln-Gln-Thr-Ser-Ser-Arg-Thr-Ile-Leu-Phe-Pro-Ser-Y-(X)-Z

Peptide II-p19

(A)-(B)-(X)-Y-Pro-Thr-Thr-Thr-Pro-Pro-Pro-Pro-Pro-Pro-Ser-Pro-Glu-Ala-His-Val-Pro-Pro-Pro-Tyr-Val-Glu-Pro-Thr-Thr-Thr-Gln-Cys-Phe-Y-(X)-Z

These above-mentioned biotinylated peptides were synthesized and found to be specifically recognized by antisera from infected humans or primates are considered particularly advantageous. All these above-mentioned peptides are new.

The process of the invention enables to increase the antigenicity of these HIV peptides, which can however be bound to a support, even when they are not biotinylated.

The HCV peptide sequences which follow have been found to be specifically recognized by antisera from infected humans or primates and which are considered particularly advantageous. The non-biotinylated amino acid sequences can be synthesized according to classical methods.

The peptides of interest are intended to mimic immunologically proteins or domains of proteins encoded by HCV. Since sequence variability has been observed for HCV, it may be desirable to vary one or more amino acids so as to better mimic the epitopes of different strains. It should be understood that the peptides described need not be identical to any particular HCV sequence as long as the subject compounds are capable of providing for immunological competition with at least one strain of HCV. The peptides may therefore be subject to insertions, deletions and conservative as well as non-conservative amino acid substitutions where such changes might provide for certain advantages in their use. The peptides will preferably be as short as possible while still maintaining all of the sensitivity of the larger sequence. In certain

cases, it may be desirable to join two or more peptides together into a single structure. The formation of such a composite may involve covalent or non-covalent linkages.

Of particular interest are biotinylated peptides of HCV into which cysteine, thioglycolic acid, or other thiol-containing compounds have been incorporated into the peptide chain for the purpose of providing mercapto-groups which can be used for cyclization of the peptides.

The following peptides from the Core region of HCV were determined as corresponding to immunologically important epitopes.

1. Peptide I or Core 1 (aa. 1-20) has the following amino acid sequence:

(I)

(A)-(B)-(X)-Y-Met-Ser-Thr-Ile-Pro-Lys-Pro-Gln-Arg-Lys-Thr-Lys-Arg-Asn-Thr-Asn-Arg-Arg-Pro-Gln-Y-(X)-Z

2. Peptide II or Core 2 (aa. 7-26) has the amino acid sequence:

(II)

(A)-(B)-(X)-Y-Pro-Gln-Arg-Lys-Thr-Lys-Arg-Asn-Thr-Asn-Arg-Arg-Pro-Gln-Asp-Val-Lys-Phe-Pro-Gly-Y-(X)-Z

Of particular interest is the oligopeptide IIA (aa. 8 to 18):

(IIA)

(A)-(B)-(X)-Y-Gln-Arg-Lys-Thr-Lys-Arg-Asn-Thr-Asn-Arg-Arg-Y-(X)-Z.

3. Peptide III or Core 3 (aa 13-32) has the sequence:

(III)

(A)-(B)-(X)-Y-Arg-Asn-Thr-Asn-Arg-Arg-Pro-Gln-Asp-Val-Lys-Phe-Pro-Gly-Gly-Gly-Gln-Ile-Val-Gly-Y-(X)-Z

4. Peptide IV or Core 7 (aa 37-56) has the sequences:

(IV)

(A)-(B)-(X)-Y-Leu-Pro-Arg-Arg-Gly-Pro-Arg-Leu-Gly-Val-Arg-Ala-Thr-Arg-Lys-Thr-Ser-Glu-Arg-Ser-Y-(X)-Z

Of particular interest is the oligopeptide IVa or Core 6 (aa. 31 to 50):

(IVa)

(A)-(B)-(X)-Y-Val-Gly-Gly-Val-Tyr-Leu-Leu-Pro-Arg-Arg-Gly-Pro-Arg-Leu-Gly-Val-Arg-Ala-Thr-Arg-Y-(X)-Z

5. Peptide V or Core 9 (aa 49-68) has the sequence:

(V)

(A)-(B)-(X)-Y-Thr-Arg-Lys-Thr-Ser-Glu-Arg-Ser-Gln-Pro-Arg-Gly-Arg-Arg-Gln-Pro-Ile-Pro-Lys-Val-Y-(X)-Z

Of particular interest is the oligopeptide Va (aa. 55 to 74):

(Va)

(A)-(B)-(X)-Y-Arg-Ser-Gln-Pro-Arg-Gly-Arg-Arg-Gln-Pro-Ile-Pro-Lys-Val-Arg-Arg-Pro-Glu-Gly-Arg-Y-(X)-Z

6. Peptide VI or Core 11 (aa 61-80) has the following sequence:

(VI)

(A)-(B)-(X)-Y-Arg-Arg-Gln-Pro-Ile-Pro-Lys-Val-Arg-Arg-Pro-Glu-Gly-Arg-Thr-Trp-Ala-Gln-Pro-Gly-Y-(X)-Z

7. Peptide VII (aa 73-92) or core 13 has the sequence:

(VII)

(A)-(B)-(X)-Y-Gly-Arg-Thr-Trp-Ala-Gln-Pro-Gly-Tyr-Pro-Trp-Pro-Leu-Tyr-Gly-Asn-Glu-Gly-Cys-Gly-Y-(X)-Z

8. Peptide Core 123 (aa. 1-32):

(A)-(B)-(X)-Y-Met-Ser-Thr-Ile-Pro-Gln-Arg-Lys-Thr-Lys-Arg-Asn-Thr-Asn-Arg-Arg-Pro-Gln-Asp-Val-Lys-Phe-Pro-Gly-Gly-Gly-Gln-Ile-Val-Gly-Y-(X)-Z

9. Peptide Core 7910 (aa. 37-80):

(A)-(B)-(X)-Y-Gly-Gly-Val-Tyr-Leu-Pro-Arg-Arg-Gly-Pro-Arg-Leu-Gly-Val-Arg-Arg-Ala-Thr-Arg-Lys-Thr-Ser-Glu-Arg-Ser-Gln-Pro-Arg-Gly-Arg-Arg-Gln-Pro-Ile-Pro-Lys-Val-Arg-Arg-Y-(X)-Z

The following peptides from the NS4 region of HCV were found to correspond to immunologically important epitopes.

Peptide VIII or NS4-1 or HCV1 (aa 1688 - 1707) has the sequence:

(VIII)

(A)-(B)-(X)-Y-Leu-Ser-Gly-Lys-Pro-Ala-Ile-Ile-Pro-Asp-Arg-Glu-Val-Leu-Tyr-Arg-Glu-Phe-Asp-Glu-Y-(X)-Z

Peptide IX or HCV2 (aa 1694 - 1713) has the sequence:

(IX)

(A)-(B)-(X)-Y-Ile-Ile-Pro-Asp-Arg-Glu-Val-Leu-Tyr-Arg-Glu-Phe-Asp-Glu-Met-Glu-Glu-Cys-Ser-Gln-Y-(X)-Z

Peptide HCV3

(A)-(B)-(X)-Y-Val-Leu-Tyr-Arg-Glu-Phe-Asp-Glu-Met-Glu-Glu-Cys-Ser-Gln-His-Leu-Pro-Tyr-Ile-Glu-Y-(X)-Z

Peptide X or HCV4 (aa 1706 - 1725) has the sequence:

(X)

(A)-(B)-(X)-Y-Asp-Glu-Met-Glu-Glu-Cys-Ser-Gln-His-Leu-Pro-Tyr-Ile-Glu-Gln-Gly-Met-Met-Leu-Ala-Y-(X)-Z

11. Peptide XI or NS4-5 or HCV5 (aa 1712 - 1731) has the sequence:

(XI)

(A)-(B)-(X)-Y-Ser-Gln-His-Leu-Pro-Tyr-Ile-Glu-Gln-Gly-Met-Met-Leu-Ala-Glu-Gln-Phe-Lys-Gln-Lys-Y-(X)-Z

12. Peptide XII or HCV6 (aa 1718 - 1737) has the sequence:
(XII)

(A)-(B)-(X)-Y-Ile-Glu-Gln-Gly-Met-Met-Leu-Ala-Glu-Gln-Phe-Lys-Gln-Lys-Ala-Leu-Gly-Leu-Leu-Gln-Y-(X)-Z

13. Peptide XIII or NS4-7 or HCV7 (aa 1724 - 1743) has the sequence:
(XIII)

(A)-(B)-(X)-Y-Leu-Ala-Glu-Gln-Phe-Lys-Gln-Lys-Ala-Leu-Gly-Leu-Gln-Thr-Ala-Ser-Arg-Gln-Ala-Y-(X)-Z

14. Peptide XIV or HCV8 (aa 1730 - 1749) has the sequence:
(XIV)

(A)-(B)-(X)-Y-Gln-Lys-Ala-Leu-Gly-Leu-Leu-Gln-Thr-Ala-Ser-Arg-Gln-Ala-Glu-Val-Ile-Ala-Pro-Ala-Y-(X)-Z

15. Peptide NS4-27 or HCV9 (aa. 1712 - 1743):

(A)-(B)-(X)-Y-Ser-Gln-His-Leu-Pro-Tyr-Ile-Glu-Gln-Glu-Met-Leu-Ala-Glu-Gln-Phe-Lys-Gln-Lys-Ala-Leu-Gly-Leu-Leu-Gln-Thr-Ala-Ser-Arg-Gln-Ala-Y-(X)-Z

16. Peptide NS4e:

(A)-(B)-(X)-Y-Gly-Glu-Gly-Ala-Val-Gln-Trp-Met-Asn-Arg-Leu-Ile-Ala-Phe-Ala-Ser-Arg-Gly-Asn-His-Y-(X)-Z

The following peptides of the NS5 region of HCV were found to correspond to immunologically important epitopes.

Peptide XV or NS5-25 (aa 2263 - 2282) has the sequence:
(XV)

(A)-(B)-(X)-Y-Glu-Asp-Glu-Arg-Glu-Ile-Ser-Val-Pro-Ala-Glu-Ile-Leu-Arg-Lys-Ser-Arg-Arg-Phe-Ala-Y-(X)-Z

Peptide XVI or NS5-27 (aa 2275 - 2294) has the sequence:
(XVI)

(A)-(B)-(X)-Y-Leu-Arg-Lys-Ser-Arg-Arg-Phe-Ala-Gln-Ala-Leu-Pro-Val-Trp-Ala-Arg-Pro-Asp-Tyr-Asn-Y-(X)-Z

Peptide XVII or NS5-29 (aa 2287 - 2306) has the sequence:
(XVII)

(A)-(B)-(X)-Y-Val-Trp-Ala-Arg-Pro-Asp-Tyr-Asn-Pro-Pro-Leu-Val-Glu-Thr-Trp-Lys-Lys-Pro-Asp-Tyr-Y-(X)-Z

Peptide XVIII or NS5-31 (aa 2299 - 2318) has the sequence:
(XVIII)

(A)-(B)-(X)-Y-Glu-Thr-Trp-Lys-Lys-Pro-Asp-Tyr-Glu-Pro-Pro-Val-Val-His-Gly-Cys-Pro-Leu-Pro-Pro-Y-(X)-Z

Peptide XIX or NS5-33 (aa 2311 - 2330) has the sequence:
(XIX)

(A)-(B)-(X)-Y-Val-His-Gly-Cys-Pro-Leu-Pro-Pro-Pro-Lys-

Ser-Pro-Pro-Val-Pro-Pro-Pro-Arg-Lys-Lys-Y-(X)-Z

Peptide NS5-2527 (aa. 2263 to 2294):

(A)-(B)-(X)-Y-Glu-Asp-Glu-Arg-Glu-Ile-Ser-Val-Pro-Ala-Glu-Ile-Leu-Arg-Lys-Ser-Arg-Lys-Ser-Arg-Arg-Phe-Ala-Gln-Ala-Leu-Pro-Val-Trp-Ala-Arg-Pro-Asp-Tyr-Asp-Tyr-Asn-Y-(X)-Z

The following peptides from the N-terminal region of the E2/NS1 region of HCV were found to correspond to immunologically important epitopes.

peptide XXa (aa. 383-416)

(A)-(B)-(X)-Y-Gly-Glu-Thr-Tyr-Thr-Ser-Gly-Gly-Ala-Ala-Ser-His-Thr-Thr-Ser-Thr-Leu-Ala-Ser-Leu-Phe-Ser-Pro-Gly-Ala-Ser-Gln-Arg-Ile-Gln-Leu-Val-Asn-Thr-Y-(X)-Z

peptide XXa-1 (aa. 383-404)

(A)-(B)-(X)-Y-Gly-Glu-Thr-Tyr-Thr-Ser-Gly-Gly-Ala-Ala-Ser-His-Thr-Thr-Ser-Thr-Leu-Ala-Ser-Leu-Phe-Ser-Y-(X)-Z

peptide XXa-2 (aa. 393-416)

(A)-(B)-(X)-Y-Ser-His-Thr-Thr-Ser-Thr-Leu-Ala-Ser-Leu-Phe-Ser-Pro-Gly-Ala-Ser-Gln-Arg-Ile-Gln-Leu-Val-Asn-Thr-Y-(X)-Z

peptide XXb (aa. 383-416)

(A)-(B)-(X)-Y-Gly-His-Thr-Arg-Val-Ser-Gly-Gly-Ala-Ala-Ala-Ser-Asp-Thr-Arg-Gly-Leu-Val-Ser-Leu-Phe-Ser-Pro-Gly-Ser-Ala-Gln-Lys-Ile-Gln-Leu-Val-Asn-Thr-Y-(X)-Z

peptide XXb-1 (aa. 383-404)

(A)-(B)-(X)-Y-Gly-His-Thr-Arg-Val-Ser-Gly-Gly-Ala-Ala-Ala-Ser-Asp-Thr-Arg-Gly-Leu-Val-Ser-Leu-Phe-Ser-Y-(X)-Z

peptide XXb-2 (aa. 393-416)

(A)-(B)-(X)-Y-Ala-Ser-Asp-Thr-Arg-Gly-Leu-Val-Ser-Leu-Phe-Ser-Pro-Gly-Ser-Ala-Gln-Lys-Ile-Gln-Leu-Val-Asn-Thr-Y-(X)-Z

peptide XXc (aa. 383-416)

(A)-(B)-(X)-Y-Gly-His-Thr-Arg-Val-Thr-Gly-Gly-Val-Gln-Gly-His-Val-Thr-Cys-Thr-Leu-Thr-Ser-Leu-Phe-Arg-Pro-Gly-Ala-Ser-Gln-Lys-Ile-Gln-Leu-Val-Asn-Thr-Y-(X)-Z

peptide XXc-1 (aa. 383-404)

(A)-(B)-(X)-Y-Gly-His-Thr-Arg-Val-Thr-Gly-Gly-Val-Gln-
Gly-His-Val-Thr-Cys-Thr-Leu-Thr-Ser-Leu-Phe-Arg-Y-(X)-Z

peptide XXc-2 (aa. 393-416)

(A)-(B)-(X)-Y-Gly-His-Val-Thr-Cys-Thr-Leu-Thr-Ser-Leu-
Phe-Arg-Pro-Gly-Ala-Ser-Gln-Lys-Ile-Gln-Leu-Val-Asn-
Thr-Y-(X)-Z

peptide XXd (aa. 383-416)

(A)-(B)-(X)-Y-Gly-His-Thr-His-Val-Thr-Gly-Gly-Arg-Val-
Ala-Ser-Ser-Thr-Gln-Ser-Leu-Val-Ser-Trp-Leu-Ser-Gln-
Gly-Pro-Ser-Gln-Lys-Ile-Gln-Leu-Val-Asn-Thr-Y-(X)-Z

peptide XXd-1 (aa. 383-404)

(A)-(B)-(X)-Y-Gly-His-Thr-His-Val-Thr-Gly-Gly-Arg-Val-
Ala-Ser-Ser-Thr-Gln-Ser-Leu-Val-Ser-Trp-Leu-Ser-Y-(X)-Z

peptide XXd-2 (aa. 393-416)

(A)-(B)-(X)-Y-Ala-Ser-Ser-Thr-Gln-Ser-Leu-Val-Ser-
Trp-Leu-Ser-Gln-Gly-Pro-Ser-Gln-Lys-Ile-Gln-Leu-Val-
Asn-Thr-Y-(X)-Z

peptide XXe (aa. 383-416)

(A)-(B)-(X)-Y-Gly-Asp-Thr-His-Val-Thr-Gly-Gly-Ala-
Gln-Ala-Lys-Thr-Thr-Asn-Arg-Leu-Val-Ser-Met-Phe-Ala-
Ser-Gly-Pro-Ser-Gln-Lys-Ile-Gln-Leu-Ile-Asn-Thr-Y-
(X)-Z

peptide XXe-1 (aa. 383-404)

(A)-(B)-(X)-Y-Gly-Asp-Thr-His-Val-Thr-Gly-Gly-Ala-
Gln-Ala-Lys-Thr-Thr-Asn-Arg-Leu-Val-Ser-Met-Phe-Ala-
-Y-(X)-Z

peptide XXe-2 (aa. 393-416)

(A)-(B)-(X)-Y-Ala-Lys-Thr-Thr-Asn-Arg-Leu-Val-Ser-
Met-Phe-Ala-Ser-Gly-Pro-Ser-Gln-Lys-Ile-Gln-Leu-Ile-
Asn-Thr-Y-(X)-Z

peptide XXf (aa. 383-416)

(A)-(B)-(X)-Y-Ala-Glu-Thr-Tyr-Thr-Ser-Gly-Gly-Asn-
Ala-Gly-His-Thr-Met-Thr-Gly-Ile-Val-Arg-Phe-Phe-Ala-
Pro-Gly-Pro-Lys-Gln-Asn-Val-His-Leu-Ile-Asn-Thr-Y-(X)-Z

peptide XXf-1 (aa. 383-404)

(A)-(B)-(X)-Y-Ala-Glu-Thr-Tyr-Thr-Ser-Gly-Gly-Asn-Ala-

Gly-His-Thr-Met-Thr-Gly-Ile-Val-Arg-Phe-Phe-Ala-Y-(X)-Z

peptide XXf-2 (aa. 393-416)

(A)-(B)-(X)-Y-Gly-His-Thr-Met-Thr-Gly-Ile-Val-Arg-Phe-
Phe-Ala-Pro-Gly-Pro-Lys-Gln-Asn-Val-His-Leu-Ile-Asn-
Thr-Y-(X)-Z

peptide XXg (aa. 383-416)

(A)-(B)-(X)-Y-Ala-Glu-Thr-Ile-Val-Ser-Gly-Gly-Gln-Ala-
Ala-Arg-Ala-Met-Ser-Gly-Leu-Val-Ser-Leu-Phe-Thr-Pro-
Gly-Ala-Lys-Gln-Asn-Ile-Gln-Leu-Ile-Asn-Thr-Y-(X)-Z

peptide XXg-1 (aa. 383-404)

(A)-(B)-(X)-Y-Ala-Glu-Thr-Ile-Val-Ser-Gly-Gly-Gln-Ala-
Ala-Arg-Ala-Met-Ser-Gly-Leu-Val-Ser-Leu-Phe-Thr-Y-(X)-Z

peptide XXg-2 (aa. 393-416)

(A)-(B)-(X)-Y-Ala-Arg-Ala-Met-Ser-Gly-Leu-Val-Ser-Leu-
Phe-Thr-Pro-Gly-Ala-Lys-Gln-Asn-Ile-Gln-Leu-Ile-Asn-
Thr-Y-(X)-Z

peptide XXh (aa. 383-416)

(A)-(B)-(X)-Y-Ala-Glu-Thr-Tyr-Thr-Thr-Gly-Gly-Ser-Thr-
Ala-Arg-Thr-Thr-Gln-Gly-Leu-Val-Ser-Leu-Phe-Ser-Arg-
Gly-Ala-Lys-Gln-Asp-Ile-Gln-Leu-Ile-Asn-Thr-Y-(X)-Z

peptide XXh-1 (aa. 383-404)

(A)-(B)-(X)-Y-Ala-Glu-Thr-Tyr-Thr-Thr-Gly-Gly-Ser-Thr-
Ala-Arg-Thr-Thr-Gln-Gly-Leu-Val-Ser-Leu-Phe-Ser-Y-(X)-Z

peptide XXh-2 (aa. 393-416)

(A)-(B)-(X)-Y-Ala-Arg-Thr-Thr-Gln-Gly-Leu-Val-Ser-Leu-
Phe-Ser-Arg-Gly-Ala-Lys-Gln-Asp-Ile-Gln-Leu-Ile-Asn-
Thr-Y-(X)-Z

The above-mentioned sequences correspond to epitopes localized on the HCV type-1 isolate HCV-1 (Choo et al. Proc. Natl. Acad. Sci. 88, 2451-2455, 1991) and HC-J1 (Okamoto et al., Jap. J. Exp. Med. 60, 167-177, 1990) sequence. It is, however, to be understood that also peptides from other type-1 HCV isolate sequences which correspond to the above-mentioned immunologically important regions may also be comprised in the composition according to the invention. An example of variant HCV sequences also falling within the present invention may be derived from the HCV-J isolate (Kato et al., Proc. Natl. Acad. Sci. 87, 9524-9528).

The following peptides derived from the same regions as the above-cited peptide regions from the type 2 HCV sequences.

peptide XX/2

(A)-(B)-(X)-Y-Ala-Gln-Thr-His-Thr-Val-Gly-Gly-Ser-Thr-Ala-His-Asn-Ala-Arg-Thr-Leu-Thr-Gly-Met-Phe-Ser-Leu-Gly-Ala-Arg-Gln-Lys-Ile-Gln-Leu-Ile-Asn-Thr-Y-(X)-Z

peptide XX/2-1

(A)-(B)-(X)-Y-Ala-Gln-Thr-His-Thr-Val-Gly-Gly-Ser-Thr-Ala-His-Asn-Ala-Arg-Thr-Leu-Thr-Gly-Met-Phe-Ser-Y-(X)-Z

peptide XX/2-2

(A)-(B)-(X)-Y-Ala-His-Asn-Ala-Arg-Thr-Leu-Thr-Gly-Met-Phe-Ser-Leu-Gly-Ala-Arg-Gln-Lys-Ile-Gln-Leu-Ile-Asn-Thr-Y-(X)-Z

peptide VIII-2 or NS4-1 (2)

(A)-(B)-(X)-Y-Val-Asn-Gln-Arg-Ala-Val-Val-Ala-Pro-Asp-Lys-Glu-Val-Leu-Tyr-Glu-Ala-Phe-Asp-Glu-Y-(X)-Z

peptide IX-2

(A)-(B)-(X)-Y-Val-Ala-Pro-Asp-Lys-Glu-Val-Leu-Tyr-Glu-Ala-Phe-Asp-Glu-Met-Glu-Glu-Cys-Ala-Ser-Y-(X)-Z

peptide X-2

(A)-(B)-(X)-Y-Asp-Glu-Met-Glu-Glu-Cys-Ala-Ser-Arg-Ala-Ala-Leu-Ile-Glu-Glu-Gly-Gln-Arg-Ile-Ala-Y-(X)-Z

peptide XI-2 or NS4-5 (2)

(A)-(B)-(X)-Y-Ala-Ser-Arg-Ala-Ala-Leu-Ile-Glu-Glu-Gly-Gln-Arg-Ile-Ala-Glu-Met-Leu-Lys-Ser-Lys-Y-(X)-Z

peptide XII-2

(A)-(B)-(X)-Y-Ile-Glu-Glu-Gly-Gln-Arg-Ile-Ala-Glu-Met-Leu-Lys-Ser-Lys-Ile-Gln-Gly-Leu-Leu-Gln-Y-(X)-Z

peptide XIII-2 or NS4-7(2)

(A)-(B)-(X)-Y-Ile-Ala-Glu-Met-Leu-Lys-Ser-Lys-Ile-Gln-Gly-Leu-Leu-Gln-Gln-Ala-Ser-Lys-Gln-Ala-Y-(X)-Z

peptide XIV-2

(A)-(B)-(X)-Y-Ser-Lys-Ile-Gln-Gly-Leu-Leu-Gln-Gln-Ala-Ser-Lys-Gln-Ala-Gln-Asp-Ile-Gln-Pro-Ala-Y-(X)-Z

peptide XV-2

(A)-(B)-(X)-Y-Arg-Ser-Asp-Leu-Glu-Pro-Ser-Ile-Pro-Ser-
Glu-Tyr-Met-Leu-Pro-Lys-Lys-Arg-Phe-Pro-(X)-Y-Z

peptide XVI-2

(A)-(B)-(X)-Y-Met-Leu-Pro-Lys-Lys-Arg-Phe-Pro-Pro-Ala-
Leu-Pro-Ala-Trp-Ala-Arg-Pro-Asp-Tyr-Asn-Y-(X)-Z

peptide XVII-2

(A)-(B)-(X)-Y-Ala-Trp-Ala-Arg-Pro-Asp-Tyr-Asn-Pro-Pro-
Leu-Val-Glu-Ser-Trp-Lys-Arg-Pro-Asp-Tyr-Y-(X)-Z

peptide XVIII-2

(A)-(B)-(X)-Y-Glu-Ser-Trp-Lys-Arg-Pro-Asp-Tyr-Gln-Pro-
Ala-Thr-Val-Ala-Gly-Cys-Ala-Leu-Pro-Pro-Y-(X)-Z

peptide XIX-2

(A)-(B)-(X)-Y-Val-Ala-Gly-Cys-Ala-Leu-Pro-Pro-Pro-Lys-
Lys-Thr-Pro-Thr-Pro-Pro-Pro-Arg-Arg-Arg-Y-(X)-Z

The above-mentioned sequences correspond to epitopes localized on the HCV type-2 isolate HC-J6 sequence (Okamoto et al., J. Gen. Virology 72, 2697-2704, 1991). It is, however, to be understood that also peptides from other type-2 HCV isolate sequences which correspond to the above-mentioned immunologically important regions may also be comprised in the composition according to the invention. Examples of variant sequences also falling within the present invention may be derived from HCV isolate HC-J8 (Okamoto et al., Virology 188, 331-341, 1992).

The following peptides from the NS4 region of HCV type 3 are also preferred peptides according to the present invention:

Peptide NS4-1 (3)

(A)-(B)-(X)-Y-Leu-Gly-Gly-Lys-Pro-Ala-Ile-Val-Pro-Asp-Lys-
Glu-Val-leu-Tyr-Gln-Gln-Tyr-Asp-Glu-Y-(X)-Z

Peptide NS4-5 (3)

(A)-(B)-(X)-Y-Ser-Gln-Ala-Ala-Pro-Tyr-Ile-Glu-Gln-Ala-Gln-
Val-Ile-Ala-His-Gln-Phe-Lys-Glu-Lys-Y-(X)-Z

Peptide NS4-7 (3)

(A)-(B)-(X)-Y-Ile-Ala-His-Gln-His-Gln-Phe-Lys-Glu-Lys-Val-
Leu-Gly-Leu-Leu-Gln-Arg-Ala-Thr-Gln-Gln-Gln-Y-(X)-Z

It is to be understood that also other peptides corresponding to HCV type-3 isolate sequences which

correspond to immunologically important regions as determined for HCV type-1 and type-2 may also be comprised in the composition according to the invention.

The composition according to the present invention may also comprise hybrid HCV peptide sequences consisting of combinations of the core epitopes of the HCV core (table 9) HCV NS4 (table 10) or the HCV NS5 (table 11) region separated by Gly and/or Ser residues, and preferentially the following hybrid HCV sequences:

Epi-152

(A)-(B)-(X)-Y-Ile-Pro-Asp-Arg-Glu-Val-Leu-Tyr-Arg-Gly-Gly-Lys-Lys-Pro-Asp-Tyr-Glu-Pro-Pro-Val-Gly-Gly-Arg-Arg-Pro-Gln-Asp-Val-Lys-Phe-Pro-Y-(X)-Z

Epi-33B3A

(A)-(B)-(X)-Y-Trp-Ala-Arg-Pro-Asp-Tyr-Asn-Pro-Pro-Gly-Gly-Gln-Phe-Lys-Gln-Lys-Ala-Leu-Gly-Leu-Gly-Ser-Gly-Val-Tyr-Leu-Leu-Pro-Arg-Arg-Gly-Y-(X)-Z

Epi-4B2A6

(A)-(B)-(X)-Y-Arg-Gly-Arg-Arg-Gln-Pro-Ile-Pro-Lys-Gly-Gly-Ser-Gln-His-Leu-Pro-Tyr-Ile-Glu-Gln-Ser-Gly-Pro-Val-Val-His-Gly-Cys-Pro-Leu-Pro-Y-(X)-Z

The composition according to the present invention may also comprise so called biotinylated mixotope sequences consisting of peptides containing at each position all the amino acids found in the naturally occurring isolates, with said peptides being derived from any of the above-mentioned immunologically important regions (see Figure 14).

(2) A preferred mixture of biotinylated peptides for detecting and/or immunizing against Hepatitis C Virus, Human Immunodeficiency Virus type 1 and Human Immunodeficiency Virus type 2 consists of:

A. II, III, IVa, Va, IX, XI, XIII, XV, XVI, XVIII,

1a.3, 1a.4, 1a.b, 1b.1a, 2b, 2d,

B. II, III, IVa, Va, IX, IX-2, XI, XI-2, XIII, XIII-2, XV, XV-2, XVI, XVI-2, XVIII, XVIII-2,

1a.3, 1a.4, 1a.b, 1b.1a, 2b, 2d.

(3) A preferred mixture of biotinylated peptides for detecting and/or immunizing against Human Immunodeficiency Virus types 1 and 2 and Human Lymphotropic Virus types I and II consists of:

1a.3, 1a.4, 1b.1, 2b, 2c, 2d, I-gp46-3, I-gp46-4, I-gp46-5, I-gp46-6, II-gp52-2, II-gp52-3, I-p21-2, I-p19, II-p19.

(4) Another preferred mixture of biotinylated peptides for detecting and/or immunizing against Hepatitis C Virus, Human Immunodeficiency Virus types 1 and 2 and Human Lymphotropic Virus types I and II consists of:

1a.3, 1a.4, 1a.6, 1b.1a, 2d, II, III, IVa, Va, IX, XI, XIII, XV, XVI, XVIII, XXa-2, XXc-2, XXg-2, XXh-2, I-gp46-3, I-gp46-4, I-gp46-5, I-gp46-6, II-gp52-3, I-p21-2, I-p19, II-p19.

(5) The present invention relates also to compositions of biotinylated peptides which are considered particularly advantageous, for diagnostic as well as immunogenic purposes for Hepatitis C Virus, and which advantageously comprise the following mixtures:

- A. I, III, IVa, Va,
- B. II, III, IVa, Va,
- C. IX, XI, XIII,
- D. XV, XVI, XVIII, XIX,
- E. XXc-2, XXa-1, XXa-2, XXh-1, XXh-2, XXg-2, XX/2-2,
- F. IX-2, XI-2, XIII-2,
- G. XV-2, XVI-2, XVIII-2, XIX-2,
- H. IX, IX-2, XI, XI-2, XIII, XIII-2,
- I. XV, XV-2, XVI, XVI-2, XVIII, XVIII-2, XIX, XIX-2,
- J. II, III, IVa, Va, IX, IX-2, XI, XI-2, XIII, XIII-2, XV, XV-2, XVI, XVI-2, XVIII, XVIII-2,
- K. II, III, IVa, Va, IX, XI, XIII, XV, XVI, XVIII,
- L. II, III, IV, V, IX, XI, XIII, XV, XVI, XVIII,
- M. II, III, IVa, Va, IX, XI, XIII, XV, XVI, XVIII, XXa-2, XXc-2, XXg-2, XXh-2.

(6) The present invention relates also to compositions of biotinylated peptides which are considered particularly advantageous, for diagnostic as well as immunogenic purposes for Human Immunodeficiency Virus, and which are advantageously selected from the following mixtures:
for type 1:

- A. 1a.3, 1a.4, 1a.5, 1a.b
- B. 1a.3, 1a.4, 1b.1, 1b.3, 1b.6, 1b.10,
- C. 1b.1, 1b.2, 1b.3, 1b.4, 1b.5, 1b.6, 1b.7, 1b.8, 1b.9, 1b.10
- D. 1b.1, 1b.2, 1b.3, 1b.4, 1b.6, 1b.10,

E. 1a.3, 1a.4, 1a.5, 1a.b, 1b.1a.
for type 2:

A. 2b, 2c, 2d, 2e.

for types 1 and 2:

A. 1a.3, 1a.4, 1b.1, 2b, 2c, 2d,

B. 1a.3, 1a.4, 1b.1a, 2b, 2d.

(7) The present invention relates also to compositions comprising biotinylated peptides which are considered particularly advantageous, for diagnostic as well as immunogenic purposes for Human T-cell Lymphotropic Virus and are advantageously selected from the following mixtures:

for Human T-Lymphotropic virus type I:

Peptides I-gp46-3, I-gp46-4, I-gp46-5,
I-gp46-6, I-p21-2, I-pl9

for Human T-Lymphotropic virus type II:

Peptides II-gp52-1, II-gp52-2, II-gp52-3,
I-gp46-4, II-pl9, I-p21-2.

for Human lymphotropic virus types I and II:

Peptides I-gp46-3, I-gp46-4, I-gp46-5, I-gp46-6,
II-gp52-1, II-gp52-2, II-gp52-3, I-p21-2,
I-pl9, II-pl9.

The synthesis of the peptides may be achieved in solution or on a solid support. Synthesis protocols generally employ t-butyloxycarbonyl- or 9-fluorenylmethoxycarbonyl-protected activated amino acids. The procedures for carrying out the synthesis, the amino acid activation techniques, the types of side-chain production, and the cleavage procedures used are amply described in, for example, Stewart and Young, Solid Phase Peptide Synthesis, 2nd Edition, Pierce Chemical Company, 1984; and Atherton and Sheppard, Solid Phase Peptide Synthesis, IRL Press, 1989.

(8) The present invention also relates to a process for in vitro determination of antibodies using the above defined biotinylated peptides, wherein said biotinylated peptides are preferably in the form of streptavidin-biotinylated peptide complexes or avidin-biotinylated peptide complexes.

In the complex of streptavidin-biotinylated peptides or avidin-biotinylated peptides, the peptides may be biotinylated either N-terminally, C-terminally or internally.

This approach for the determination of antibodies is not limited with respect to peptide length and avoids the difficulties inherent in coating peptides directly onto the solid phase for immunological evaluation.

The use of biotinylated peptides, in the process of the invention, makes the anchorage of peptides to a solid support such that it leaves their essential amino acids free to be recognized by antibodies.

The expression anchoring peptide to a solid support means the attachment of the peptide to a support via covalent bonds or non-covalent interactions such that the peptide becomes immobilized.

The solid support can be nitrocellulose, polystyrene, nylon or any other natural or synthetic polymer.

The expression "their essential amino acids are left free to be recognized by antibodies" means that amino acid side chains of the peptide proper are neither chemically modified in any way nor involved in the interaction between the peptide and the solid phase.

The use of biotinylated peptides in the process of the invention enables said biotinylated peptides to be free to assume a wide range of conformations, among which at least one is appropriate for the binding of antibodies to said biotinylated peptides.

Any biotinylated peptide can be selected to be used in the process of the invention. However, some of them are able to be anchored on solid support and to react with antibodies specifically recognizing the epitope within this peptide even without being biotinylated and without being involved in a complex of avidin or streptavidin. In this case, the use of biotinylated peptides results in an apparent increase of the antigenicity of peptides with respect to the antigenicity observed when the peptides are not biotinylated. The expression "apparent" is meant to indicate an observed change obtained under similar test conditions without regard to the absolute cause of the observed change.

By "antigenicity" is meant the property of a peptide to be bound by an antibody.

By "increase of antigenicity" is meant that a positive signal is obtained for a dilution which is at least two times the dilution of the non-biotinylated peptides. Said positive signal is of the same magnitude as the one obtained for non-biotinylated peptides.

In other words, obtaining a positive signal can be obtained for a smaller amount of biotinylated peptide, compared to the amount of non-biotinylated peptide.

The present invention also illustrated a process for the identification of epitopes in a protein sequence comprises the following steps:

- the preparation of peptides corresponding to portions of the amino acid sequence of the protein or polypeptide to be analyzed, said peptides being either contiguous, or preferably overlapping each other, the amount of overlapping being at least 3 amino acids, and preferably about 6 to about 12, the length of the peptides being at least about 5 amino acids and no more than about 50, preferably no more than about 40 amino acids, and more preferably from 9 to about 30 amino acids, with said peptides being characterized in that they are biotinylated;

- binding the peptides to a solid phase through the interaction between the biotinyl group and streptavidin or avidin and measuring antibody binding to the individual peptides using classical methods.

(9) The present invention also relates to a process for the in vitro determination of antibodies to HIV or diagnosis of HIV infection by using a peptide composition as defined above in an immunoassay procedure, wherein the biotinylated peptides used are in the form of complexes of streptavidin-biotinylated or of avidin-biotinylated peptides.

(10) The present invention relates also to a process for the in vitro determination of antibodies to HCV or diagnosis of HCV infection by using a peptide composition as defined above in an immunoassay procedure, wherein the biotinylated peptides used are in the form of complexes of streptavidin-biotinylated or of avidin-biotinylated peptides.

(11) The present invention relates also to a process for the in vitro determination of antibodies to HTLV I or II or diagnosis of HTLV I or II infection by using a peptide composition as defined above in an immunoassay procedure, wherein the biotinylated peptides used are in the form of complexes of streptavidin-biotinylated or of avidin-biotinylated peptides.

A preferred method for carrying out the in vitro determination of antibodies is by means of an enzyme-linked immunosorbant assay (ELISA). This assay employs a solid phase which is generally a polystyrene microtiter plate or bead. The solid phase may, however, be any material which is capable of binding a protein, either chemically via a

covalent linkage or by passive adsorption. In this regard, nylon-based membranes are also considered to be particularly advantageous. The solid phase is coated with streptavidin or avidin and after a suitable period, excess unbound protein is removed by washing. Any unoccupied binding sites on the solid phase are then blocked with an irrelevant protein such as bovine serum albumin or casein.

A solution containing the mixture or selection of biotinylated peptides is subsequently brought into contact with the streptavidin- or avidin-coated surface and allowed to bind. Unbound peptide is removed by washing. Alternatively, biotinylated peptides are allowed to form complexes with either avidin or streptavidin. The resulting complexes are used to coat the solid phase. After a suitable incubation period, unbound complex is removed by washing. An appropriate dilution of an antiserum or other body fluid is brought into contact with the solid phase to which the peptide is bound. The incubation is carried out for a time necessary to allow the binding reaction to occur. Subsequently, unbound components are removed by washing the solid phase. The detection of immune complexes is achieved by using heterologous antibodies which specifically bind to the antibodies present in the test serum and which have been conjugated with an enzyme, preferably but not limited to either horseradish peroxidase, alkaline phosphatase, or β -galactosidase, which is capable of converting a colorless or nearly colorless substrate or co-substrate into a highly colored product or a product capable of forming a colored complex with a chromogen which can be detected visually or measured spectrophotometrically.

Other detection systems known in the art may however be employed and include those in which the amount of product formed is measured electrochemically or luminometrically. The detection system may also employ radioactively labeled antibodies, in which case the amount of immune complex is quantified by scintillation counting or counting. In principle, any type of immunological test for the detection of antibodies may be used, as long as the test makes use of the complex between either streptavidin or avidin and (a) biotinylated peptide(s) synthesized as described.

Also included are competition assays in which streptavidin- or avidin- biotinylated peptide complexes in solution are permitted to compete with the solid phase-bound antigen for antibody binding or assays in which free peptide in solution is permitted to compete with solid phase-bound streptavidin or avidin: biotinylated peptide complexes. By way of example, the many types of immunological assays for the detection and quantitation of antibodies and antigen are discussed in detail (Tijssen,

P., Practice and Theory of Enzyme Immunoassays, Elsevier Press, Amsterdam, Oxford, New York, 1985).

The immunological assays may be restricted to single biotinylated peptides. Preferably, however, a mixture of biotinylated peptides is used which includes more than one epitope derived from the infectious agent(s) to which the presence of specific antibodies is to be measured.

Another preferred method for carrying out the in vitro determination of antibody detection is the line immunoassay (LIA).


This method of antibody detection consists essentially of the following steps:

- the antigens, in the form of biotinylated peptide: streptavidin or avidin complexes, to be tested or used are applied as parallel lines onto a membrane which is capable of binding, covalently or non-covalently, the antigen to be tested,
- unoccupied binding sites on the membrane are blocked with an irrelevant protein such as casein or bovine serum albumin,
- the membrane is cut into strips in a direction perpendicular to the direction in which the antigen (biotinylated peptide) lines are applied,
- an appropriate dilution of an antiserum or other body fluid (containing antibodies to be detected) is brought into contact with a strip to which the antigens are bound and allowed to incubate for a period of time sufficient to permit the binding reaction to occur,
- unbound components are removed by washing the strip,
- the detection of immune complexes is achieved by incubating the strip with heterologous antibodies which specifically bind to the antibodies in the test serum and which have been conjugated to an enzyme such as horseradish peroxidase,
- the incubation is carried out for a period sufficient to allow binding to occur,
- the presence of bound conjugate is detected by addition of the required substrate or co-substrates which are converted to a colored product by the action of the enzyme,
- the reactions are detected visually or may be quantified by densitometry.

(12) As demonstrated in the Examples section the present invention relates also to the use of a peptide composition as defined above, for immunization against HIV, and/or HCV, and/or HTLV I or II infection.

(13) The present invention also relates to a method for preparing the biotinylated peptides used in the invention

involves the use of N- α -Fmoc-X (N-y-biotin) or N- α -Fmoc-X (N-y-biotin) derivative, wherein X represents



where n is at least 1 but less than 10 and is preferably between 2 and 6, one amino group being attached to the Ca atom while the other being attached to carbon Cy, which is the most distal carbon in the side chain; or their esters obtained with alcohol ROH and more particularly pentafluorophenyl ester;

- y representing position y with respect to the carbon atom carrying the COOH group in the radical.

This biotin derivative will be called intermediary product, and the above-defined intermediary products are new compounds determined according to the process of the invention.

(14) In an advantageous method for preparing the compounds of the invention, the intermediary product can be represented by one of the following formula:

N- α -Fmoc- (N-y-biotin) is N- α -Fmoc-lysine (ϵ -biotin) or N- α -Fmoc-ornithine (N- δ -biotin)

(15) The N-terminal biotinylated peptides can be prepared according to the method which comprises the following steps:

- addition of the successive amino acids duly protected onto the resin to give:

Fmoc - AA_n AA₁ - resin,

- deprotection of the NH₂-terminal for instance by means of piperidine,

- addition of the intermediary product:

(B)

Fmoc - L

through its COOH onto the NH₂-terminal to obtain:


(B)

Fmoc - L - AA_n AA₁ - resin,

- deprotection of the NH₂-terminal group of the compound obtained, cleavage from the resin, extraction and purification of the peptide obtained, biotinylated at its amino terminal, the steps of side chain deprotection and

peptide cleavage being liable to be performed simultaneously or separately, and particularly

- deprotection of the NH_2 -terminal group of the intermediary group, for instance by means of piperidine,
- cleavage from the resin for instance with an acid such as trifluoroacetic acid, in the presence of scavengers such as ethanedithiol, thioanisole, or anisole,
- extraction of the peptide with a solvent such as diethylether to remove most the acid and scavengers,
- purification, such as with HPLC to obtain:



Biotin can be conveniently coupled to the free amino-terminus of an otherwise fully protected peptide chain using also conventional activation procedures. Since biotin possesses one carboxyl group and no amino groups, biotin essentially functions as a chain terminator. Preferred activating agents for in situ activation include but are not limited to benzotriazol-1-yl-oxy-tripyrrolidinophosphonium hexafluorophosphate (PyBOP), O-benzotriazol-1-yl-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU), and O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU). The activation procedures employing these and related compounds are known to those versed in the art of solid phase peptide synthesis and the coupling of biotin does not entail a significant departure from standard coupling protocols.


Biotin in a pre-activated form may also be used. Either N-hydroxysuccinimidobiotin or biotinamidocaproate N-hydroxysuccinimide ester are conveniently employed and both are commercially available. This method of coupling has been described by Lobl, T.J., Deibel, M.R., and Yem, A.W., Anal. Biochem. (1988) 170(2):502-511. Following addition of the N-terminal biotin, the peptide is cleaved from the resin in the presence of scavengers, the choice of which will depend on the usual considerations of peptide amino acid composition and the nature of the protecting groups used.

(16) The carboxy terminal biotinylated peptides involved in the process of the invention can be prepared according to a method which comprises


- coupling of a carboxy-activated form of the intermediary product as defined above to a cleavable linker attached to the resin, for instance to obtain the following compound:

(B)


- Fmoc - L - resin,
 - deprotection of the α amino group of the intermediary compound, for instance by means of piperidine to obtain:



- successive addition of the subsequent amino acids $\text{AA}_1, \dots, \text{AA}_n$ duly protected onto



to obtain:



- deprotection of the NH_2 -terminal for instance by means of piperidine,
- deprotection of the compound obtained, cleavage from the resin, extraction and purification of the peptide obtained, biotinylated at its carboxy terminal end, the steps of side chain deprotection and peptide cleavage being liable to be performed simultaneously or separately, and particularly
- deprotection of the NH_2 -terminal, for instance by means of piperidine,
- cleavage from the resin for instance with trifluoroacetic acid, in the presence of scavengers such as ethanedithiol, or thioanisole, or anisole,
- extraction of the peptide with a solvent such as diethylether to remove most of the acid and scavengers,
- purification, such as with HPLC to obtain:




(17) The internally biotinylated peptides can be prepared according to a method which comprises the following steps:

- addition of successive amino acids duly protected onto the resin to give:



- deprotection of the NH_2 -terminal,
- addition of the intermediary product:



through its COOH onto the NH_2 -terminal to obtain:

(3) 30

Fmoc - L - AA_n AA₁ - resin,
 - deprotection of the α amino group of the intermediary compound, for instance by means of piperidine to obtain:

(B)

L - AA_n AA₁ - resin,
 - addition of the subsequent amino acids duly protected onto the resin to give:

(B)

Fmoc - AA_n AA₁ - L - AA_n AA₁ - resin,
 - deprotection of the NH₂ terminal group of the compound obtained; cleavage from the resin, extraction and purification of the peptide obtained, biotinylated at its amino-terminal, the steps of side chain deprotection and peptide cleavage being liable to be performed simultaneously or separately, and particularly,
 - deprotection of the NH₂-terminus, for instance by means of piperidine,
 - cleavage from the resin for instance with trifluoroacetic acid, in the presence of scavengers such as ethanedithiol, or thioanisole, or anisole,
 - extraction of the peptide with a solvent such as diethylether to remove most of the acid and scavengers,
 - purification, such as with HPLC to obtain:

(B)

AA_n AA₁ - L - AA_n AA₁

Under certain circumstances, it may prove particularly advantageous to be able to biotinylate a peptide internally or at its carboxy-terminus. Such instances arise, for example, when the amino acid sequence of a peptide corresponds to the amino-terminal sequence of a protein. Attachment of a biotin to the amino-terminus of such a peptide results in a structure which is significantly different from that found in the native protein and may, as a consequence, adversely affect the binding properties of biochemical properties of the peptide. It is also possible that even for peptides corresponding to internal protein sequences, their recognition by binding proteins or immunoglobulins may depend on which end of the peptide and the manner in which it is presented for binding. The importance of peptide orientation has been described by Dyrberg, T. and Oldstone, M.B.A., J. Exp. Med. (1986) 164:1344-1349.

In order to be able to incorporate a biotinyl moiety into a peptide in a position and sequence independent manner, efforts were made to synthesize a suitable reagent which can be coupled using conventional procedures. A convenient reagent for C-terminal or internal biotinylation is N-ε-biotinyl-lysine. Provided the α-amino group of this

compound is suitably protected (Fmoc and tBoc), this reagent may be used to introduce a biotin anywhere in the peptide chain, including at the amino terminus, by the standard procedures used in solid phase peptide synthesis. The synthesis of the t-Boc-protected derivative has been described (Bodansky, M., and Fagan, DT., J. Am. Chem. Soc. (1977) 99:235-239) and was used to synthesize short peptides for use in studying the enzyme activities of certain transcarboxylases.

Unlike the t-Boc derivative, the synthesis of N- α -Fmoc-Lys (N- ϵ -biotin) has not been described and given the growing interest in Fmoc-based synthesis strategies, this compound is considered particularly advantageous.

There are a number of possible routes which can be taken to arrive at the desired Fmoc-protected compound. These are shown in Figure 1. In the first approach, commercially available N- α -Fmoc-Lys (N- ϵ -tBoc) can be used as the starting material. The N- ϵ -tBoc protection is removed using trifluoroacetic acid and a scavenger such as water. A slight molar excess of the N- α -Fmoc-lysine so obtained is then reacted with carboxy-activated biotin. The resulting product can be readily purified by selective extractions and standard chromatographic techniques. In an alternative approach, N- α -Fmoc-Lys (N- ϵ -biotin) can be produced from commercially available N- ϵ -biotinyl lysine (biocytin) by reaction with fluorenylmethylsuccinimidyl carbonate. Numerous examples of these reactions which can be used as guidelines are given in Atherton and Sheppard, Solid Phase Peptide Synthesis, IRL Press, 1989.

The strategy shown in Figure 1 (method A) may also be applied to synthesize N- α -Fmoc-ornithine (N- δ -biotin) from commercially available N- α -Fmoc-ornithine (N- δ -tBoc). The ornithine derivative differs from the lysine derivative only in the length of the side chain which, for the ornithine derivative, is shorter by one carbon atom. The N- α -Fmoc-Lys can be conveniently incorporated into the peptide chain using the same reagents for in situ activation described for free biotin.

Alternatively, N- α -Fmoc-Lys (N- ϵ -biotin)-O-pentafluorophenyl ester can be conveniently synthesized from N- α -Fmoc-Lys (N- ϵ -biotin) and pentafluorophenyl trifluoroacetate using the base-catalyzed transesterification reaction described by Green, M. and Berman, J., Tetrahedron Lett. (1990) 31:5851-5852, for the preparation of O-pentafluorophenyl esters of amino acids. This active ester can be used directly to incorporate N- α -Fmoc-Lys (N- ϵ -biotin) into the peptide chain. The class of above-defined intermediary products can be prepared according to a method which comprises the following steps:

- reaction of a diamino-, monocarboxylic acid previously described with fluorenylmethylsuccinimidylcarbonate or fluorenylmethyl chloroformate under conditions of carefully controlled pH to give the singly protected N- α -Fmoc derivative,
- or alternatively, use of commercially available N- α -Fmoc-protected diamino-monocarboxylic acids when the side chain amino group is provided with a protecting group which is different from the Fmoc group used to protect the α -amino group, the side chain amino group protection being liable to be selectively removed under conditions which leave the N- α -Fmoc group intact,
- purification of the mono-protected N- α -Fmoc-diamino-monocarboxylic acid derivative by selective extractions and chromatography,
- reaction of the derivative obtained with a carboxy-activated derivative of biotin, such as N-hydroxysuccinimide biotin, to obtain the (N- α -Fmoc)-(N- γ -biotin) derivative which is the desired intermediary product,
- purification of the intermediary product by selective extractions, precipitations, or chromatography.

When the biotinylated peptides used in the process of the invention are to be provided with linker arms, these chemical entities may be conveniently attached to either the N- or C-terminus of a peptide sequence during solid phase synthesis using standard coupling protocols, as long as the amino groups of these compounds are provided with appropriate temporary amino group protection.

All these specific biotinylated peptides are new.

DESCRIPTION OF THE FIGURES:

All the samples and sera mentioned in the figures and tables are randomly chosen samples and sera, containing antibodies produced as a result of naturally occurring infection by a viral agent.

Figure 1 represents the strategies for the synthesis of N- α -Fmoc-lysine (N- ϵ -Biotin).

More particularly:

Method A corresponds to the synthesis of (N- α -Fmoc-Lys(N- ϵ -biotin) from N- ϵ -Fmoc-Lys(N- ϵ -tBoc) and Method B corresponds to the synthesis of (N- α -Fmoc-Lys(N- ϵ -biotin) from N- ϵ -biotinyl lysine.

Figure 2 represents the diagram obtained in reverse phase chromatography of the precursors involved in the preparation of the intermediary products defined above, and of the intermediary compounds.

The reverse phase chromatography has been carried out in the following conditions:

- gradient specifications:
 - buffer A: 0.1% TFA in H₂O,
 - buffer B: 0.1% TFA in acetonitrile,
 - column: C2/C18 reverse phase (Pharmacia, Pep-S),
 - detection wavelength: 255 nanometers;
- gradient:
 - 0% B from 0 to 1 minute,
 - 0% B to 100% B from 1 minute to 60 minutes,
 - 0% B from 60 minutes to 70 minutes.

The first diagram corresponds to method A (see Figure 1) and the second diagram corresponds to method B (see Figure 1).

Figure 3a represents the antibody binding to HCV peptide II (in an ELISA).

The upper left curve corresponds to sample 8320.

The upper right curve corresponds to sample 8242.

The lower left curve corresponds to sample 8243.

The lower right curve corresponds to sample 8318.

In each of these samples, the optical density (at 450 nm) is plotted against the coating concentration expressed in $\mu\text{g/ml}$.

The curve with crosses corresponds to non-biotinylated HCV peptide II and the curve with dots corresponds to biotinylated HCV peptide II.

Figure 3b represents the antibody binding to HCV peptide XI (in an ELISA).

The upper left curve corresponds to sample 8320.

The upper right curve corresponds to sample 8326.

The lower left curve corresponds to sample 8242.

The lower right curve corresponds to sample 8243.

In each of these samples, the optical density (at 450 nm) is plotted against the coating concentration expressed in $\mu\text{g/ml}$.

The curve with crosses corresponds to non-biotinylated HCV peptide XI and the curve with dots corresponds to biotinylated HCV peptide XI.

Figure 3c represents the antibody binding to HCV peptide XVI (in an ELISA).

The upper left curve corresponds to sample 8326.

The upper right curve corresponds to sample 8242.

The lower left curve corresponds to sample 8243.

The lower right curve corresponds to sample 8318.

In each of these samples, the optical density (at 450 nm) is plotted against the coating concentration expressed in $\mu\text{g/ml}$.

The curve with crosses corresponds to non-biotinylated HCV peptide XVI and the curve with dots corresponds to biotinylated HCV peptide XVI.

Figure 4 corresponds to the detection of biotinylated peptides coated directly (in an ELISA).

The first curve corresponds to biotinylated HCV peptide II, the second curve to biotinylated HCV peptide XI and the third curve to biotinylated HCV peptide XVI.

In each of these samples, the optical density (at 450 nm) is plotted against the coating concentration expressed in $\mu\text{g/ml}$.

Figure 5 represents the structures of N- and C-terminally biotinylated HIV-1 peptides (hereabove designated by 1a.1) originating from the transmembrane (TM) protein of HIV-1.

Figure 6a represents the detection of core epitopes in the Core region of HCV using overlapping 9-mers (in an ELISA).

The sera used are indicated above each diagram.
The ordinates correspond to the optical density at 450 nm.

The abscissae correspond to the sequence of the protein in which the location of the epitope(s) is to be determined. For purposes of graphic illustration, the optical density is assigned to the first amino acid in the respective nine-mer sequences.

Figure 6b represents the detection of core epitopes in the NS4 region of HCV using overlapping 9-mers (in an ELISA).

The sera used are indicated above each diagram.
The ordinates correspond to the optical density at 450 nm.

The abscissae correspond to the sequence of the protein in which the location of the epitope(s) is to be determined. For purposes of graphic illustration, the optical density is assigned to the first amino acid in the respective nine-mer sequences.

Figure 6c represents the detection of core epitopes in the NS5 region of HCV using overlapping 9-mers (in an ELISA).

The sera used are indicated above each diagram.
The ordinates correspond to the optical density at 450 nm.

The abscissae correspond to the sequence of the protein in which the location of the epitope(s) is to be determined. For purposes of graphic illustration, the optical density is assigned to the first amino acid in the respective nine-mer sequences.

Figure 7a corresponds to the positions of biotinylated 20-mers with respect to overlapping 9-mers (in an ELISA).

The abscissae corresponds to the protein sequence in which the epitope(s) is to be determined.

Figure 7b corresponds to the positions of biotinylated 20-mers with respect to overlapping 9-mers (in an ELISA).

The abscissae corresponds to the protein sequence in which the epitope(s) is to be determined.

Figure 7c corresponds to the positions of biotinylated 20-mers with respect to overlapping 9-mers (in an ELISA).

The abscissae corresponds to the protein sequence in which the epitope(s) is to be determined.

Figure 8 represents a comparison of antibody recognition of biotinylated and unbiotinylated HCV peptides by line immunoassay (LIA).

Figure 9 represents a comparison of antibody recognition of biotinylated core peptides by line immunoassay (LIA).

The shorter and longer peptides are compared.

Figure 10 represents an evaluation of type-specific HCV NS4 peptides by Line immunoassay (LIA).

Figure 11 represents the amino acid sequence of peptides NS4-a to NS4-e.

Figure 12 represents the composition of hybrid HCV peptides.

Figure 13 represents the antibody recognition of hybrid HCV peptides.

Figure 14 represents the construction scheme for mixotope peptides from the N-terminus of E2/NS1 of HCV type 1.

Figure 15 represents the mixotope synthesis strategy.

Figure 16 represents the synthesis of multiple antigen peptides (MAPs).

Figure 17 represents the recognition of E2/NS1 peptides by sera from rabbits immunized with E2/NS1 "b" peptide MAPs.

Figure 18 represents the recognition of a commercially available serum panel with a number of biotinylated HTLV-I and HTLV-II peptides incorporated into LIA strips.

Table 1 represents the antibody recognition of unbiotinylated HIV-1 and HIV-2 peptides (designated by TM-HIV-1 and TM-HIV-2) and biotinylated HIV-1 and HIV-2 peptides (hereabove referred to as 1a.1 and 2a, and also designated by TM-HIV-1 Bio and TM-HIV-2 Bio) in an ELISA.

Table 2 represents the comparison of antibody recognition of unbiotinylated and biotinylated peptides from the V3 sequence of isolate HIV-1 mn (also referred as 1b.4) in an ELISA.

Table 3 represents the comparison of antibody recognition of the biotinylated V3-mn peptide (referred to as 1b.4) bound to streptavidin and avidin, in an ELISA.

Table 4 represents the comparison of antibody recognition of biotinylated and unbiotinylated HCV peptides, in an ELISA.

More particularly:

Table 4A corresponds to the antibody binding to HCV peptide XI.

Table 4B corresponds to the antibody binding to HCV peptide XVI.

Table 4C corresponds to the antibody binding to HCV peptide II.

Table 4D corresponds to the antibody binding to HCV peptide III.

Table 4E corresponds to the antibody binding to HCV peptide V.

Table 4F corresponds to the antibody binding to HCV peptide IX.

Table 4G corresponds to the antibody binding to HCV peptide XVIII.

Table 5 represents a comparison of antibody binding to biotinylated and non-biotinylated peptides, at different peptide coating concentrations, in an ELISA.

Table 6 represents the comparison of N- and C-terminally biotinylated TM-HIV-1 peptide (referred to as 1a.1), in an ELISA.

Table 7 represents a comparison of antibody recognition of unbiotinylated and carboxy-biotinylated HCV peptide I.

Table 8 represents the use of mixtures of biotinylated HIV and HCV peptides for antibody detection, in an ELISA.

Table 9 represents sequences of the core epitopes of the HCV Core protein.

Table 10 represents sequences of the core epitopes of the HCV NS4 protein.

Table 11 represents sequences of the core epitopes of the HCV NS5 protein.

Table 12 represents the antibody binding of various Core, NS4, and NS5 biotinylated 20-mers by 10 test sera.

Table 13 represents the antibody recognition of individual E2/NS1 peptides (percent of all sera giving a positive reaction).

Table 14 represents the overall recognition of HIV V3-loop peptides.

Table 15 represents the recognition of HIV peptides according to the geographical region.

Table 16 represents the recognition of European, African and Brazilian HIV-1-positive sera to HIV-I V3-loop peptides V3-con and V3-368.

Table 17 represents the recognition of HIV-2 positive sera to two HIV-2 V3 loop peptides.

Table 18 represents the antibody recognition of hybrid peptides.

Table 19 represents the antibody recognition of mixed HTLV I and II peptides.

All amino acid sequences are given in the conventional and universally accepted three-letter code and where indicated in the one-letter code. The peptide sequences are given left to right which, by convention, is the direction from the amino terminus to the carboxy-terminus.

A number of unconventional codes are also used to represent chemical groups or modifications and are defined as follows:

Group	Code
Ac	acetyl
Bio	D-biotinyl
Fmoc	9-fluorenylmethoxycarbonyl
tBoc	tertiary butyloxycarbonyl

EXAMPLE 1: PEPTIDE SYNTHESIS

All of the peptides described were synthesized on TentaGel S-RAM (Rapp Polymere, Tübingen, Germany), a polystyrene-polyoxyethylene graft copolymerfunctionalized with the acid-labile linker 4-(α -Fmoc-amino-2',4'-dimethoxybenzyl) phenoxyacetic acid (Rink, Tetrahedron Lett. (1987) 28:3787) in order to generate peptide carboxy-terminal amides upon cleavage. t-Butyl-based side chain protection and Fmoc- α -amino-protection was used. The guanidine-group of arginine was protected with the 2,2,5,7,8-pentamethylchroman-6-sulfonyl moiety. The imidazole group of histidine was protected with either t-Boc or trityl and the sulfhydryl group of cysteine was protected with a trityl group. Couplings were carried out using preformed O-pentafluorophenyl esters except in the case of arginine where TBTU was used as the activating agent in the presence of 1.5 equivalents of the base N-methylmorpholine. Occasionally, glutamine and asparagine were also coupled using TBTU activation. In these cases, the trityl-protected derivatives of these amino acids were employed. Biotin was coupled using either TBTU or HBTU. All syntheses were carried out on a Milligen 9050 PepSynthesizer (Novato, California) using continuous flow procedures. Following cleavage with trifluoroacetic acid in the presence of scavengers and extraction with diethylether, all peptides were analyzed by C18-reverse phase chromatography.

EXAMPLE 2: SYNTHESIS OF N- α -Fmoc-Lys (N- ϵ -biotin)

A. Method A

Commercially available N- α -Fmoc-L-lysine (N- ϵ -tBoc) (1.5 grams) was treated with 20 milliliters of 95% trifluoroacetic acid, 5% H₂O for 2 hours at room

temperature. Most of the acid was then evaporated under a stream of nitrogen. Ten milliliters of water was added and the solution was extracted 3 times with diethylether. The aqueous phase was then evaporated to dryness in vacuo over phosphorus pentoxide. The resulting powder (N- α -Fmoc-L-lysine) was analyzed by reverse phase chromatography and revealed a homogeneous product which was, as expected, more hydrophilic than the starting material.

N- α -Fmoc-lysine (190 mg, 0.49 mmol) was dissolved in 8 milliliters of 0.1 M borate buffer, pH 8.7. N-hydroxysuccinimidobiotin (162 mg, 0.47 mmol) was dissolved in 4 milliliters of dimethylformamide and added to the solution of N- α -Fmoc-lysine. The pH was monitored and titrated as necessary, with NaOH. After 2 hours, the solution was acidified with HCl to pH 2.0, at which time a white precipitate was obtained.

Following extraction with ethylacetate and centrifugation, the white precipitate was found at the H₂O: ethylacetate interface. Both phases were removed and the precipitate extracted twice with 10 mM HCl, once with ethylacetate, followed by two extractions with diethylether. The precipitate was dissolved in DMF and precipitated by addition of diethylether. The crystalline powder was then dried in vacuo over phosphorus pentoxide. The resulting product was analyzed by reverse phase chromatography and revealed a major peak which, as expected, eluted later than N- α -Fmoc-Lys. A very small peak of N- α -Fmoc-Lys was also observed. (Figure 2a).

B. Method B

Commercially available N- ϵ -biotinyl lysine (biocytin, Sigma, 249 mg, 0.67 mmol) was dissolved in 8 milliliters of 1 M Na₂CO₃ and cooled on ice. Fluorenylmethylsuccinimidyl carbonate (222 mg, 0.66 mmol) was dissolved in 2 milliliters of acetone and was added to the biotinyl lysine solution over a period of 30 minutes with vigorous stirring. Stirring was continued for 5 hours at room temperature. The pH was maintained between 8 and 9 by addition of 1 M Na₂CO₃ as necessary. The acetone was then evaporated off under vacuum, and 1.0 M HCl was added until the pH of the solution was approximately 2. Upon acidification of the solution, a white precipitate appeared which was washed twice with 10 mM HCl, twice with ethyl acetate, and twice with diethylether. The precipitate was dissolved in DMF and precipitated by addition of diethylether. The crystalline powder was then thoroughly dried in vacuo over phosphorus pentoxide. The resulting product was analyzed by reverse phase chromatography and revealed a major peak which eluted with the same retention time (30.5 minutes) as the product obtained using method 1 (Figure 2b).

EXAMPLE 3: METHODS FOR THE DETERMINATION OF PEPTIDES CORRESPONDING TO IMMUNOLOGICALLY IMPORTANT EPITOPES IN AN ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) USING SPECIFIC ANTIBODIES

Where peptides were to be coated directly, stock solutions of the peptides were diluted in sodium carbonate buffer, pH 9.6 and used to coat polystyrene microtiter plates at a peptide concentration of 2 to 5 micrograms per milliliter for 1 hour at 37°C.

In cases where biotinylated peptides were to be evaluated, plates were first coated with streptavidin in sodium carbonate buffer, pH 9.6 at a concentration of 3 micrograms per milliliter for 1 hour at 37°C. The plates were then washed to remove excess, unbound protein. A working solution of the biotinylated peptide at 1 microgram per milliliter in sodium carbonate buffer was then added to the wells of the microtiter plate and incubated for 1 hours at 37°C.

Once the plates had been coated with antigen, any remaining free binding sites on the plastic were blocked with casein. After washing, a dilution of the appropriate antisera, usually 1:100, was added to the wells of the plates and incubated for 1 hour at 37°C.

After washing to remove unbound material, specific antibody binding was detected by incubating the plates with goat anti-human immunoglobulin antibodies conjugated to the enzyme horseradish peroxidase. Following removal of unbound conjugate by washing, a solution containing H_2O_2 and 3,3',5,5'-tetramethylbenzidine was added.

Reactions were stopped after a suitable interval by addition of sulfuric acid. Positive reactions gave rise to a yellow color which was quantified using a conventional microtiter plate reader. Absorbance measurements were made at a wavelength of 450 nanometers and all data are expressed as an optical density value at this wavelength.

EXAMPLE 4: USE OF BIOTINYLATED HIV PEPTIDES FOR THE DETECTION OF HIV-SPECIFIC ANTIBODIES

Experiments were performed to evaluate antibody recognition of short, 10 amino acid-long, N-acetylated peptides corresponding to other contained within the transmembrane proteins of HIV-1 and HIV-2. Direct coating of these peptides in the wells of microtiter plates gave very poor results when antibody binding was evaluated in an ELISA. Since it was suspected that the peptides did not bind well to the polystyrene solid phase, the peptides were resynthesized in the same way except that biotin was attached to the amino terminus of the peptides, separated

from the decamer peptide sequence by three glycine residues whose function it was to serve as a linker arm. The peptides used for the comparison were as follows:

TM-HIV-1:

Ac-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-
Cys-NH₂

TM-HIV-1 Bio

Bio-Gly-Gly-Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-
Cys-NH₂

TM-HIV-2

Ac-Ser-Trp-Gly-Cys-Ala-Phe-Arg-Gln-Val-
Cys-NH₂

TM-HIV-2 Bio

Bio-Gly-Gly-Gly-Ser-Trp-Gly-Cys-Ala-Phe-Arg-Gln-Val-
Cys-NH₂

The biotinylated peptides were loaded onto microtiter plates which had been coated with streptavidin. Antibody binding to these peptides was compared to antibody binding to the unbiotinylated peptides which were coated directly onto microtiter plates. The results are shown in Table 1. It is evident that the biotinylated peptides from the HIV-1 or HIV-2 transmembrane proteins bound to streptavidin are recognized very well by antisera from HIV-1 or HIV-2 infected persons respectively. This is in contrast to the unbiotinylated versions of these peptides coated directly onto the polystyrene plates. Addition control experiments showed that the increase in antibody binding was the result of the specific interaction between the biotinylated peptide and streptavidin, since there was no difference in antibody recognition of the biotinylated or unbiotinylated peptides when both were coated directly onto the microtiter plate.

Some peptides, particularly ones which are 15 amino acids in length or longer, bind sufficiently to the solid phase to allow the detection of specific antibodies which recognize (an) epitope(s) present in the peptide sequence.

To ascertain whether biotinylation would also improve antibody recognition of longer peptides, both the biotinylated and unbiotinylated versions of the partial V3 loop sequence of isolate HIV-1 mn were synthesized. The sequence and method of synthesis of both peptides were identical except at the amino terminus. The unbiotinylated peptide was simply acetylated whereas in the biotinylated version, two glycine residues were added as a linker arm to separate the peptide from the biotinyl moiety.

The sequences of the two peptides used are as follows:

- unbiotinylated V3 mn peptide

Ac-Tyr-Asn-Lys-Arg-Lys-Arg-Ile-His-Ile-Gly-Pro-Gly-Arg-Ala-Phe-Tyr-Thr-Thr-Lys-Asn-Ile-Ile-Gly-NH₂,

- biotinylated V3 mn peptide (peptide 1b.4)

Bio-Gly-Gly-Tyr-Asn-Lys-Arg-Lys-Arg-Ile-His-Ile-Gly-Pro-Gly-Arg-Ala-Phe-Tyr-Thr-Thr-Lys-Asn-Ile-Ile-Gly-NH₂.

The unbiotinylated peptide was coated directly onto the wells of a polystyrene microtiter plate while the biotinylated peptide was bound to wells which had previously been coated with streptavidin. The results shown in Table 2 demonstrate that antibody binding to the biotinylated peptide is superior to antibody binding to peptide coated directly onto the plastic.

EXAMPLE 5: USE OF BIOTINYLATED PEPTIDES - AVIDIN COMPLEXES FOR ANTIBODY DETECTION

Having demonstrated that antibody recognition of this peptide is improved when the peptide is biotinylated and bound to streptavidin, an additional experiment was performed to determine whether streptavidin could be substituted by avidin. The results shown in Table 3 indicate that this is the case and that biotinylated peptides bound to avidin are recognized very efficiently by specific antibodies.

EXAMPLE 6: USE OF BIOTINYLATED HCV PEPTIDES FOR DETECTION OF HCV SPECIFIC ANTIBODIES

In order to determine whether the enhanced antibody recognition of biotinylated peptides was a general phenomenon, a number of additional twenty amino acid-long peptides were synthesized which correspond to sequences derived from the hepatitis C virus (HCV) polyprotein. The amino acid sequences evaluated were as follows:

a. HCV peptide XI

Ser-Gln-His-Leu-Pro-Tyr-Ile-Glu-Gln-Gly-Met-Met-Leu-Ala-Glu-Gln-Phe-Lys-Gln-Lys

b. HCV peptide XVI

Leu-Arg-Lys-Ser-Arg-Arg-Phe-Ala-Gln-Ala-Leu-Pro-Val-Trp-Ala-Arg-Pro-Asp-Tyr-Asn

c. HCV peptide II

Pro-Gln-Arg-Lys-Thr-Lys-Arg-Asn-Thr-Asn-Arg-Arg-Pro-Gln-Asp-Val-Lys-Phe-Pro-Gly

d. HCV peptide III

Arg-Asn-Thr-Asn-Arg-Arg-Pro-Gln-Asp-Val-Lys-Phe-Pro-Gly-Gly-Gly-Gln-Ile-Val-Gly

e. HCV peptide V

Thr-Arg-Lys-Thr-Ser-Glu-Arg-Ser-Gln-Pro-Arg-Gly-Arg-Arg-Gln-Pro-Ile-Pro-Lys-Val

f. HCV peptide IX

Ile-Ile-Pro-Asp-Arg-Glu-Val-Leu-Tyr-Arg-Glu-Phe-Asp-Glu-Met-Glu-Glu-Cys-Ser-Gln

g. HCV peptide XVIII

Glu-Thr-Trp-Lys-Lys-Pro-Asp-Tyr-Glu-Pro-Pro-Val-Val-His-Gly-Cys-Pro-Leu-Pro-Pro

In each case, two versions of the peptide were synthesized. In the unbiotinylated version, the peptide was acetylated at the amino terminus. The biotinylated versions were all N-terminally biotinylated. A linker arm consisting of two glycine residues separated the biotinyl moiety from the amino acids comprising the HCV sequence.

The unbiotinylated peptides were adsorbed onto the wells of polystyrene microtiter plates at a concentration of 3 micrograms per milliliter.

The biotinylated peptides were bound at a concentration of 1 microgram per milliliter to streptavidin-coated microtiter plates. Sera known to contain antibodies to these peptides were used for the evaluation and were tested at a 20-fold dilution. The results of these comparisons are shown in Table 4, a to g.

These results clearly indicate that antibody recognition of biotinylated peptides bound to streptavidin is enhanced relative to that of peptides coated directly onto the wells of the microtiter plate.

EXAMPLE 7: INFLUENCE OF COATING CONCENTRATION ON ANTIBODY DETECTION

To investigate further the enhanced antibody recognition of biotinylated HCV peptides bound to streptavidin or avidin as compared to direct adsorption on plastic, the influence of peptide coating concentration was investigated. Three peptides (HCV peptides II, XI, and XVI)

were coated in concentrations ranging from 10 nanograms per milliliter to 3 micrograms per milliliter in a volume of 200 microliters per microtiter plate well. For direct coating, the unbiotinylated versions of these peptides were used. The biotinylated versions of these peptides were used to coat wells to which streptavidin had previously been adsorbed. Sera known to contain antibodies to these peptides were used at a dilution of 1 to 100 to evaluate the magnitude of antibody binding.

The numerical results of this experiment are shown in Table 5 and are depicted graphically in Figure 3, a-c.

It is evident that with few exceptions, the biotinylated peptide is recognized very well even at the lowest concentration tested (10 nanograms per milliliter, 2 nanograms per well). In many cases, optical density values close to the maximum attainable are observed at a peptide concentration of only 30 nanograms per milliliter (6 nanograms per well). In contrast, however, the unbiotinylated peptides adsorbed directly onto the plastic are poorly bound by antibody, if at all.

EXAMPLE 8: INFLUENCE OF BIOTINYLATION OF PEPTIDES ON COATING EFFICIENCY OF THE PEPTIDES ON A SOLID PHASE

To determine if the absence of a signal was due to lack of peptide adsorption when the peptides were coated directly, an additional experiment was performed. In this case, the biotinylated versions of the peptides were coated directly onto the plastic at the same concentrations used in the previous experiment for the unbiotinylated versions. To ascertain whether biotin-labeled peptide was bound, the microtiter plates were incubated with a streptavidin: horseradish peroxidase conjugate. Since each peptide contains a single biotinyl group, the resulting optical densities are a measure of the amount of peptide bound, although the absolute amount of bound peptide is not known. The results presented graphically in Figure 4 demonstrate that plastic-bound peptide can be detected. As expected, the curves are different for each peptide which is a reflection of their chemical uniqueness. Two of the peptides, HCV peptides XI and XVI, appear to bind only weakly to the wells of the polystyrene microtiter plate and this poor binding is reflected in the low optical density values obtained in the ELISA. Since the binding of the biotinylated peptides to streptavidin-coated wells results in very good antibody recognition, it is obvious that poor binding of the peptide to the solid phase is not a limitation when use is made of interaction between biotin and streptavidin.

On the other hand, one of the peptides, HCV peptide II, shows very significant binding to the solid phase,

particularly at higher coating concentrations. However, at no coating concentration did the signal obtained when the peptide was coated directly ever equal the signal obtained when the biotinylated peptide was bound to streptavidin. Since even at the lowest concentration tested, the streptavidin-bound biotinylated versions of this peptide clearly gives a positive signal with the antisera tested, the results would seem to indicate either that the direct coating of this peptide is extraordinarily inefficient or that other factors are important besides the simple binding of peptide to the solid phase.

Although difficult to quantify, one of the factors almost certainly involves the manner in which the peptide is bound and available for antibody binding. In the case of peptides coated directly onto the solid phase, it is virtually inevitable that some proportion of the peptide molecules will interact with the solid phase through amino acid side chains which are also essential for antibody recognition. These peptide molecules will therefore be unable to participate in the binding reaction with antibodies. This problem is not encountered with the biotinylated peptides which are all bound to the solid phase through the interaction between biotin and the solid phase-bound streptavidin.

EXAMPLE 9: USE OF C-TERMINALLY BIOTINYLATED HIV PEPTIDES FOR SPECIFIC ANTIBODY RECOGNITION

In order to determine whether the peptides biotinylated at their carboxy-terminus also give use to enhanced antibody recognition, a carboxy-biotinylated version of the TM-HIV-1 peptide was synthesized. N- α -Fmoc-Lys (N- ϵ -biotin) prepared by method A as described was coupled directly to resin functionalized with the acid labile linker 4-(α -Fmoc-amino-2',4'-dimethoxybenzyl) phenoxyacetic acid after removal of the linker-bound Fmoc group with 20 percent piperidine. The coupling was performed using a 3-fold molar excess of N- α -Fmoc-Lys (N- ϵ -biotin) relative to resin functional groups. Carboxyl group activation was achieved using one equivalent of HBTU, one equivalent of 1-hydroxybenzotriazole and 1.5 equivalents of N-methylmorpholine. N-methyl morpholine was dispensed as a 0.6 M solution in dimethylformamide containing 40 percent dimethylsulfoxide which was necessary to achieve complete dissolution of the N- α -Fmoc-Lys (N- ϵ -biotin). Inspection of the Fmoc deprotection peak following coupling of the N- α -Fmoc-Lys (N- ϵ -biotin) indicated that coupling had proceeded smoothly and efficiently. Two glycine residues were coupled to separate the biotinyl lysine from the TM-HIV-1 amino acid sequence. Following synthesis of the peptide, the amino terminus was acetylated with acetic anhydride. The resulting structure of the carboxy-biotinylated peptide differs significantly from the

peptide biotinylated at the amino terminus. A comparison of these structures is shown in Figure 5.

In order to evaluate antibody recognition of these two peptides, the peptides were bound individually to streptavidin-coated microtiter plates and tested using a panel of antisera from HIV-1 seropositive donors. The results of this comparison is shown in Table 6. Clearly, antibody recognition of the C-terminally biotinylated peptide compares very favorably with that of the N-terminally biotinylated peptide. These results also confirm the utility of the reagent N- α -Fmoc-Lys (N- ϵ -biotin) for carboxy-terminal biotinylation.

EXAMPLE 10: COMPARISON OF ANTIBODY RECOGNITION OF HCV PEPTIDE I, COATED DIRECTLY (UNBIOTINYLATED) OR BOUND TO STREPTAVIDIN-COATED PLATED (CARBOXY-TERMINAL BIOTINYLATION)

A similar experiment was performed using a peptide which binds relatively well to polystyrene ELISA plates in order to determine whether the carboxy-biotinylated form of the peptide would result in superior antibody recognition relative to the unbiotinylated form of the peptide. The peptide chosen was HCV peptide I, which was synthesized in the following versions:

a. unbiotinylated version:

H2N-Met-Ser-Thr-Ile-Pro-Lys-Pro-Gln-Arg-Lys-Thr-Lys-Arg-Asn-Thr-Asn-Arg-Arg-Pro-Gln-CONH₂

b. carboxy-biotinylated version:

H2N-Met-Ser-Thr-Ile-Pro-Lys-Pro-Gln-Arg-Lys-Thr-Lys-Arg-Asn-Thr-Asn-Arg-Arg-Pro-Gln-Gly-Gly-Lys(Bio)-CONH₂.

A spacer consisting of two glycine residues was added at the carboxy-terminus to physically separate the HCV portion of the peptide proper from the Lys(N- ϵ -Bio). Synthesis was performed on resin functionalized with 4-(α -Fmoc-amino-2',4'-dimethoxybenzyl) phenoxyacetic acid linker in order to generate carboxy-terminal amides upon cleavage. Coupling of the N- α -Fmoc-Lys(N- ϵ -biotin) to the linker was performed using a 3-fold molar excess of the intermediate product relative to the linker. Activation of the N- α -Fmoc-Lys(N- ϵ -biotin) was achieved using one equivalent of TBTU, one equivalent of 1-hydroxybenzotriazole, and 1.5 equivalents of N-methylmorpholine. The coupling of all other amino acids was performed according to conventional protocols. Following cleavage of the peptides in trifluoroacetic acid in the presence of the appropriate scavengers, the peptides were precipitated and extracted with diethylether.

Unbiotinylated HCV peptide I was coated directly onto the wells of a polystyrene ELISA plate at a concentration of 3 micrograms per milliliter in sodium carbonate buffer, pH 9.6. Biotinylated HCV peptide I was bound to streptavidin-coated wells using a stock solution containing the peptide at a concentration of 1 microgram per milliliter. The resulting plates were then incubated in parallel with a panel of sera from HCV-seropositive donors. The results of this comparison are shown in Table 7. The biotinylated peptide clearly gives superior results relative to the unbiotinylated version of the same sequence. Two of the sera (8326 and 8244) recognize the biotinylated version of this peptide far better than the unbiotinylated version. The specificity of the antibody reaction is also reflected by the low optical density values obtained for 5 serum samples from uninfected donors (F88, F89, F76, F136, and F6).

EXAMPLE 11: USE OF MIXTURES OF BIOTINYLATED HIV AND HCV PEPTIDES

In many cases, the use of mixtures of peptides is required to give the desired result. Mixtures of peptides may be used for the detection of antibodies directed against one or more proteins of a single virus, or for the detection of antibodies directed against proteins of several viruses in a single test. Such tests are considered particularly advantageous for the screening of blood donations for their suitability for use in transfusions and as a source of blood products. In such cases, ELISA plates or other solid supports coated with suitable mixtures of peptides may be used to screen samples for the presence of antibodies to one or more infectious agents whose presence would render the sample unsuitable for use. For the diagnosis of specific infectious agents, appropriate mixtures of peptides are required in order to obtain accurate determinations. Antibodies to individual viral antigens derived from one or more infectious agents may be individually detected and identified simultaneously when use is made of test systems in which individual peptides or mixtures of peptides are bound to the solid phase but are physically separated as they are, for example, in the line immunoassay, such that individual reactions can be observed and evaluated. Such tests require the use of an appropriate combination of peptide mixtures to achieve the desired result.

It is frequently preferable to use mixtures of peptides rather than a single peptide for the diagnosis of ongoing or past infections. Since individual responses to single epitopes may be quite variable, more reliable results are often obtained when several immunologically important epitopes are present in the antibody test. However, since each peptide is chemically unique, it is

frequently difficult to incorporate all of the desired peptides into one test, particularly when the peptides are to be coated directly onto the solid phase. Not all peptides are capable of binding to the solid phase and the peptides in the mixture may also exhibit very different optimal coating conditions in terms of pH, ionic strength, and buffer composition.

To determine how well biotinylated peptides would function in a mixture when bound to streptavidin- or avidin-coated plates, two mixtures were made of the N-terminally biotinylated versions of the HIV-1 peptides TM-HIV (hereabove referred to as 1a.1) and V3-mn (hereabove referred to as 1b.4), the HIV-2 peptide TM-HIV-2 (hereabove referred to as 2a), and the hepatitis C virus peptides II, IX, and XVIII. Mixture A contained each of the six biotinylated peptides at a concentration of 1 microgram per milliliter (6 micrograms per milliliter peptide, total) while in mixture B, each peptide was present at a concentration of 0.1 microgram per milliliter (0.6 microgram per milliliter peptide, total). The individual peptides were coated at a concentration of 1 microgram per milliliter. For purposes of comparison, mixtures A and B were also coated directly onto the wells of a microtiter plate. Samples from HIV-1, HIV-2, and HCV-seropositive donors were tested and compared to sera from seronegative blood donors. A cut-off absorbance value of 0.250 was used to determine whether a reaction was positive or negative. Absorbance values equal or greater than 0.250 were considered positive while absorbance values below this value were considered negative. The results of this experiment are shown in Table 8.

Based on the reactions to the individual peptides, all of the HCV serum samples were negative for antibodies to either HIV-1 or HIV-2. One HIV-2 sample (no. 1400) had antibodies to HCV peptide XVIII. Of the HIV samples tested, there was no indication of cross reactivity and the ELISA based on individual peptides is specific.

Both mixtures A and B gave good results when bound to avidin-coated microtiter plates. As expected, these mixtures were recognized by HIV-1, HIV-2, and HCV-positive sera but not by sera from seronegative blood donors. In contrast, when these mixtures were coated directly onto the microtiter plates, the results were considerably less satisfactory, with many samples giving a reaction which fell below the cut-off value applied. These results serve to illustrate quite convincingly the enhanced immunological recognition of biotinylated peptides bound to avidin as compared to peptides coated directly onto the solid phase as well as the advantages of using mixtures of peptides for multiple antibody detection.

EXAMPLE 12 USE OF BIOTINYLATED PEPTIDES FOR MAPPING OF EPITOPES IN DIAGNOSTICALLY USEFUL REGIONS OF HCV

It was demonstrated in Example 6 that several diagnostically important regions of the HCV polyprotein, such as Core, NS4, and NS5, can be identified using overlapping 20-mer biotinylated peptides. Extensive serological testing identified the most useful 20-mer biotinylated peptides which permitted to develop a line immunoassay utilizing these biotinylated peptides. However, it was desirable to know more exactly where in these 20 amino acid-long sequences the epitopes were located. One reason is that, if shorter sequences could be identified, it would be possible to make synthetic peptides containing two or three epitopes without the peptide becoming prohibitively long.

Epitopes present in a position of the putative HCV proteins were mapped using the method originally described by Geysen, H.M., Meloen, R.H., and Barteling, S.J.; Proc. Natl. Acad. Sci. USA (1984) 81:3998-4002. Consecutive peptides nine amino acids in length with an eight amino acid overlap were synthesized on polyethylene pins derivatized with a non-cleavable linker. This peptide length was chosen because it is larger than the size of typical linear epitopes which are generally between 5 and 7 amino acids in length. By synthesizing 9-mers, the probability that epitopes would be missed was minimized.

The regions in the HCV polyprotein which were scanned contain Core sequences (aa. 1 to 80), NS4 (aa. 1688 to 1755), and NS5 (aa. 2191 to 2330). These regions correspond to the previously determined 20-mers: Peptide I to VII (Core 1 to 13), Peptide VIII to XIV (NS4-1 to 9), and peptide XV to XIX (NS5-13 to 33).

Following synthesis, all peptides were N-acetylated prior to side chain deprotection in order to remove the unnatural positive charge at the amino terminus.

The peptides were then assayed for their ability to be recognized by antibodies present in sera from HCV seropositive donors. The results of these experiments are shown in Figure 6a to 6c. The optical density values shown are the average of duplicate determinations and have been assigned to the first amino acid of the 9-mer sequence.

The antibody binding profiles for 10 different HCV sera are shown in figure 6a. It is clear that the core protein of HCV presents well-defined linear epitopes which are readily stimulated by synthetic peptides. At least superficially, most sera appear to give very similar patterns. Closer inspection, however, reveals that there are individual differences. The various regions of the HCV

core protein which are recognized by antibodies are perhaps more properly termed epitopic clusters rather than epitopes as such, since each region is undoubtedly composed of several overlapping epitopes which are difficult, if not impossible, to distinguish using polyclonal sera. An attempt was made to identify core epitopes in each of the epitopic clusters. Used in this sense, the word "core" refers to the minimal amino acid sequence recognizable by antibodies. It should be emphasized, however, that amino acids in addition to the core sequence may improve reactivity particularly in the case of polyclonal sera. An analysis of the epitopes is given in Table 9. By comparing the reactions of the various sera, subdomains of epitopic clusters could be identified. Some sera react predominantly with one subdomain and not with others, while other sera recognize all of the subdomains but still allow the subdomains to be distinguished because each forms a shoulder in the large peak which defines that particular epitopic clusters. Table 9 and Figure 7a shows the locations of the core epitopes with respect to the sequences of the 20-mers.

The series of 9-mers corresponding to each of the 20-mer Core peptides are shown in Figure 7a together with the placement of each of these sequences in relation to an antibody recognition profile for one of the antisera tested.

The antigenic profiles for the NS4 protein obtained with the 10 sera are shown in Figure 6b. In general, the reaction of these sera with the 9-mers was less pronounced than with the peptides from the Core protein. It was, nevertheless, still possible to identify epitopic regions in the N-terminal sequences of the viral NS4 protein. The core sequences of these epitopes are analyzed in Table 10 and show their relation to the 20-mer synthetic peptides which are diagnostically important in this region. The 9-mers corresponding to the different 20-mers are shown in Figure 7b together with their placement in relation to an example of an antigenic profile. It can be seen that the 20-mers correspond quite well to the epitopes in this region.

The portion of the NS5 protein which was scanned corresponds to the region covered by the 20-mer peptides 13 to 33. The antigenic profiles obtained in this region are shown in Figure 6c. Again, an attempt was made to define core epitopes and these are listed in Table 11. Little antibody binding was observed in the amino terminal portion of this sequence. In Figure 7c, the 9-mers corresponding to the 20-mer peptides NS5-21 to NS5-31 are listed and their positions are shown relative to one of the antigenic profiles.

In particular, it is apparent that, the importance of the sequence represented by HCV peptide XVI (NS5-27) would be severely underestimated based on the results obtained with the overlapping 9-mers. The importance of this sequence would also be underestimated if unbiotinylated HCV peptide XVI (NS5-27) were evaluated in an ELISA following direct coating onto the microtiter plate (see Table 4B). However, the biotinylated version of this peptide when bound to streptavidin- or avidin-coated plates reveals the presence of a very important epitope which is of diagnostic value.

In contrast to the often weak binding observed with the 9-mers, the binding with the 20-mers was frequently quite strong (see table 12). In several cases the differences are dramatic. For example, serum 8241 does not recognize any of the 9-mers, whereas the binding to the peptides HCV2 (peptide IX) and HCV5 (peptide XI) is very strong. Moderate binding was also observed to the peptide HCV7 (peptide XIII). This would seem to indicate that there is an important structural component to these epitopes which is present in the 20-mers but which is absent in the 9-mers.

EXAMPLE 13 USE OF BIOTINYLATED PEPTIDES FOR IDENTIFICATION OF EPITOPES IN THE N-TERMINUS OF NS1 REGION OF HCV LINE IMMUNOASSAY

Epitopes can also be identified using the line immunoassay (LIA). In general, unbiotinylated peptides bind better to nylon membranes than to polystyrene ELISA plates. Nevertheless, biotinylated peptides complexed with streptavidin or avidin give superior results in the line immunoassay than do their unbiotinylated counterparts bound directly to the membrane. In order to illustrate this, unbiotinylated and N-terminally biotinylated versions of HCV peptides XXg-1 and XXg-2 were synthesized. The unbiotinylated peptides were applied to the membrane as a stock solution containing 100 micrograms per milliliter peptide, whereas the biotinylated peptides were bound to streptavidin and applied as a stock solution of 100 micrograms per milliliter complex. The amount of biotinylated peptide in the stock solution was therefore approximately 10 micrograms per milliliter. Three human IgG control lines were also applied to the strips in order to assist in evaluating the intensity of the reactions. Following application of the antigen lines, excess binding sites on the membrane were blocked with casein in phosphate-buffered saline. The membrane was subsequently cut into strips perpendicular to the direction in which the antigen lines were applied and the resulting strips were incubated with a panel of sera from HCV-seropositive donors. Bound antibody was detected visually using goat anti-human IgG antibodies conjugated to the enzyme alkaline

phosphatase after addition of 5-bromo-4-chloro-3-indolylphosphate and Nitro Blue tetrazolium. The results are shown in Figure 8.

The specificity of the reactions is demonstrated by the absence of detectable antibody binding to any of the HCV peptides by three sera (33, 34, and 35) obtained from HCV-seronegative donors. The reactions of sera 1 to 32 to the unbiotinylated HCV peptides XX-1 and XX-2 are generally absent or exceedingly weak. In contrast, many of the sera tested recognized the biotinylated versions of these peptides when complexed to streptavidin. The antibody reactions to the biotinylated peptides are significantly stronger in spite of the fact that only approximately one-tenth the amount of peptide was present in these stock solutions compared to the amount present in the stock solutions of the unbiotinylated peptides. The results obtained using the biotinylated peptides demonstrate the presence of a diagnostically useful epitope in these peptide sequences which is not evident when the unbiotinylated versions of the peptides are used.

A total of 8 sequences spanning the hypervariable N-terminus of the HCV E2-NS1 region (aa 383 to 416 of the HCV polyprotein) of different HCV isolates were chosen for further evaluation. These aligned sequences (One-letter code) are as following:

```

XXa  GETYTSGGAASHTTSTLASLFSPGASQRIQLVNT (1)
XXb  GHTRVSGGAAASDTRGLVSLFSPGSAQKIQLVNT (2)
XXc  GHTRVTGGVQGHVTC TLTS LFRPGASQKIQLVNT (3)
XXd  GHTHVTGGRVASSTQSLVSWLSQGPSQKIQLVNT (4)
XXe  GDTHVTGGAQAKTTNRLVSMFASGPSQKIQLINT (5)
XXf  AETYTSGGNAGHTMTGIVRFFAPGPKQNVHLINT (6)
XXg  AETIVSGGQAARAMSGLVSLFTPGAKQNIQLINT (7)
XXh  AETYTTGGSTARTTQGLVSLFSRGAKQDIQLINT (8)

```

These sequences are derived from isolates described by the following groups:

- (1) Hijikata et al., Biochem. Biophys. Res. Comm. 175:220-228, 1991.
- (2) unpublished results
- (3) Hijikata et al., Biochem. Biophys. Res. Comm. 175:220-228, 1991.
- (4) Kato et al., Proc. Natl. Acad. sci. USA 87:9524-9528, 1990.
- (5) Takamizawa et al., J. Virology 65:1105-1113, 1991.
- (6) Weiner et al., Virology 180:842-848, 1991.
- (7) Okamoto et al., Japan. J. Exptl. Med. 60:167-177, 1990.
- (8) Kremsdorfl et al., Abstract V64, Third International Symposium on HCV, Strasbourg, France, September, 1991.

Since the sequences are rather long and because secondary structure - related difficulties were predicted to occur during synthesis, it was decided to split the sequences into two overlapping parts ("a"= amino acid 383 to 404 and "b"= amino acid 393 to 416 of the HCV polyprotein). Subdividing the sequence also allows the position of the epitopes to be more accurately defined.

All of the peptides were N-terminally biotinylated, complexed with streptavidin and used to prepare LIA-strips (data not shown).

When only the LIA-positive samples are considered, the detection rate on the E2/NS1 peptides was found to be on the order of 90 percent. The correlations between recognition of the E2/NS1 peptides and LIA reactivity as well as the scores for the individual peptides are shown in Table 13. It was also clear from the observed reactions that the primary epitope in this sequence is located towards the carboxy-terminus of the hypervariable region. There were exceptions to this, however. Each serum appeared to have its own recognition pattern which underscores the importance of using a mixture of different sequences if this epitope is to be included as a line in the LIA. It would also appear that either there is a considerable degree of crossreactivity between the type 1a and type 1b sequences, or that most people are doubly infected. It is a simple matter to distinguish between these two possibilities by selectively removing the antibodies which bind to one sequence and looking to see what the effect is on antibody recognition of the other sequences. A number of samples gave a rather weak reaction to one or more E2/NS1 peptides but were LIA negative. While most probably false positive reactions, these sera may also be from people who were previously infected but who have resolved the infection.

EXAMPLE 14: USE OF COMBINED HCV PEPTIDES FROM THE CORE REGION OF HCV FOR THE DETECTION OF ANTIBODIES BY LIA

In order to reduce the overall number of peptides in a HCV ELISA or LIA, biotinylated peptides can be synthesized which span other immunologically important peptides. Examples of such "combined" HCV peptides from the core protein NS3 region of HCV are given below:

Peptide	Sequence
core 1 (I)	M S T I P K P Q R K T K R N T N R R P Q
core 2 (II)	P K P Q R K T K R N T N R R P
core 3 (III)	R N T N R R P Q D V K F P G G G Q I V G
core 123	M S T I P K P Q R K T K R N T N R R P Q D V K F P G G G Q I V G
core 6 (IVa)	V G G V Y L L P R R G P R L G V R A T R
core 7 (IV)	L P R R G P R L G V R A T R K T S E R S
core 9 (V)	T R K T S E R S Q P R G R R Q P I P K V
core 10 (VI)	R S Q P R G R R Q P I P K V R R P E G R
core 7910	G G V Y L L P R R G P R L G V R A T R K T S E R S Q P R G R R Q P I P K V R R

All of these peptides have been provided with a Gly-Gly spacers and a biotin at the amino terminus. The peptides were evaluated in a line immunoassay experiment (LIA) and compared to the shorter core peptides. The results are shown in Figure 9. The longer core peptides compare very favorably to the shorter peptides and consistently give a more intense reaction. This is could be explained if (i) the longer peptides incorporate two or more epitopes which were previously spread over two separate peptides and/or (2) there is any conformational contribution which may be more prominent in the longer peptides.

EXAMPLE 15: USE OF COMBINED HCV PEPTIDES FROM THE NS4 AND NS5 REGIONS OF HCV FOR THE DETECTION OF ANTIBODIES BY LIA

Other peptides combine sequences in NS4 and NS5 which are as following:

Peptide	Sequence
NS4-5 (XI)	S Q H L P Y I E Q G M M L A E Q F K Q K
NS4-7 (XIII)	L A E Q F K Q K A L G L L Q T A S R Q A
NS4-57	S Q H L P Y I E Q G M M L A E Q F K Q K A L G L L Q T A S R Q A
NS5-25 (XV)	E D E R E I S V P A E I L R K S R R F A
NS5-27 (XVI)	L R K S R R F A Q A L P V W A R P D Y N
NS5-2527	E D E R E I S V P A E I L R K S R R F A Q A L P V W A R P D Y N

The general advantage in using the longer peptides lies in the fact that their use in an ELISA or LIA leaves more space for the incorporation of other peptides carrying immunologically important epitopes.

EXAMPLE 16: USE OF TYPE-SPECIFIC HCV NS4 PEPTIDES FOR THE DETECTION OF ANTIBODIES BY LIA

Equivalent peptides containing HCV type 2 and type 3 NS4 sequences which correspond to the type 1 peptides found to contain epitopes in NS4 were synthesized. The sequences of these peptides are shown below for comparison:

Peptide	Sequence
NS4-1 (1)	L S G K P A I I P D R E V L Y R E F D E
NS4-1 (2)	V N Q R A V V A P D K E V L Y E A F D E
NS4-5 (1)	S Q H L P Y I E Q G M M L A E Q F K Q K
NS4-5 (2)	A S R A A L I E E G Q R I A E M L K S K
NS4-7 (1)	L A E Q F K Q K A L G L L Q T A S R Q A
NS4-7 (2)	I A E M L K S K I Q G L L Q Q A S K Q A

LIA strips were prepared using these nine peptides which were subsequently incubated with different sera. The results are shown in figure 10. Two of the sera which were previously negative on type 1 NS4 peptides gave a positive

reaction to the type 3 and type 2 peptides. This indicates that it is possible to increase the NS4 detection rate using these peptides.

EXAMPLE 17: USE OF BIOTINYLATED PEPTIDES FROM THE V3 LOOP REGION OF GP120 OF DIFFERENT HIV-1 ISOLATES IN A LINE IMMUNOASSAY FOR THE DETECTION OF HIV ANTIBODIES

In order to determine the general diagnostic value of the V3 loop region of gp120, nine peptides derived from this region of nine different HIV-1 isolates were synthesized and included in a LIA. All nine peptides were provided with a Gly-Gly spacer and an N-terminal biotin. The aligned peptides (one-letter amino acid code) sequences are as following:

CON	NNTRKSIHI--GPGRAFYTTGEIIG	23
SF2	NNTRKSIYI--GPGRAFHHTGRIIG	23
SC	NNTTRSIHI--GPGRAFYATGDIIG	23
MN	YNKRKRIHI--GPGRAFYTTKNIIG	23
RF	NNTRKSITK--GPGRVYIATGQIIG	23
MAL	NNTRRGIHF--GPGQALYTTG-IVG	22
BH	NNTRKSIRIQRGPGRAFVTIGKI-G	24
ELI	QNTRQRTPI--GLGQSLYTT-RSRS	22
ANT70	QIDIQEMRI--GP-MAWYSMG-IGG	21

The peptides were mixed with streptavidin in a slight molar excess over biotin binding sites and the peptide:streptavidin complexes were separated from unbound material over Sephadex G-25. Material eluting in the void volume was used in the preparation of the LIA.

A total of 332 sera were tested which had been obtained from various geographical regions. Since it is known that virus strains isolated in Europe or North America exhibit less strain-to-strain variability than African isolates, geographical differences in the V3-loop sequence recognition were to be expected. The reactions of the various lines were evaluated as positive (i) or negative (o) (data not shown).

A complete evaluation of the sera is given in Table 14. In total, 307 of the 332 sera gave a reaction to at least one peptide on the V3-loop LIA. Those sera which failed to give a reaction to any peptide on the V3-loop LIA were tested by Western Blot to determine whether the sera were indeed positive for anti- HIV-I antibodies. It was found that 6 sera were in fact negative. The total number of positive sera tested was therefore 326. There were, however, 19 sera which contained antibodies to gp120 which failed to react with any of the V3-loop LIA, the percentage of sera giving a positive reaction was, in global terms,

94%. There were, however, significant geographical differences. These differences are shown in Table 15.

The total percentage of sera from the different geographical regions giving at least one positive reaction can be summarized as follows:

European	100%
African	94%
Brazilian	92%

Additional evaluations with European samples indicate that this percentage is, in fact, some what less than 100% (data not shown). African samples which failed to give a reaction in the LIA have not been tested by Western Blot to confirm the presence of other HIV antibodies.

That the European sera would score well was expected. The lower score obtained for the African sera was also not totally unexpected, since it is known that there is more viral heterogeneity in Africa. Since V3-loop sequences of African strains of HIV have not been as extensively characterized as the European or North American strains, it is clear that we either do not have a representative sequence, or that attempting to characterize African strains in terms of a consensus sequence is not possible exercise since there is too much sequence divergence. The results obtained with the Brazilian sera were unexpected since nothing has ever been reported concerning HIV variability in Brazil. From these results, it appears that the situation in Brazil more closely resembles the situation in Africa and not the situation in North America or Europe.

Example 18: IMPROVED DETECTION OF HIV-1 ANTI-V3 DOMAIN ANTIBODIES IN BRAZILIAN SERA USING A V3 SEQUENCE DERIVED FROM A BRAZILIAN ISOLATE.

Brazilian serum samples which failed to recognize any HIV-1 V3 loop sequences present on the previously described LIA strips but which were positive for antibodies which recognized the HIV-1 gp120 protein on Western blots were selected for further study. In one of these samples, V3 loop sequences of virus present in the serum sample could be amplified using the polymerase chain reaction using primers derived from the more constant regions flanking the hypervariable domain. The resulting DNA fragment was subsequently cloned and the nucleotide sequence was determined. A peptide corresponding to the deduced amino acid sequence encoded by this fragment was synthesized and tested for its ability to be recognized by various HIV-1 antibody-positive sera. The sequence of this peptide was as follows:

Peptide V3-368:

Asn Asn Thr Arg Arg Gly Ile His Met Gly Trp Gly Arg Thr Phe
Tyr Ala Thr Gly Glu Ile Ile Gly

A spacer consisting of two glycine residues was added to the amino terminus. Thereafter, the resulting N-terminal glycine residue was biotinylated. The ability of European, African, and Brazilian HIV-1 antibody-positive sera to recognize this peptide was investigated and compared to the ability of these same sera to recognize the consensus sequence peptide in an ELISA. The two peptides were also evaluated together as a mixture. These results are summarized in table 16. These results demonstrate that with sera of European or African origin, the V3-368 peptide does not result in an increased anti-V3 loop antibody detection over that which is observed with the V3con peptide. In contrast, the use of the V3-368 peptide results in a marked improvement in V3 antibody detection with Brazilian sera. Although this peptide is recognized less frequently than the V3con peptide, the two peptides complement each other to raise the detection rate from 83.3 percent using the V3con peptide alone to 97.2 percent when the two peptides are used together.

Example 19 : ANTIBODY RECOGNITION OF HIV-2 V3 LOOP SEQUENCES

The outer membrane glycoprotein of HIV-2 (gp105) is similar to that of HIV-1 with respect to its organization. Like the gp120 protein of HIV-1, the gp105 protein of HIV-2 consists of domains of variable sequence flanked by domains of relatively conserved amino acid sequence. In order to detect antibodies specific for the V3 domain of HIV-2 produced in response to infection by this virus, biotinylated peptides were synthesized corresponding to the V3 sequences of the HIV-2/SIV isolates GB12 and isolate SIV mm 239 (Boeri, E., Giri, A., Lillo, F. et al.; J. Virol. (1992) 66(7):4546-4550). The sequences of the peptides synthesized are as follows:

V3-GB12:

Asn Lys Thr Val Val Pro Ile Thr Leu Met Ser Gly Leu Val Phe
His Ser Gln Pro Ile Asn Lys

V3-239:

Asn Lys Thr Val Leu Pro Val Thr Ile Met Ser Gly Leu Val Phe
His Ser Gln Pro Ile Asn Asp

Two glycine residues were added at the N-terminus of each peptide to serve as a spacer and a biotin was coupled to the α -amino group of the resulting N-terminal glycine. The peptides were bound to streptavidin and coated in the wells of microwell plates. HIV-2 antibody-positive sera were

used to evaluate these two peptides in an ELISA. These results are summarized in Table 17. The results clearly demonstrate the usefulness of these two peptide sequences for the diagnosis of HIV-2 infection.

EXAMPLE 20: LOCALIZATION OF THE EPITOPE AT THE CARBOXY TERMINUS OF C-100 WITH BIOTINYLATED PEPTIDES

There have been various reports of an epitope located towards the carboxy-terminal portion of the C-100 protein (EP-A-0 468 527, EP-A-0 484 787). Reactivity of certain sera toward this epitope and not to epitopes located within the 5-1-1 fragment could explain why these sera give a positive reaction on C-100 but not to the above-described peptides described in the above-mentioned examples. The five overlapping biotinylated peptides synthesized NS4-a, b, c, d and e are shown in Figure 11 and cover the carboxy-terminus of C-100 except for the last three amino acids. LIA strips prepared with these peptides were tested using a series of HCV Ab-positive and negative sera. The results of this experiment (data not shown) are summarized below:

Peptide	Nr. of reactive sera	Percentage
NS4-a	0	0%
NS4-b	2	3%
NS4-c	0	0%
NS4-d	0	0%
NS4-e	16	27%

EXAMPLE 21: USE OF BIOTINYLATED HYBRID PEPTIDES CONTAINING EPITOPES FROM DIFFERENT HCV PROTEINS

A fine mapping of the epitopes in the immunologically most important regions of the HCV polyprotein using 9-mers was performed as illustrated in Example 12. Using this information, 3 peptide sequences were devised which consisted of three 9-mer stretches of HCV sequence separated by 2 amino acid-long spacers. In general, Gly-Gly, Gly-Ser or Ser-Gly spacers were used to provide chain flexibility. The arrangement of the epitopes in the three hybrid peptides synthesized and their sequences are shown in Figure 12. The three peptides were evaluated on a LIA strip. In the first evaluation, the sera originally used for the epitope fine mapping experiments were used since the precise interactions of these sera with the epitopes is known. These results are shown in Figure 13 and are summarized in Table 16. The order in which the epitopes were incorporated into these three hybrid peptides was arbitrary. It is advantageous, however, to link the epitopes together in a limited number of peptide chains rather than attempting to develop a test based on individual 9-mers. The use of separate 9-mers would rapidly saturate the streptavidin binding sites on the plate (one

biotin binding site/9-mer) whereas incorporating the 9-mers into a limited number of peptides as was done in these experiments would enable one to bind 3 times as much (one biotin binding site/three 9-mers).

EXAMPLE 22: E2/NS1 "b" SEQUENCE MIXOTOPE PEPTIDES

The results using synthetic peptides (see Examples above) have indicated that most HCV seropositive sera contain antibodies directed towards the hypervariable N-terminus of E2/NS1. However, because of the hypervariable nature of this region of the protein, it is necessary to use a rather wide spectrum of sequences in order to detect these antibodies in an acceptably high percentage of sera. Analysis of available sequences revealed that the observed amino acid substitutions were not entirely random and that certain amino acids were preferred in certain positions within the sequence. Since the hypervariable sequence is rather long, this sequence was divided into two overlapping portions ("a" and "b") to improve the quality of the product and simplify the synthesis. Subdividing this region also permitted the determination of that the portion of this N-terminal segment of the E2/NS1 protein which was most frequently recognized by antibodies was located in the region encompassed by the "b" versions of these sequences. Given the sequence information shown in Figure 14 a "mixotope" was synthesized which contains at each position all the amino acids found in the naturally occurring isolates examined. The strategy followed in the synthesis of the mixotope is depicted in Figure 15. The strategy for designing mixotopes is reviewed in Gras-massé et al., Peptide Res. (1992) 5:211-216. The resin was divided into a number of portions equal to the number of amino acids to be coupled. The coupling reactions were carried out individually so as to avoid problems arising due to differences in coupling kinetics between the various amino acids. Following the coupling reactions, the resin portions were pooled and mixed thoroughly. The total number of variants obtained for this 23 amino acid-long sequence was $+ 1.147 \times 10^{10}$. The increasing number of variants as a function of chain length as measured from the carboxy-terminus or amino-terminus is shown in Figure 14. The rationale behind the mixotope approach is that epitopes are composed of amino acids whose contribution to antibody binding is not equal. Antibodies may recognize an epitope even though there may be a relatively large number of (generally not random) substitutions in certain positions. In this respect, the antigenic complexity of the mixotope should be substantially less than the number of variants comprising the mixture. For the sake of illustration, if it is assumed that an average epitope is 6 amino acids in length, it is possible to calculate the number variants for each successive 6 amino acid long segment in the sequence. The number of variants as a function of position in the

sequence is shown in Figure 14. The actual number of functional variant sequences will be equal to the number shown for any 6 amino acid-long sequence which happens to correspond to an epitope, divided by a degeneracy factor equal to the number of tolerated substitutions in each position of the epitope but modified to reflect the degree to which the particular substitutions are tolerated. Unfortunately, the exact position(s) of the epitope(s) are not known. It should be stated explicitly that this is not a random peptide library. Key positions in the total sequence which do not tolerate substitutions, as evidenced by the absence of amino acid variations in naturally occurring isolates, are preserved. One disadvantage to this synthetic approach is that rare amino acid substitutions are overrepresented and will tend to dilute out the more commonly encountered amino acids. On the other hand, the possibility existed that overrepresentation of rare substitutions might allow the detection of antibodies not detectable with epitope sequences comprised of more frequently encountered amino acids. Following completion of the synthesis of the mixotope, all peptide chains were provided with a (Gly)₂ spacer and a biotin to facilitate immunological evaluation. A multiple antigen peptide (MAP) version of the mixotope may also be synthesized in parallel.

One result of previous studies was that while approximately 90 percent of HCV-positive sera could be shown to contain anti-E2/NS1 antibodies directed against the N-terminal hypervariable region with the 16 "a" and "b" sequences investigated. The apparent lack of these antibodies in the remaining 10 percent of HCV antibody-positive sera could be due to two factors: 1) these patients fail to produce antibodies against this portion of E2/NS1, or 2) has not yet been identified the correct sequence with which to detect these antibodies. Based on experiments with the HIV-1 V3 loop, this latter possibility did not seem at all unrealistic. LIA strips were prepared which contained the 8 "b" sequences previously used in addition to the mixotope. Sera were selected which previously scored positive on at least one of the eight defined sequences as well as sera which scored negative. In total, 60 sera were tested, of which 56 previously gave a positive reaction and 4 were previously found to be negative. Of the 56 sera which had previously scored positive, 21 reacted with only one or two of the peptides on the strip or only gave a very weak reaction. (data not shown) The mixotope was recognized by approximately one-third of all the sera tested. The reaction of some sera to the mixotope was surprisingly strong, however, it may be possible that the collection of E2/NS1 sequences on which the mixotope was based is not truly representative. It is expected that the mixotope MAP will elicit the production

of broad specificity antisera directed against the amino-terminus of E2/NS1.

EXAMPLE 23: USE OF BRANCHED HCV N-TERMINAL E2/NS1 REGION PEPTIDES FOR RAISING ANTIBODIES

Several sequences from the N-terminus of E2/NS1 were selected for synthesis as multiple antigen peptides (MAP's) using the technique described by Tam (Proc. Natl. Acad. Sci. USA 85:5409- 5413,1988). The strategy used to synthesize the branched peptides is shown schematically in Figure 16. Rabbits (two for each MAP) were given an initial injection and were boosted once before blood was drawn for a first evaluation of antibody production. The antisera were tested on LIA strips containing a total of 16 E2 peptides (sequences derived from 8 type 1 isolates, "a" and "b" versions of each). Examination of the LIA strips reveals that there is considerable cross-reaction between the antibodies raised in the rabbits and the various E2 peptides on the strips (Figure 17). The fact that both "a" and "b" versions can be found which are recognized by the different antisera indicates that there is at least one epitope located in the region where these two versions overlap.

EXAMPLE 24 DIAGNOSIS OF HTLV INFECTION USING BIOTINYLATED SYNTHETIC PEPTIDES

HTLV-I and II are antigenically related members of a family of oncogenic retroviruses. HTLV-I infection has been shown to be associated with two disease syndromes: HTLV-I-associated myelopathy/tropical spastic paraparesis (neurological disorders) and adult T-cell leukemia (ATL). In contrast, HTLV-II has not been conclusively linked to any known disease syndrome. This virus was originally isolated from a patient with hairy cell leukemia, however, no causal relationship between HTLV-II infection and the disease state could be established. Since HTLV-I infection has definitely been demonstrated to have the potential to result in human disease while HTLV-II infection has not, it is of clinical interest to be able to differentiate between these two infectious agents. Since these two viruses are antigenically highly related, it is difficult to discriminate between HTLV-I and HTLV-II infections when viral or recombinant antigens are used for antibody detection. A number of biotinylated peptides were synthesized and evaluated for their ability to detect antibodies raised in response to infection by either HTLV-I or HTLV-II. Some of the peptides were chosen because they contain epitopes which are highly conserved between HTLV-I and HTLV-II and should therefore be useful reagents for detecting HTLV infection without regard to virus type. Still other peptides were chosen because they contain epitopes which should allow HTLV-I and HTLV-II infections

to be discriminated. The peptides synthesized are as follows:

I-gp46-3:

Bio Gly Gly Val Leu Tyr Ser Pro Asn Val Ser Val Pro Ser Ser
Ser Ser Thr Leu Leu Tyr Pro Ser Leu Ala

I-gp46-5:

Bio Gly Gly Tyr Thr Cys Ile Val Cys Ile Asp Arg Ala Ser Leu
Ser Thr Trp His Val Leu Tyr Ser Pro

I-gp46-4:

Bio Gly Gly Asn Ser Leu Ile Leu Pro Pro Phe Ser Leu Ser Pro
Val Pro Thr Leu Gly Ser Arg Ser Arg Arg

I-gp46-6:

Bio Gly Gly Asp Ala Pro Gly Tyr Asp Pro Ile Trp Phe Leu Asn
Thr Glu Pro Ser Gln Leu Pro Pro Thr Ala Pro Pro Leu Leu Pro
His Ser Asn Leu Asp His Ile Leu Glu

I-p21-2:

Bio Gly Gly Gln Tyr Ala Ala Gln Asn Arg Arg Gly Leu Asp Leu
Leu Phe Trp Glu Gln Gly Gly Leu Cys Lys Ala Leu Gln Glu Gln
Cys Arg Phe Pro

I-p19:

Bio Gly Gly Pro Pro Pro Pro Ser Ser Pro Thr His Asp Pro Pro
Asp Ser Asp Pro Gln Ile Pro Pro Pro Tyr Val Glu Pro Thr Ala
Pro Gln Val Leu

II-gp52-1:

Bio Gly Gly Lys Lys Pro Asn Arg Gln Gly Leu Gly Tyr Tyr Ser
Pro Ser Tyr Asn Asp Pro

II-gp52-2:

Bio Gly Gly Asp Ala Pro Gly Tyr Asp Pro Leu Trp Phe Ile Thr
Ser Glu Pro Thr Gln Pro Pro Pro Thr Ser Pro Pro Leu Val His
Asp Ser Asp Leu Glu His Val Leu Thr

II-gp52-3:

Bio Gly Gly Tyr Ser Cys Met Val Cys Val Asp Arg Ser Ser Leu
Ser Ser Trp His Val Leu Tyr Thr Pro Asn Ile Ser Ile Pro Gln
Gln Thr Ser Ser Arg Thr Ile Leu Phe Pro Ser

II-p19:

Bio Gly Gly Pro Thr Thr Thr Pro Pro Pro Pro Pro Pro Pro Ser
Pro Glu Ala His Val Pro Pro Pro Tyr Val Glu Pro Thr Thr Thr
Gln Cys Phe

A number of these peptides were used to prepare LIA strips for the detection of antibodies to HTLV. Several of the peptides, such as I-p19 and I-gp46-4, which are derived from regions of the HTLV-I p19 gag protein and envelope glycoprotein, respectively, are expected to be recognized by antibodies produced as a result of both HTLV-I and HTLV-II infection since these sequences are highly homologous in the two viruses. Others, such as I-gp46-3, I-gp46-6 for HTLV-I, and II-gp52-1, II-gp52-2 and II-gp52-3 for HTLV-II may be useful for detection of antibodies as well as discrimination. Since there is some homology between the HTLV-I and HTLV-II sequences, cross-reactions are to be expected. Nevertheless, the intensities of the reactions to the various peptides should reveal the identity of the virus to which the antibodies were produced.

An example of LIA strips prepared with a number of the biotinylated HTLV-I and HTLV-II peptides is shown in figure XXX. The LIA strips were evaluated using a commercially available serum panel (Boston Biomedica Inc., mixed titer panel, PRP203). The test results are in complete agreement with the analysis provided by distributor. Only one sample (nr. 9) is positive for HTLV-I. Sample nr.12 is detected as positive because of the positive reaction to the peptide I-p19. This sample could not be differentiated using these peptides, nor could this sample be differentiated by any other test used by the distributor of the serum panel. Sample nr. 11 was found to be negative and all other samples were found to be positive for HTLV-II. In an additional experiment, an ELISA was performed using all 10 of the biotinylated HTLV-I and HTLV-II peptides. The peptides were complexed with streptavidin individually and then mixed prior to coating. Some of the samples from the panel used to evaluate the LIA strips were used to evaluate the peptides in the ELISA. These results are shown in table . The ELISA in this configuration cannot be used to differentiate HTLV-I and -II infections but should identify HTLV-positive samples in general regardless of virus type. The results further demonstrate the utility of these peptides for the diagnosis of HTLV infection.

Table 1 : Antibody recognition of biotinylated and unbiotinylated HIV-1 and HIV-2 peptides

Serum		TM-HIV-1	TM-HIV-1 Bio	TM-HIV-2	TM-HIV-2 Bio
HIV-1 positive	0724	0.174	2.570	0.000	0.000
	mm	0.051	2.579	0.000	0.000
	YEMO	0.162	2.357	0.000	0.000
	PL	0.000	1.559	0.000	0.000
	VE	0.052	2.551	0.000	0.000
HIV-2 positive	1400	0.000	0.000	0.000	1.982
	AG	0.000	0.000	0.000	2.323
	53-3	0.000	0.000	0.000	2.365
Seronegative donors	194	0.000	0.000	0.000	0.000
	195	0.000	0.000	0.000	0.000
	180	0.000	0.005	0.000	0.000
	204	0.000	0.001	0.000	0.000

Table 2: Comparison of antibody recognition of biotinylated and unbiotinylated peptides from the V3 sequence of isolate HIV-1 mn.

Sample identity	V3-mn	V3-mn Bio
negative control		
blank	0.063	0.069
YS	0.053	0.051
DV	1.442	2.784
VE	1.314	2.881
	1.717	overflow*
OOST 6	1.025	2.855
OOST 8	1.389	overflow*
3990	1.442	overflow*
PL	0.531	2.351
MM	0.791	2.542
4436	0.388	2.268
4438	0.736	2.554
266	0.951	2.591
OOST 4	1.106	overflow*

*: Absorbance value greater than 3.000

Table 3: Comparison of antibody recognition of the biotinylated V3-mn peptide bound to streptavidin and avidin

Serum	Streptavidin	Avidin
YS	1.236	1.721
DV	1.041	1.748
PL	0.222	0.983
3990	1.391	1.854
VE	1.526	1.908
4436	0.596	1.519
Control	0.050	0.063

Table 4 : Comparison of antibody recognition of biotinylated and unbiotinylated HCV peptides.

Table 4A
Antibody binding to HCV peptide XI

Serum	Unbiotinylated peptide XI	Peptide XI
2	0.090	1.971
3	0.443	2.086
4	0.473	1.976
6	0.053	0.518
8	1.275	2.624
10	0.764	2.321
11	0.569	2.378
23	0.775	2.503
31	0.497	2.104
77	0.093	0.159
33	0.832	1.857
49	0.515	2.180
negative serum	0.053	0.095

Table 4B : Antibody binding to HCV peptide XVI

Serum	Unbiotinylated peptide XVI	Peptide XVI
1	1.038	2.435
2	0.616	1.239
6	0.100	1.595
8	0.329	1.599
10	1.033	2.847
26	0.053	1.522
83	0.912	2.221
88	1.187	2.519
89	0.495	1.530
91	0.197	2.169
95	0.109	1.484
99	0.814	2.045
100	0.474	1.637
104	0.205	0.942
105	0.313	2.186
110	0.762	1.484
111	0.193	1.465
112	0.253	1.084
113	0.833	2.535
116	0.058	1.918
120	0.964	2.332
11476	0.068	2.197
24758	0.071	0.062
266	0.712	2.262
8247	0.059	0.618
negative serum	0.063	0.067

Table 4C : Antibody binding to HCV peptide II

Serum	Unblotinylated peptide II	Peptide II
8241	0.444	0.545
8242	1.682	2.415
8243	2.181	2.306
8247	1.518	1.975
8250	0.110	0.357
8271	0.912	1.284
8273	2.468	2.769
8274	2.700	2.943
8275	1.489	2.030
8276	2.133	2.348
8277	1.771	2.572
8278	1.907	2.022
negative serum	0.047	0.070

Table 4D

Antibody binding to HCV peptide III

Serum	Unbiotinylated peptide III	Peptide III
8241	1.219	2.066
8242	1.976	2.197
8243	1.859	2.368
8247	1.072	2.398
8248	2.742	2.918
8250	2.471	2.626
8271	1.471	2.066
8272	2.471	2.638
8273	1.543	2.697
8274	2.503	2.905
8275	1.595	2.640
8276	1.976	2.674
8277	0.735	2.327
negative serum	0.050	0.06

Table 4F

Antibody binding to HCV peptide V

Serum	Unbiotinylated peptide V	Peptide V
8272	0.589	1.220
8273	0.294	1.026
8274	1.820	2.662
8275	1.728	1.724
8276	2.194	2.616
8277	0.770	1.796
8278	1.391	1.746
8284	0.040	0.757
negative serum	0.047	0.070

Table 4F

Antibody binding to HCV peptide IX

Serum	Unbiotinylated peptide IX	Peptide IX
8315	2.614	2.672
8316	0.133	0.367
8317	0.855	1.634
8318	1.965	2.431
8320	0.721	0.896
8321	0.283	0.457
8326	2.219	2.540
negative serum	0.052	0.005

Table 4G

Antibody binding to HCV peptide XVIII

Serum	Unbiotinylated peptide XVIII	Peptide XVIII
79	1.739	2.105
83	1.121	1.232
88	0.972	1.858
89	2.079	2.309
91	2.202	2.132
99	1.253	1.526
104	1.864	1.998
105	1.522	2.053
110	1.981	2.065
111	1.363	1.542
112	1.172	1.408
116	1.534	1.978
120	1.599	2.031
1	2.523	2.691
33	1.463	1.813
39	0.068	0.213
47	2.117	2.611
negative serum	0.001	0.001

Table 5

Peptide concentration ¹		3.0		1.0		0.3		0.1		0.03		0.01	
coupling method ²		1	2	1	2	1	2	1	2	1	2	1	2
Unbiotinylated HCV peptide II and HCV peptide IX													
sample positive		2.718	2.278	2.684	2.163	2.684	2.004	2.718	1.838	2.757	1.272	2.519	0.479
8320		1.427	0.539	1.368	0.408	1.365	0.234	1.399	0.058	1.481	0.048	1.196	0.051
8242		1.668	1.341	1.652	1.221	1.608	0.831	1.639	0.181	1.597	0.057	1.088	0.056
8318		2.016	0.791	1.993	0.626	1.958	0.347	2.001	0.181	2.181	0.095	2.002	0.048
sample negative		0.064	0.049	0.071	0.046	0.046	0.041	0.045	0.044	0.045	0.043	0.045	0.041
1747		0.057	0.053	0.055	0.053	0.051	0.045	0.047	0.046	0.049	0.053	0.053	0.046
1781													
Unbiotinylated HCV peptide IX and HCV peptide IX													
sample positive		1.779	0.129	0.802	0.093	1.798	0.122	1.244	0.063	1.007	0.057	0.461	0.059
8320		2.284	0.084	2.271	0.068	2.271	0.078	2.284	0.068	2.193	0.051	1.812	0.049
8326		0.791	0.059	0.777	0.052	0.795	0.048	0.911	0.046	0.496	0.047	0.215	0.049
8242		1.959	0.063	1.953	0.053	1.892	0.051	1.834	0.051	1.421	0.051	0.639	0.054
sample negative		0.051	0.046	0.049	0.046	0.046	0.044	0.042	0.045	0.044	0.045	0.043	0.045
1747		0.053	0.053	0.051	0.052	0.051	0.051	0.047	0.052	0.048	0.049	0.049	0.051
1781													
Unbiotinylated HCV peptide XVIII and HCV peptide XVIII													
sample positive		2.315	0.052	2.331	0.053	2.331	0.053	2.331	0.049	2.219	0.051	1.848	0.051
8326		0.749	0.053	0.839	0.049	0.873	0.048	0.946	0.047	1.188	0.049	1.185	0.048
8242		0.671	0.057	0.627	0.053	0.629	0.054	0.661	0.051	0.611	0.053	0.462	0.053
8318		2.391	0.051	2.396	0.045	2.392	0.047	2.409	0.047	2.308	0.047	1.711	0.048
sample negative		0.047	0.048	0.042	0.045	0.061	0.046	0.044	0.045	0.058	0.044	0.042	0.047
1747		0.053	0.055	0.048	0.054	0.048	0.051	0.048	0.051	0.051	0.051	0.045	0.053
1781													

In microgram per milliliter

1. biotinylated peptide on streptavidin coated plate
2. unbiotinylated peptide directly

Table 6: Comparison of N- and C-terminally biotinylated TM-HIV-1 peptide.

	Serum	TM-HIV-1	
		C-terminal biotin	N-terminal biotin
HIV positive	VE	2.079	2.240
	OOST 6	1.992	2.003
	MM	2.097	2.308
	0724	2.322	2.291
	DV	0.903	1.579
	PL	1.893	1.849
	2049	1.780	2.058
	3990	1.959	1.870
	4438	1.622	1.697
	4436	2.190	2.110
	OOST 7	1.728	2.027
	OOST 8	2.117	2.237
	OOST 9	2.119	2.222
	VCN	2.131	2.263
	1164	1.865	1.919
Seronegative blood donors	1252	2.244	2.356
	0369/87	2.059	2.042
	1784	0.000	0.000
	1747	0.000	0.000
	1733	0.014	0.000

Table 7

HCV antibody-positive sera	HCV peptide I (coated directly)	HCV peptide I carboxy-biotinylated (bound to streptavidin-coated wells)
8316	2.394	2.541
8318	2.385	2.404
8320	2.760	2.762
8326	0.525	1.775
8329	2.633	2.672
8333	2.143	2.545
8334	2.271	2.549
8336	1.558	2.016
8344	1.878	2.010
8248	2.042	2.493
8244	0.077	1.399
8243	2.211	2.541
8242	1.367	2.389
8364	2.705	2.705
8374	1.070	2.151
8378	2.161	2.531
8330	1.985	2.651
8387	1.427	2.628
HCV antibody-negative sera		
F88	0.000	0.026
F89	0.017	0.001
F76	0.000	0.022
F136	0.006	0.002
F8	0.000	0.000

Table 8: Use of mixtures of biotinylated peptides for antibody detection.

	Serum	1H-11IV-1-B10 Avidin	1H-11IV-2-B10 Avidin	V3-mn-B10 Avidin	11V peptide 11-B10 Avidin	11V peptide 1X-B10 Avidin	11V peptide XVII-B10 Avidin	Mixture A Avidin	Mixture B Avidin	Mixture A Direct coating	Mixture Direct coating
HCV	8243	0.108	0.109	0.114	1.430	1.213	0.118	1.590	1.638	0.542	0.184
	8247	0.042	0.048	0.052	1.356	0.756	0.046	0.840	1.149	0.049	0.049
	8248	0.043	0.046	0.048	2.287	0.047	0.905	1.859	2.154	0.407	0.54
	8269	0.053	0.049	0.056	1.213	0.051	1.513	0.923	1.268	0.078	0.067
	8290	0.045	0.047	0.050	0.060	0.048	2.323	1.210	1.761	0.559	0.717
	8278	0.046	0.045	0.053	1.878	0.074	0.052	1.806	1.944	0.540	0.152
	8273	0.053	0.050	0.056	2.017	0.053	0.052	2.037	2.113	0.773	0.185
HIV-2	8285	0.134	0.163	0.143	1.592	0.270	0.146	1.746	1.822	0.908	0.401
	8291	0.048	0.050	0.053	1.539	0.052	0.049	1.591	1.809	0.335	0.098
	AG	0.054	2.065	0.068	0.081	0.064	0.058	1.833	1.880	0.054	0.056
HIV-1	1400	0.051	1.781	0.055	0.121	0.052	1.362	1.692	2.031	0.214	0.326
	YS	0.046	0.046	2.201	0.048	0.049	0.049	2.045	1.845	0.200	0.052
	PL	1.974	0.051	1.321	0.052	0.056	0.052	1.587	1.776	0.052	0.055
	DV	1.329	0.048	2.340	0.047	0.049	0.047	1.969	1.742	0.100	0.049
	3990	1.602	0.054	2.319	0.054	0.066	0.056	2.217	1.926	0.390	0.041
Blood donor	1785	0.046	0.047	0.048	0.045	0.050	0.047	0.047	0.049	0.045	0.049
	1794	0.124	0.090	0.091	0.153	0.098	0.104	0.152	0.161	0.050	0.058
	1784	0.044	0.046	0.046	0.045	0.050	0.047	0.047	0.047	0.045	0.048
	1782	0.052	0.057	0.059	0.057	0.062	0.053	0.057	0.059	0.049	0.056

TABLE 9: Sequences of the Core Epitopes of the HCV Core Protein

HCV CORE PROTEIN AMINO ACIDS 1-50			
Positions of core epitopes			
Epitope 1A:	I P K <u>P O R K T K</u> P K <u>P O R K T K</u> R K <u>P O R K T K</u> R N P O R K T K R N T	M S T I P K <u>P O R K T K R N T N R R P O</u> <u>P O R K T K R N T N R R P O D V K F P G</u>	CORE 1 CORE 2
Epitope 1B:	O R <u>K T K R N T N</u> R <u>K T K R N T N R</u> K T K R N T N R R	M S T I P K <u>P O R K T K R N T N R R P O</u> <u>P O R K T K R N T N R R P O D V K F P G</u>	CORE 1 CORE 2
Epitope 2:	R R <u>P O D V K F P</u> R <u>P O D V K F P</u> G P O D V K F P G G	P O R K T K R N T N R R <u>P O D V K F P G</u> R N T N R R <u>P O D V K F P G G G O I Y G</u>	CORE 2 CORE 3
Epitope 3A:	G G V <u>T L L P R R</u> G V <u>T L L P R R</u> G V <u>T L L P R R</u> G P T L L P R R G P R	P G G G O I V G G V <u>T L L P R R G P R L</u>	CORE 5
Epitope 3B:	L L <u>P R R G P R L</u> L <u>P R R G P R L</u> G P R R G P R L G V	P G G G O I V G G V <u>T L L P R R G P R L</u> L <u>P R R G P R L</u> G V R A T A K I S E R S	CORE 5 CORE 7
Epitope 3C:	G P <u>R L G V R A T</u> P <u>R L G V R A T</u> R R L G V R A T R K	L P R R G P R L <u>G V R A T A K I S E R S</u>	CORE 7
Epitope 4A:	E R <u>S O P R G R R</u> R <u>S O P R G R R</u> O S O P R G R R O P	T R K T S E R S <u>S O P R G R R O P I P K V</u>	CORE 9
Epitope 4B:	R G <u>R R O P I P K</u> G <u>R R O P I P K</u> V R R O P I P K V R	T R K T S E R S O P R <u>G R R O P I P K V</u> <u>R R O P I P K V R R P E G R T W A O P G</u>	CORE 9 CORE 11
Epitope 5A:	P E G <u>R T W A O P</u> E G <u>R T W A O P</u> G G <u>R T W A O P</u> G T R T W A O P G T P	R R O P I P K V R R P E <u>G R T W A O P G</u> <u>G R T W A O P G T P W P L T G N E C C G</u>	CORE 11 CORE 13
Epitope 5B: (nona)	A <u>O P G T P W P L</u> O P G T P W P L Y	G R T W A O P <u>G T P W P L T G N E C C G</u>	CORE 13

TABLE 10: Sequences of the Core Epitopes of the HCV NS₄ Protein

HCV NS ₄ PROTEIN			
Positions of core epitopes			
Epitope 1:	A I I P D R E V L I I P D R E V L T I P D R E V L Y R P D R E V L Y R E	L S G K P A I I P D R E V L Y R E F D E I I P D R E V L Y R E F D E M E E C S O	HCV1 HCV2
Epitope 2A:	C S C H L P T I E S O H L P T I E O Q H L P T I E O G H L P T I E O G M	V L Y R E F D E M E E C S O H L P T I E D E M E E C S O H L P T I E O G M M L A S O H L P T I E O G M M L A E O F K O K	HCV3 HCV4 HCV5
Epitope 2B: universal	P T I E O G M M L Y I E O G M M L A	D E M E E C S O H L P T I E O G M M L A S O H L P T I E O G M M L A E O F K O K	HCV4 HCV5
Epitope 3A:	M L A E O F K O K L A E O F K O K A A E O F K O K A L	S O H L P T I E O G M M L A E O F K O K I E O G M M L A E O F K O K A L G L L O L A E O F K O K A L G L L C T A S R O A	HCV5 HCV6 HCV7
Epitope 3B	E G F K K A L G O F K O K A L G L F K O K A L G L L Y O K A L G L L O	I E O G M M L A E O F K O K A L G L L O L A E O F K O K A L G L L O T A S R O A	HCV6 HCV7
Epitope 4:	K A L G L L O T A A L G L L O T A S L G L L O T A S R	L A E O F K O K A L G L L O T A S R O A O K A L G L L O T A S R O A E V I A P A	HCV7 HCV8

TABLE III: Sequences of the Core Epitopes of the HCV NS5 Protein

NS5 PROTEIN			
Positions of the core epitopes			
Epitope 1A:	<div> <div>SVP AEILRK</div> <div>VPAEILRK</div> </div>	EDEREISVP AEILRKSRRA	NS5-25
Epitope 1B:	<div> <div>PAEILRKSR</div> <div>AEILRKSR</div> <div>SEILRKSR</div> </div>	EDEREISVP AEILRKSRRA	NS5-25
Epitope 2:	<div> <div>FAOALPVWA</div> <div>AOALPVWA</div> <div>AOALPVWA</div> </div>	LRKSRRAOALPVWA RPDYN	NS5-27
Epitope 3:	<div> <div>WAPDYNPP</div> <div>APDYNPP</div> <div>APDYNPP</div> </div>	VWAPDYNHPLVETWKKPDY	NS5-29
Epitope 4: minor	<div> <div>FLVETWKKP</div> <div>FLVETWKKP</div> <div>FLVETWKKP</div> </div>	VWAPDYNHPLVETWKKPDY	NS5-29
Epitope 5:	<div> <div>KKPDTEPPV</div> <div>KPDTEPPV</div> <div>KPDTEPPV</div> </div>	ETWKKPDTEPPVVHGCLPP	NS5-31
Epitope 6:	<div> <div>PPVYHGCLP</div> <div>PPVYHGCLP</div> <div>PPVYHGCLP</div> </div>	ETWKKPDTEPPVVHGCLPP VHGCLPPPKSPVPVPPRKK	NS5-31 NS5-33

TABLE 12. Antibody Binding of Various Core, NS4, and NS5 Peptide-ylated 20-mers by the 10 Test Sera

SERUM	PEPTIDE ELISA (O.D.)									
	Core-2	Core-3	Core-7	Core-9	HCV-2	HCV-5	HCV-7	NS5-25	NS5-27	NS5-31
8242	2.415	2.197	0.632	2.315	2.114	1.625	1.252	0.260	2.310	2.453
8248	2.441	2.918	1.529	2.021	0.142	0.102	1.963	0.054	0.300	1.511
8332	1.977	2.054	1.387	1.455	0.392	0.575	0.945	0.047	2.130	2.290
8339	2.030	2.765	0.166	2.698	2.497	0.043	0.041	1.495	2.359	2.757
8350	1.982	2.135	0.357	0.685	1.779	0.623	0.590	0.069	2.249	0.102
8377	2.181	2.368	0.221	0.076	2.360	2.227	1.829	1.092	2.336	1.378
8378	2.140	2.369	1.089	1.228	1.859	1.449	2.006	0.279	1.602	2.337
8383	2.463	2.463	0.970	2.162	2.300	1.018	2.504	0.055	2.390	2.350
8241	0.545	2.066	0.448	0.274	2.421	2.280	0.960	0.050	2.456	0.273
8243	2.306	2.368	1.251	1.378	2.203	2.260	2.251	0.062	1.444	0.127

TABLE 13: Antibody recognition of individual E2/NS1 peptides.
(percent of all sera giving a positive reaction.)

CL14-A	7 (51)	13.7%
B	36 (51)	70.6%
KATO-A	2 (51)	3.92%
B	26 (51)	50.98%
HCJ4-A	32 (51)	62.74%
B	41 (51)	80.39%
FRENCH-A	30 (51)	58.8%
B	42 (51)	82.35%
YEK-A	7 (51)	13.72%
B	49 (51)	96.07%
TAMI-A	12 (51)	23.52%
B	36 (51)	70.58%
18CH1-A	5 (51)	9.8%
B	30 (51)	58.82%
CHIR-A	32 (51)	62.7%
B	40 (51)	78.43%

TABLE 14: Overall Recognition of V3-Loop Peptides

	CON	SC	MN	SF2	BH	RF	MAL	ELI	70
Total SUM	287	261	275	258	108	146	140	24	6
COUNT	326	326	326	326	326	326	326	326	326
gp120 positive									
% Reactive	88	80	84	79	33	45	43	7	2
Total SUM	287	261	275	258	108	146	140	24	6
COUNT	307	307	307	307	307	307	307	307	307
HIV-V3 positive									
% Reactive	93	85	90	84	35	48	46	8	2

TABLE 15: Recognition of Peptides According to Geographical Region

EUROPEAN	%	AFRICAN	%	BRAZILIAN	%
Consensus	98	Consensus	89	Consensus	82
HIV-1 (SC)	98	HIV-1 (MN)	85	HIV-1 (MN)	78
HIV-1 (SF2)	98	HIV-1 (SF2)	79	HIV-1 (SC)	75
HIV-1 (MN)	97	HIV-1 (SC)	73	HIV-1 (SF2)	72
HIV-1 (RF)	75	HIV-1 (MAL)	60	HIV-1 (RF)	38
HIV-1 (MAL)	68	HIV-1 (RF)	34	HIV-1 (MAL)	30
HIV-1 (IIIB)	61	HIV-1 (IIIB)	27	HIV-1 (IIIB)	26
HIV-1 (ELI)	8	HIV-1 (ELI)	13	HIV-1 (ELI)	5
ANT 70	2	ANT 70	2	ANT 70	2

Table 16. Recognition of European, African and Brazilian HIV-1 antibody-positive sera to HIV-1 V3 loop peptides V3-con and V3-368

European sera

	V3-con	V3-368	V3con + V3-368
number tested	36	36	36
number positive	33	4	33
number negative	0	12	0
number borderline	3	20	3
percent positive	92	11	92
percent negative	0	33	0
percent borderline	8	56	8

African sera

	V3-con	V3-368	V3con + V3-368
number tested	45	45	45
number positive	40	5	40
number negative	4	31	2
number borderline	1	9	3
percent positive	89	11	89
percent negative	9	69	4
percent borderline	2	20	7

Brazilian sera

	V3-con	V3-368	V3con + V3-368
number tested	36	36	36
number positive	30	16	35
number negative	1	5	1
number borderline	5	15	0
percent positive	83.3	44.4	97.2
percent negative	2.8	13.9	2.8
percent borderline	13.9	41.7	0

Table 17. Recognition of HIV-2 positive sera to peptides from the V3 loop region of HIV-2

	V3-GB12	V3-239
number tested	21	21
number positive	21	19
number negative	0	0
number borderline	0	2
percent positive	100	90.5
percent negative	0	0
percent borderline	0	9.5

TABLE 18. Antibody recognition of hybrid peptides

Discrepancies

A.

Serum	NS4 Epitope 1	NS5 Epitope 5	Core Epitope 2	LIA Epi-152
8241	-	-	-	- weak
8242	-	-	-	-
8243	-	-	-	-
8246	-	-	-	-
8332	-	-	-	-
8339	-	-	-	-
8353	-	-	-	-
8377	-	-	-	-
8378	-	-	-	-
8383	-	-	-	-

B.

Serum	NS5 Epitope 3	NS4 Epitope 3B	Core Epitope 3A	LIA Epi-33334
8241	-	-	-	-
8242	-	-	-	-
8243	-	-	-	-
8248	-	-	-	-
8332	-	-	-	-
8339	-	-	-	-
8353	-	-	-	-
8377	-	-	-	-
8378	-	-	-	-
8383	-	-	-	-

C.

Serum	Core Epitope 4B	NS4 Epitope 2A	NS5 Epitope 6	LIA Epi-48246
8241	-	-	-	-
8242	-	-	-	-
8243	-	-	-	-
8248	-	-	-	-
8332	-	-	-	- weak
8339	-	-	-	-
8353	-	-	-	-
8377	-	-	-	-
8378	-	-	-	-
8383	-	-	-	-

TABLE 19: ANTIBODY RECOGNITION OF HTLV PEPTIDES

Serum number	Optical density
1	0.302
2	3.001
3	0.644
4	1.262
6	3.001
7	2.623
9	2.607 (HTLV-D)
10	3.001
11	0.058 (negative)
13	3.001
14	3.001
15	0.850
16	0.278
19	1.348
20	3.001
21	0.805
22	0.812
23	3.001
24	0.405
25	1.521

CLAIMS

1. A process for the in vitro determination of peptides corresponding to immunologically important epitopes comprising the steps of:

(a) preparing peptides corresponding to portions of the amino acid sequence of the protein or polypeptide to be analysed wherein said peptides are either contiguous or preferably overlapping by at least 3 amino acids;

(b) biotinylation of said peptides;

(c) binding said biotinylated peptides to a solid phase by interaction of the biotylated group and streptavidin or avidin; and

(d) measuring antibodies which bind to the individual peptides.

2. The process according to Claim 1 wherein said a.a. overlap by about 6 to about 12 amino acids.

3. A composition of matter which can be represented as follows:

(A)-(B)-(X)-Y-[amino acids]_n-Y-(X)-Z

where

- [amino acids]_n is meant to designate the length of the peptide chain where n is the number of residues, being an integer from about 4 to about 50, preferably less than about 35, more preferably less than about 30, and advantageously from about 4 to about 25;

- B represents biotin,

- X represents a biotinylation compound which is incorporated during the synthetic process,

- Y represents a covalent bond or one or more chemical entities which singly or together form a linker arm separating the amino acids of the peptide proper from the biotinyl moiety B or X, the function of which is to minimize steric hindrance which may interfere with the binding of the biotinyl moiety B or X to avidin or streptavidin, wherein Y is not a covalent bond, it is advantageously at least one chemical entity and may consist of as many as 30 chemical entities but will consist most frequently of 1 to 10 chemical entities, which may be identical or different, more preferably glycine residues, β -alanine, 4-aminobutyric acid, 5-aminovaleric acid, or 6-aminohexanoic acid,

- B and X being enclosed in parentheses to indicate that the presence of biotin or biotinylated compound in these positions is optional, the only stipulation being that B or X be present in at least one of the positions shown,

- A, when present, as indicated by parentheses, represents (an amino acid(s), an amino group, or a chemical modification of the amino terminus of the peptide chain;

- Z represents (an) amino acid(s), an OH-group, an NH₂-group or a linkage involving either of these two groups, wherein the amino acids are selectively chosen to be immunodominant epitopes which are recognized by a large percentage of true positive sera or are able to complement other antigens in the test to increase the detection rate and B interacts with the selected amino acids to produce a compound with greater diagnostic sensitivity.

4. Peptide composition comprising at least one peptide having an amino acid sequence selected from the group consisting of :

(A)-(B)-(X)-Y-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Ile-Cys-Y-(X)-Z
(1a.1)

(A)-(B)-(X)-Y-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-Cys-Thr-Thr-Ala-Val-Pro-Trp-Asn-Ala-Ser-Y-(X)-Z (1a.2)

(A)-(B)-(X)-Y-Glu-Arg-Tyr-Leu-Lys-Asp-Gln-Gln-Leu-Leu-Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-Y-(X)-Z (1a.3)

(A)-(B)-(X)-Y-Leu-Gln-Ala-Arg-Ile-Leu-Ala-Val-Glu-Arg-Tyr-Leu-Lys-Asp-Gln-Gln-Leu-Y-(X)-Z (1a.4)

(A)-(B)-(X)-Y-Leu-Trp-Gly-Cys-Lys-Gly-Lys-Leu-Val-Cys-Y-(X)-Z (1a.5)

(A)-(B)-(X)-Y-Asp-Gln-Gln-Leu-Leu-Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-His-Ile-Cys-Thr-Thr-Asn-Val-Pro-Trp-Asn-Y-(X)-Z (1a.6)

(A)-(B)-(X)-Y-Asn-Asn-Thr-Arg-Lys-Ser-Ile-His-Ile-Gly-Pro-Gly-Arg-Ala-Phe-Tyr-Thr-Thr-Gly-Glu-Ile-Ile-Gly-Y-(X)-Z (1b.1)

(A)-(B)-(X)-Y-Cys-Thr-Arg-Pro-Asn-Asn-Asn-Thr-Arg-Lys-Ser-Ile-His-Ile-Gly-Pro-Gly-Arg-Ala-Phe-Tyr-Thr-Thr-Gly-Glu-Ile-Ile-Gly-Asp-Ile-Arg-Gln-Ala-His-Cys-Y-(X)-Z (1b.1a)

(A)-(B)-(X)-Y-Asn-Asn-Thr-Arg-Lys-Ser-Ile-Tyr-Ile-Gly-Pro-Gly-Arg-Ala-Phe-His-Thr-Thr-Gly-Arg-Ile-Ile-Gly-Y-(X)-Z (1b.2)

(A)-(B)-(X)-Y-Asn-Asn-Thr-Thr-Arg-Ser-Ile-His-Ile-Gly-
Pro-Gly-Arg-Ala-Phe-Tyr-Ala-Thr-Gly-Asp-Ile-Ile-Gly-Y-
(X)-Z (1b.3)

(A)-(B)-(X)-Y-Tyr-Ala-Lys-Arg-Lys-Arg-Ile-His-Ile-Gly-
Pro-Gly-Arg-Ala-Phe-Tyr-Thr-Thr-Lys-Asn-Ile-Ile-Gly-Y-
(X)-Z (1b.4)

(A)-(B)-(X)-Y-Asn-Asn-Thr-Arg-Lys-Ser-Ile-Thr-Lys-Gly-
Pro-Gly-Arg-Val-Ile-Tyr-Ala-Thr-Gly-Gln-Ile-Ile-Gly-Y-
(X)-Z (1b.5)

(A)-(B)-(X)-Y-Asn-Asn-Thr-Arg-Arg-Gly-Ile-His-Phe-Gly-
Pro-Gly-Gln-Ala-Leu-Tyr-Thr-Thr-Gly-Ile-Val-Gly-Y-
(X)-Z (1b.6)

(A)-(B)-(X)-Y-Asn-Asn-Thr-Arg-Lys-Ser-Ile-Arg-Ile-Gln-
Arg-Gly-Pro-Gly-Arg-Ala-Phe-Val-Thr-Ile-Gly-Lys-Ile-
Gly-Y-(X)-Z (1b.7)

(A)-(B)-(X)-Y-Gln-Asn-Thr-Arg-Gln-Arg-Thr-Pro-Ile-Gly-
Leu-Gly-Gln-Ser-Leu-Tyr-Thr-Thr-Arg-Ser-Arg-Ser-Y-(X)-Z
(1b.8)

(A)-(B)-(X)-Y-Gln-Ile-Asp-Ile-Gln-Glu-Met-Arg-Ile-Gly-
Pro-Met-Ala-Trp-Tyr-Ser-Met-Gly-Ile-Gly-Gly-Y-(X)-Z (1b.9)

(A)-(B)-(X)-Y-Asn-Asn-Thr-Arg-Arg-Gly-Ile-His-Met-Gly-Trp-
Gly-
Arg-Thr-Phe-Tyr-Ala-Thr-Gly-Glu-Ile-Ile-Gly-Y-(X)-Z (1b.10)

(A)-(B)-(X)-Y-Arg-Asp-Asn-Trp-Arg-Ser-Glu-Leu-Tyr-Lys-
Tyr-Lys-Val-Val-Lys-Ile-Glu-Pro-Leu-Gly-Val-Ala-Pro-
Thr-Lys-Ala-Lys-Arg-Arg-Val-Val-Gln-Arg-Glu-Lys-
Arg-Y-(X)-Z (1b.11)

(A)-(B)-(X)-Y-Ser-Trp-Gly-Cys-Ala-Phe-Arg-Gln-Val-Cys-
Y-(X)-Z (2a)

(A)-(B)-(X)-Y-Lys-Tyr-Leu-Gln-Asp-Gln-Ala-Arg-Leu-Asn-
Ser-Trp-Gly-Cys-Ala-Phe-Arg-Gln-Val-Cys-Y-(X)-Z (2b)

(A)-(B)-(X)-Y-Asn-Lys-Thr-Val-Leu-Pro-Ile-Thr-Phe-Met-
Ser-Gly-Phe-Lys-Phe-His-Ser-Gln-Pro-Val-Ile-Asn-Lys-Y-
(X)-Z (2c)

(A)-(B)-(X)-Y-Asn-Lys-Thr-Val-Val-Pro-Ile-Thr-Leu-Met-
Ser-Gly-Leu-Val-Phe-His-Ser-Gln-Pro-Ile-Asn-Lys-Y-(X)-Z
(2d)

(A)-(B)-(X)-Y-Asn-Lys-Thr-Val-Leu-Pro-Val-Thr-Ile-Met-
Ser-Gly-Leu-Val-Phe-His-Ser-Gln-Pro-Ile-Asn-Asp-Y-(X)-Z
(2e)

(A)-(B)-(X)-Y-Leu-Trp-Gly-Cys-Ser-Gly-Lys-Ala-Val-Cys-
Y-(X)-Z (3a)

(A)-(B)-(X)-Y-Ser-Trp-Gly-Cys-Ala-Trp-Lys-Gln-Val-Cys-
Y-(X)-Z. (4a)

(A)-(B)-(X)-Y-Gln-Trp-Gly-Cys-Ser-Trp-Ala-Gln-Val-Cys-
Y-(X)-Z (4b)

(A)-(B)-(X)-Y-Val-Leu-Tyr-Ser-Pro-Asn-Val-Ser-Val-Pro-
Ser-Ser-Ser-Ser-Thr-Leu-Leu-Tyr-Pro-Ser-Leu-Ala-Y-(X)-Z
(I-gp46-3)

(A)-(B)-(X)-Y-Tyr-Thr-Cys-Ile-Val-Cys-Ile-Asp-Arg-Ala-
Ser-Leu-Ser-Thr-Trp-His-Val-Leu-Tyr-Ser-Pro-Y-(X)-Z (I-
gp46-5)

(A)-(B)-(X)-Y-Asn-Ser-Leu-Ile-Leu-Pro-Pro-Phe-Ser-Leu-
Ser-Pro-Val-Pro-Thr-Leu-Gly-Ser-Arg-Ser-Arg-Arg-Y-(X)-Z
(I-gp46-4)

(A)-(B)-(X)-Y-Asp-Ala-Pro-Gly-Tyr-Asp-Pro-Ile-Trp-Phe-
Leu-Asn-Thr-Glu-Pro-Ser-Gln-Leu-Pro-Pro-Thr-Ala-Pro-
Pro-Leu-Leu-Pro-His-Ser-Asn-Leu-Asp-His-Ile-Leu-Glu-Y-(X)-Z
(I-gp46-6)

(A)-(B)-(X)-Y-Gln-Tyr-Ala-Ala-Gln-Asn-Arg-Arg-Gly-Leu-
Asp-Leu-Leu-Phe-Trp-Glu-Gln-Gly-Gly-Leu-Cys-Lys-Ala-Leu-
Gln-Glu-Gln-Cys-Arg-Phe-Pro-Y-(X)-Z (I-p21-2)

(A)-(B)-(X)-Y-Pro-Pro-Pro-Pro-Ser-Ser-Pro-Thr-His-Asp-Pro-
Pro-Asp-Ser-Asp-Pro-Gln-Ile-Pro-Pro-Pro-Tyr-Val-Glu-Pro-
Thr-Ala-Pro-Gln-Val-Leu-Y-(X)-Z (I-p19)

(A)-(B)-(X)-Y-Lys-Lys-Pro-Asn-Arg-Gln-Gly-Leu-Gly-Tyr-Tyr-
Ser-Pro-Ser-Tyr-Asn-Asp-Pro-Y-(X)-Z (II-gp52-1)

(A)-(B)-(X)-Y-Asp-Ala-Pro-Gly-Tyr-Asp-Pro-Leu-Trp-Phe-Ile-
Thr-Ser-Glu-Pro-Thr-Gln-Pro-Pro-Pro-Thr-Ser-Pro-Pro-Leu-
Val-His-Asp-Ser-Asp-Leu-Glu-His-Val-Leu-Thr-Y-(X)-Z (II-
gp52-2)

(A)-(B)-(X)-Y-Tyr-Ser-Cys-Met-Val-Cys-Val-Asp-Arg-Ser-Ser-
Leu-Ser-Ser-Trp-His-Val-Leu-Tyr-Thr-Pro-Asn-Ile-Ser-Ile-
Pro-Gln-Gln-Thr-Ser-Ser-Arg-Thr-Ile-Leu-Phe-Pro-Ser-Y-(X)-Z
(II-gp52-3)

(A)-(B)-(X)-Y-Pro-Thr-Thr-Thr-Pro-Pro-Pro-Pro-Pro-Pro-
Ser-Pro-Glu-Ala-His-Val-Pro-Pro-Pro-Tyr-Val-Glu-Pro-Thr-
Thr-Thr-Gln-Cys-Phe-Y-(X)-Z (II-p19)

(A)-(B)-(X)-Y-Met-Ser-Thr-Ile-Pro-Lys-Pro-Gln-Arg-Lys-
Thr-Lys-Arg-Asn-Thr-Asn-Arg-Arg-Pro-Gln-Y-(X)-Z (I)

(A)-(B)-(X)-Y-Pro-Gln-Arg-Lys-Thr-Lys-Arg-Asn-Thr-Asn-Arg-Arg-Pro-Gln-Asp-Val-Lys-Phe-Pro-Gly-Y-(X)-Z (II)

(A)-(B)-(X)-Y-Gln-Arg-Lys-Thr-Lys-Arg-Asn-Thr-Asn-Arg-Arg-Y-(X)-Z. (IIa)

(A)-(B)-(X)-Y-Arg-Asn-Thr-Asn-Arg-Arg-Pro-Gln-Asp-Val-Lys-Phe-Pro-Gly-Gly-Gly-Gln-Ile-Val-Gly-Y-(X)-Z (III)

(A)-(B)-(X)-Y-Leu-Pro-Arg-Arg-Gly-Pro-Arg-Leu-Gly-Val-Arg-Ala-Thr-Arg-Lys-Thr-Ser-Glu-Arg-Ser-Y-(X)-Z (IV)

(A)-(B)-(X)-Y-Val-Gly-Gly-Val-Tyr-Leu-Leu-Pro-Arg-Arg-Gly-Pro-Arg-Leu-Gly-Val-Arg-Ala-Thr-Arg-Y-(X)-Z (IVa)

(A)-(B)-(X)-Y-Thr-Arg-Lys-Thr-Ser-Glu-Arg-Ser-Gln-Pro-Arg-Gly-Arg-Arg-Gln-Pro-Ile-Pro-Lys-Val-Y-(X)-Z (V)

(A)-(B)-(X)-Y-Arg-Ser-Gln-Pro-Arg-Gly-Arg-Arg-Gln-Pro-Ile-Pro-Lys-Val-Arg-Arg-Pro-Glu-Gly-Arg-Y-(X)-Z (Va)

(A)-(B)-(X)-Y-Arg-Arg-Gln-Pro-Ile-Pro-Lys-Val-Arg-Arg-Pro-Glu-Gly-Arg-Thr-Trp-Ala-Gln-Pro-Gly-Y-(X)-Z (VI)

(A)-(B)-(X)-Y-Gly-Arg-Thr-Trp-Ala-Gln-Pro-Gly-Tyr-Pro-Trp-Pro-Leu-Tyr-Gly-Asn-Glu-Gly-Cys-Gly-Y-(X)-Z (VII)

(A)-(B)-(X)-Y-Met-Ser-Thr-Ile-Pro-Gln-Arg-Lys-Thr-Lys-Arg-Asn-Thr-Asn-Arg-Arg-Pro-Gln-Asp-Val-Lys-Phe-Pro-Gly-Gly-Gly-Gln-Ile-Val-Gly-Y-(X)-Z (core 123)

(A)-(B)-(X)-Y-Gly-Gly-Val-Tyr-Leu-Leu-Pro-Arg-Arg-Gly-Pro-Arg-Leu-Gly-Val-Arg-Arg-Ala-Thr-Arg-Lys-Thr-Ser-Glu-Arg-Ser-Gln-Pro-Arg-Gly-Arg-Arg-Gln-Pro-Ile-Pro-Lys-Val-Arg-Arg-Y-(X)-Z (core 7910)

(A)-(B)-(X)-Y-Leu-Ser-Gly-Lys-Pro-Ala-Ile-Ile-Pro-Asp-Arg-Glu-Val-Leu-Tyr-Arg-Glu-Phe-Asp-Glu-Y-(X)-Z (VIII)

(A)-(B)-(X)-Y-Ile-Ile-Pro-Asp-Arg-Glu-Val-Leu-Tyr-Arg-Glu-Phe-Asp-Glu-Met-Glu-Glu-Cys-Ser-Gln-Y-(X)-Z (IX)

(A)-(B)-(X)-Y-Val-Leu-Tyr-Arg-Glu-Phe-Asp-Glu-Met-Glu-Glu-Cys-Ser-Gln-His-Leu-Pro-Tyr-Ile-Glu-Y-(X)-Z (HCV3)

(A)-(B)-(X)-Y-Asp-Glu-Met-Glu-Glu-Cys-Ser-Gln-His-Leu-Pro-Tyr-Ile-Glu-Gln-Gly-Met-Met-Leu-Ala-Y-(X)-Z (X)

(A)-(B)-(X)-Y-Ser-Gln-His-Leu-Pro-Tyr-Ile-Glu-Gln-Gly-Met-Met-Leu-Ala-Glu-Gln-Phe-Lys-Gln-Lys-Y-(X)-Z (XI)

(A)-(B)-(X)-Y-Ile-Glu-Gln-Gly-Met-Met-Leu-Ala-Glu-Gln-Phe-Lys-Gln-Lys-Ala-Leu-Gly-Leu-Leu-Gln-Y-(X)-Z

(XII)

(A)-(B)-(X)-Y-Leu-Ala-Glu-Gln-Phe-Lys-Gln-Lys-Ala-Leu-Gly-Leu-Leu-Gln-Thr-Ala-Ser-Arg-Gln-Ala-Y-(X)-Z (XIII)

(A)-(B)-(X)-Y-Gln-Lys-Ala-Leu-Gly-Leu-Leu-Gln-Thr-Ala-Ser-Arg-Gln-Ala-Glu-Val-Ile-Ala-Pro-Ala-Y-(X)-Z

(XIV)

(A)-(B)-(X)-Y-Ser-Gen-His-Leu-Pro-Tyr-Ile-Glu-Gln-Glu-Met-Leu-Ala-Glu-Gen-Phe-Lys-Gln-Lys-Ala-Leu-Gly-Leu-Leu-Gln-Thr-Ala-Ser-Arg-Gln-Ala-Y-(X)-Z

(NS4-27)

(A)-(B)-(X)-Y-Gly-Glu-Gly-Ala-Val-Gln-Trp-Met-Asn-Arg-Leu-Ile-Ala-Phe-Ala-Ser-Arg-Gly-Asn-His-Y-(X)-Z

(NS4-e)

(A)-(B)-(X)-Y-Glu-Asp-Glu-Arg-Glu-Ile-Ser-Val-Pro-Ala-Glu-Ile-Leu-Arg-Lys-Ser-Arg-Arg-Phe-Ala-Y-(X)-Z

(XV)

(A)-(B)-(X)-Y-Leu-Arg-Lys-Ser-Arg-Arg-Phe-Ala-Gln-Ala-Leu-Pro-Val-Trp-Ala-Arg-Pro-Asp-Tyr-Asn-Y-(X)-Z

(XVI)

(A)-(B)-(X)-Y-Val-Trp-Ala-Arg-Pro-Asp-Tyr-Asn-Pro-Pro-Leu-Val-Glu-Thr-Trp-Lys-Lys-Pro-Asp-Tyr-Y-(X)-Z

(XVII)

(A)-(B)-(X)-Y-Glu-Thr-Trp-Lys-Lys-Pro-Asp-Tyr-Glu-Pro-Pro-Val-Val-His-Gly-Cys-Pro-Leu-Pro-Pro-Y-(X)-Z

(XVIII)

(A)-(B)-(X)-Y-Val-His-Gly-Cys-Pro-Leu-Pro-Pro-Pro-Lys-Ser-Pro-Pro-Val-Pro-Pro-Pro-Arg-Lys-Lys-Y-(X)-Z

(XIX)

(A)-(B)-(X)-Y-Glu-Asp-Glu-Arg-Glu-Ile-Ser-Val-Pro-Ala-Glu-Ile-Leu-Arg-Lys-Ser-Arg-Lys-Ser-Arg-Arg-Phe-Ala-Gln-Ala-Leu-Pro-Val-Trp-Ala-Arg-Pro-Asp-Tyr-Asp-Tyr-Asn-Y-(X)-Z (NS5-2527)

(A)-(B)-(X)-Y-Gly-Glu-Thr-Tyr-Thr-Ser-Gly-Gly-Ala-Ala-Ser-His-Thr-Thr-Ser-Thr-Leu-Ala-Ser-Leu-Phe-Ser-Pro-Gly-Ala-Ser-Gln-Arg-Ile-Gln-Leu-Val-Asn-Thr-Y-(X)-Z

(XXa)

(A)-(B)-(X)-Y-Gly-Glu-Thr-Tyr-Thr-Ser-Gly-Gly-Ala-Ala-Ser-His-Thr-Thr-Ser-Thr-Leu-Ala-Ser-Leu-Phe-Ser-Y-(X)-Z

(XXa-1)

(A)-(B)-(X)-Y-Ser-His-Thr-Thr-Ser-Thr-Leu-Ala-Ser-Leu-

Phe-Ser-Pro-Gly-Ala-Ser-Gln-Arg-Ile-Gln-Leu-Val-Asn-
Thr-Y-(X)-Z
(XXa-2)

(A)-(B)-(X)-Y-Gly-His-Thr-Arg-Val-Ser-Gly-Gly-Ala-Ala-
Ala-Ser-Asp-Thr-Arg-Gly-Leu-Val-Ser-Leu-Phe-Ser-Pro-
Gly-Ser-Ala-Gln-Lys-Ile-Gln-Leu-Val-Asn-Thr-Y-(X)-Z
(XXb)

(A)-(B)-(X)-Y-Gly-His-Thr-Arg-Val-Ser-Gly-Gly-Ala-Ala-
Ala-Ser-Asp-Thr-Arg-Gly-Leu-Val-Ser-Leu-Phe-Ser-
Y-(X)-Z
(XXb-1)

(A)-(B)-(X)-Y-Ala-Ser-Asp-Thr-Arg-Gly-Leu-Val-Ser-Leu-
Phe-Ser-Pro-Gly-Ser-Ala-Gln-Lys-Ile-Gln-Leu-Val-Asn-
Thr-Y-(X)-Z
(XXb-2)

(A)-(B)-(X)-Y-Gly-His-Thr-Arg-Val-Thr-Gly-Gly-Val-Gln-
Gly-His-Val-Thr-Cys-Thr-Leu-Thr-Ser-Leu-Phe-Arg-Pro-
Gly-Ala-Ser-Gln-Lys-Ile-Gln-Leu-Val-Asn-Thr-Y-(X)-Z
(XXc)

(A)-(B)-(X)-Y-Gly-His-Thr-Arg-Val-Thr-Gly-Gly-Val-Gln-
Gly-His-Val-Thr-Cys-Thr-Leu-Thr-Ser-Leu-Phe-Arg-Y-(X)-Z
(XXc-1)

(A)-(B)-(X)-Y-Gly-His-Val-Thr-Cys-Thr-Leu-Thr-Ser-Leu-
Phe-Arg-Pro-Gly-Ala-Ser-Gln-Lys-Ile-Gln-Leu-Val-Asn-
Thr-Y-(X)-Z
(XXc-2)

(A)-(B)-(X)-Y-Gly-His-Thr-His-Val-Thr-Gly-Gly-Arg-Val-
Ala-Ser-Ser-Thr-Gln-Ser-Leu-Val-Ser-Trp-Leu-Ser-Gln-
Gly-Pro-Ser-Gln-Lys-Ile-Gln-Leu-Val-Asn-Thr-Y-(X)-Z
(XXd)

(A)-(B)-(X)-Y-Gly-His-Thr-His-Val-Thr-Gly-Gly-Arg-Val-
Ala-Ser-Ser-Thr-Gln-Ser-Leu-Val-Ser-Trp-Leu-Ser-Y-(X)-Z
(XXd-1)

(A)-(B)-(X)-Y-Ala-Ser-Ser-Thr-Gln-Ser-Leu-Val-Ser-
Trp-Leu-Ser-Gln-Gly-Pro-Ser-Gln-Lys-Ile-Gln-Leu-Val-
Asn-Thr-Y-(X)-Z
(XXd-2)

(A)-(B)-(X)-Y-Gly-Asp-Thr-His-Val-Thr-Gly-Gly-Ala-
Gln-Ala-Lys-Thr-Thr-Asn-Arg-Leu-Val-Ser-Met-Phe-Ala-
Ser-Gly-Pro-Ser-Gln-Lys-Ile-Gln-Leu-Ile-Asn-Thr-Y-
(X)-Z
(XXe)

(A)-(B)-(X)-Y-Gly-Asp-Thr-His-Val-Thr-Gly-Gly-Ala-

Gln-Ala-Lys-Thr-Thr-Asn-Arg-Leu-Val-Ser-Met-Phe-Ala
-Y-(X)-Z
(XXe-1)

(A)-(B)-(X)-Y-Ala-Lys-Thr-Thr-Asn-Arg-Leu-Val-Ser-
Met-Phe-Ala-Ser-Gly-Pro-Ser-Gln-Lys-Ile-Gln-Leu-Ile-
Asn-Thr-Y-(X)-Z
(XXe-2)

(A)-(B)-(X)-Y-Ala-Glu-Thr-Tyr-Thr-Ser-Gly-Gly-Asn-
Ala-Gly-His-Thr-Met-Thr-Gly-Ile-Val-Arg-Phe-Phe-Ala-
Pro-Gly-Pro-Lys-Gln-Asn-Val-His-Leu-Ile-Asn-Thr-Y-(X)-Z
(XXf)

(A)-(B)-(X)-Y-Ala-Glu-Thr-Tyr-Thr-Ser-Gly-Gly-Asn-Ala-
Gly-His-Thr-Met-Thr-Gly-Ile-Val-Arg-Phe-Phe-Ala-Y-(X)-Z
(XXf-1)

(A)-(B)-(X)-Y-Gly-His-Thr-Met-Thr-Gly-Ile-Val-Arg-Phe-
Phe-Ala-Pro-Gly-Pro-Lys-Gln-Asn-Val-His-Leu-Ile-Asn-
Thr-Y-(X)-Z
(XXf-2)

(A)-(B)-(X)-Y-Ala-Glu-Thr-Ile-Val-Ser-Gly-Gly-Gln-Ala-
Ala-Arg-Ala-Met-Ser-Gly-Leu-Val-Ser-Leu-Phe-Thr-Pro-
Gly-Ala-Lys-Gln-Asn-Ile-Gln-Leu-Ile-Asn-Thr-Y-(X)-Z
(XXg)

(A)-(B)-(X)-Y-Ala-Glu-Thr-Ile-Val-Ser-Gly-Gly-Gln-Ala-
Ala-Arg-Ala-Met-Ser-Gly-Leu-Val-Ser-Leu-Phe-Thr-Y-(X)-Z
(XXg-1)

(A)-(B)-(X)-Y-Ala-Arg-Ala-Met-Ser-Gly-Leu-Val-Ser-Leu-
Phe-Thr-Pro-Gly-Ala-Lys-Gln-Asn-Ile-Gln-Leu-Ile-Asn-
Thr-Y-(X)-Z
(XXg-2)

(A)-(B)-(X)-Y-Ala-Glu-Thr-Tyr-Thr-Thr-Gly-Gly-Ser-Thr-
Ala-Arg-Thr-Thr-Gln-Gly-Leu-Val-Ser-Leu-Phe-Ser-Arg-
Gly-Ala-Lys-Gln-Asp-Ile-Gln-Leu-Ile-Asn-Thr-Y-(X)-Z
(XXh)

(A)-(B)-(X)-Y-Ala-Glu-Thr-Tyr-Thr-Thr-Gly-Gly-Ser-Thr-
Ala-Arg-Thr-Thr-Gln-Gly-Leu-Val-Ser-Leu-Phe-Ser-Y-(X)-Z
(XXh-1)

(A)-(B)-(X)-Y-Ala-Arg-Thr-Thr-Gln-Gly-Leu-Val-Ser-Leu-
Phe-Ser-Arg-Gly-Ala-Lys-Gln-Asp-Ile-Gln-Leu-Ile-Asn-
Thr-Y-(X)-Z
(XXh-2)

(A)-(B)-(X)-Y-Ala-Gln-Thr-His-Thr-Val-Gly-Gly-Ser-Thr-
Ala-His-Asn-Ala-Arg-Thr-Leu-Thr-Gly-Met-Phe-Ser-Leu-
Gly-Ala-Arg-Gln-Lys-Ile-Gln-Leu-Ile-Asn-Thr-Y-(X)-Z

(XX/2)

(A)-(B)-(X)-Y-Ala-Gln-Thr-His-Thr-Val-Gly-Gly-Ser-Thr-
Ala-His-Asn-Ala-Arg-Thr-Leu-Thr-Gly-Met-Phe-Ser-Y-(X)-Z
(XX/2-1)

(A)-(B)-(X)-Y-Ala-His-Asn-Ala-Arg-Thr-Leu-Thr-Gly-Met-
Phe-Ser-Leu-Gly-Ala-Arg-Gln-Lys-Ile-Gln-Leu-Ile-Asn-
Thr-Y-(X)-Z
(XX/2-2)

(A)-(B)-(X)-Y-Val-Asn-Gln-Arg-Ala-Val-Val-Ala-Pro-Asp-
Lys-Glu-Val-Leu-Tyr-Glu-Ala-Phe-Asp-Glu-Y-(X)-Z
(VIII-2)

(A)-(B)-(X)-Y-Val-Ala-Pro-Asp-Lys-Glu-Val-Leu-Tyr-Glu-
Ala-Phe-Asp-Glu-Met-Glu-Glu-Cys-Ala-Ser-Y-(X)-Z
(IX-2)

(A)-(B)-(X)-Y-Asp-Glu-Met-Glu-Glu-Cys-Ala-Ser-Arg-Ala-
Ala-Leu-Ile-Glu-Glu-Gly-Gln-Arg-Ile-Ala-Y-(X)-Z
(X-2)

(A)-(B)-(X)-Y-Ala-Ser-Arg-Ala-Ala-Leu-Ile-Glu-Glu-Gly-
Gln-Arg-Ile-Ala-Glu-Met-Leu-Lys-Ser-Lys-Y-(X)-Z
(XI-2)

(A)-(B)-(X)-Y-Ile-Glu-Glu-Gly-Gln-Arg-Ile-Ala-Glu-Met-
Leu-Lys-Ser-Lys-Ile-Gln-Gly-Leu-Leu-Gln-Y-(X)-Z
(XII-2)

(A)-(B)-(X)-Y-Ile-Ala-Glu-Met-Leu-Lys-Ser-Lys-Ile-Gln-
Gly-Leu-Leu-Gln-Gln-Ala-Ser-Lys-Gln-Ala-Y-(X)-Z
(XIII-2)

(A)-(B)-(X)-Y-Ser-Lys-Ile-Gln-Gly-Leu-Leu-Gln-Gln-Ala-
Ser-Lys-Gln-Ala-Gln-Asp-Ile-Gln-Pro-Ala-Y-(X)-Z
(XIV-2)

(A)-(B)-(X)-Y-Arg-Ser-Asp-Leu-Glu-Pro-Ser-Ile-Pro-Ser-
Glu-Tyr-Met-Leu-Pro-Lys-Lys-Arg-Phe-Pro-(X)-Y-Z
(XV-2)

(A)-(B)-(X)-Y-Met-Leu-Pro-Lys-Lys-Arg-Phe-Pro-Pro-Ala-
Leu-Pro-Ala-Trp-Ala-Arg-Pro-Asp-Tyr-Asn-Y-(X)-Z
(XVI-2)

(A)-(B)-(X)-Y-Ala-Trp-Ala-Arg-Pro-Asp-Tyr-Asn-Pro-Pro-
Leu-Val-Glu-Ser-Trp-Lys-Arg-Pro-Asp-Tyr-Y-(X)-Z
(XVII-2)

(A)-(B)-(X)-Y-Glu-Ser-Trp-Lys-Arg-Pro-Asp-Tyr-Gln-Pro-
Ala-Thr-Val-Ala-Gly-Cys-Ala-Leu-Pro-Pro-Y-(X)-Z
(XVIII-2)

(A)-(B)-(X)-Y-Val-Ala-Gly-Cys-Ala-Leu-Pro-Pro-Pro-Lys-
Lys-Thr-Pro-Thr-Pro-Pro-Pro-Arg-Arg-Arg-Y-(X)-Z
(XIX-2)

or hybrid HCV peptide sequences consisting of combinations of the core epitopes of the HCV core (table 9) HCV NS4 (table 10) or the HCV NS5 (table 11) region separated by Gly and/or Ser residues, and preferentially the following hybrid HCV sequences:

(A)-(B)-(X)-Y-Ile-Pro-Asp-Arg-Glu-Val-Leu-Tyr-Arg-Gly-Gly-
Lys-Lys-Pro-Asp-Tyr-Glu-Pro-Pro-Val-Gly-Gly-Arg-Arg-Pro-
Gln-Asp-Val-Lys-Phe-Pro-Y-(X)-Z
(Epi-152)

(A)-(B)-(X)-Y-Trp-Ala-Arg-Pro-Asp-Tyr-Asn-Pro-Pro-Gly-Gly-
Gln-Phe-Lys-Gln-Lys-Ala-Leu-Gly-Leu-Gly-Ser-Gly-Val-Tyr-
Leu-Leu-Pro-Arg-Arg-Gly-Y-(X)-Z
(Epi-33B3A)

(A)-(B)-(X)-Y-Arg-Gly-Arg-Arg-Gln-Pro-Ile-Pro-Lys-Gly-Gly-
Ser-Gln-His-Leu-Pro-Tyr-Ile-Glu-Gln-Ser-Gly-Pro-Val-Val-
His-Gly-Cys-Pro-Leu-Pro-Y-(X)-Z
(Epi-4B2A6);

wherein A, B, X, Y and Z are defined in Claim 3,

or biotinylated synthetic sequences consisting of peptides containing at each position all the amino acids found in the naturally occurring isolates, with said peptides being derived from any of the above-mentioned immunologically important regions (see Figure 14).

5. Peptide composition according to claim 4 consisting of a combination of biotinylated peptides selected from:

- A. II, III, IVa, Va, IX, XI, XIII, XV, XVI, XVIII, 1a.3, 1a.4, 1a.b, 1b.1a, 2b, 2d,
- B. II, III, IVa, Va, IX, IX-2, XI, XI-2, XIII, XIII-2, XV, XV-2, XVI, XVI-2, XVIII, XVIII-2, 1a.3, 1a.4, 1a.b, 1b.1a, 2b, 2d.

6. Peptide composition according to claim 4 consisting of a combination of biotinylated peptides comprising:

1a.3, 1a.4, 1b.1, 2b, 2c, 2d, I-gp46-3, I-gp46-4, I-gp46-5,
I-gp46-6, II-gp52-2, II-gp52-3, I-p21-2, I-p19, II-p19.

7. Peptide composition according to claim 4 consisting of a combination of biotinylated peptides comprising:

1a.3, 1a.4, 1a.6, 1b.1a, 2d, II, III, IVa, Va, IX, XI, XIII, XV, XVI, XVIII, XXa-2, XXc-2, XXg-2, XXh-2, I-gp46-3,

I-gp46-4, I-gp46-5, I-gp46-6, II-gp52-3, I-p21-2, I-p19, II-p19.

8. Peptide composition according to claim 4 for detecting or immunizing against HCV, comprising a peptide having an amino acid sequence selected from the group of :

- A. I, III, IVa, Va,
- B. II, III, IVa, Va,
- C. IX, XI, XIII,
- D. XV, XVI, XVIII, XIX,
- E. XXc-2, XXa-1, XXa-2, XXh-1, XXh-2, XXg-2, XX/2-2,
- F. IX-2, XI-2, XIII-2,
- G. XV-2, XVI-2, XVIII-2, XIX-2,
- H. IX, IX-2, XI, XI-2, XIII, XIII-2,
- I. XV, XV-2, XVI, XVI-2, XVIII, XVIII-2, XIX, XIX-2,
- J. II, III, IVa, Va, IX, IX-2, XI, XI-2, XIII, XIII-2, XV, XV-2, XVI, XVI-2, XVIII, XVIII-2,
- K. II, III, IVa, Va, IX, XI, XIII, XV, XVI, XVIII,
- L. II, III, IV, V, IX, XI, XIII, XV, XVI, XVIII,
- M. II, III, IVa, Va, IX, XI, XIII, XV, XVI, XVIII, XXa-2, XXc-2, XXg-2, XXh-2.
- N. Epi-152, Epi-33B3A, Epi-4B2A6

9. Peptide composition according to claim 4 for detecting or immunizing against HIV, comprising a peptide having an amino acid sequence selected from the group of :

for type 1:

- A. 1a.3, 1a.4, 1a.5, 1a.b
- B. 1a.3, 1a.4, 1b.1, 1b.3, 1b.6, 1b.10,
- C. 1b.1, 1b.2, 1b.3, 1b.4, 1b.5, 1b.6, 1b.7, 1b.8, 1b.9, 1b.10
- D. 1b.1, 1b.2, 1b.3, 1b.4, 1b.6, 1b.10,
- E. 1a.3, 1a.4, 1a.5, 1a.b, 1b.1a.

for type 2:

- A. 2b, 2c, 2d, 2e.

for types 1 and 2:

- A. 1a.3, 1a.4, 1b.1, 2b, 2c, 2d,
- B. 1a.3, 1a.4, 1b.1a, 2b, 2d.

10. Peptide composition according to claim 4 for detecting or immunizing against HTLV, comprising a peptide having an amino acid sequence selected from the group of:

for Human T-Lymphotropic virus I:

Peptides I-gp46-3, I-gp46-4, I-gp46-5, I-gp46-6, I-p21-2, I-p19

for Human T-Lymphotropic virus type II:

peptides II-gp52-1, II-gp52-2, II-gp52-3, I-gp46-4, II-p19, I-p21-2.

for Human lymphotropic virus types I and II:

Peptides I-gp46-3, I-gp46-4, I-gp46-5, I-gp46-6, II-gp52-1, II-gp52-2, II-gp52-3, I-p21-2, I-p19, II-p19.

11. Process for the in vitro determination of antibodies to HCV, and/or HIV, and/or HTLV I or II by using a peptide composition according to any of claims 4 to 10 in an immunoassay procedure, wherein the biotinylated peptides used are in the form of complexes of streptavidin-biotinylated or of avidin-biotinylated peptides.


12. Process for the in vitro determination of antibodies to HIV or diagnosis of HIV infection by using a peptide composition according to claims 4, 5, 6, 7 or 9 in an immunoassay procedure, wherein the biotinylated peptides used are in the form of complexes of streptavidin-biotinylated or of avidin-biotinylated peptides.

13. Process for the in vitro determination of antibodies to HCV or diagnosis of HCV infection by using a peptide composition according to claims 4, 5, 6, 7 or 8 in an immunoassay procedure, wherein the biotinylated peptides used are in the form of complexes of streptavidin-biotinylated or of avidin-biotinylated peptides.

14. Process for the in vitro determination of antibodies to HTLV I or II or diagnosis of HTLV I or II infection by using a peptide composition according to claims 4, 5, 6, 7 or 10 in an immunoassay procedure, wherein the biotinylated peptides used are in the form of complexes of streptavidin-biotinylated or of avidin-biotinylated peptides.

15. Use of a peptide composition according to any of claims 4 to 10, for immunisation against HIV, and/or HCV, and/or HTLV I or II infection.

16. Process for obtaining biotinylated peptides according to any of claims 4 to 10 in which N- α -Fmoc-X (N-y-biotin) or N- α -Fmoc-X (N-y-biotin) derivative is used as intermediary product, wherein X represents




where n is at least 1 but less than 10 and is preferably between 3 and 6, one amino group being attached to the C α atom while the other being attached to carbon C γ , which is the most distal carbon in the side chain; or their esters obtained with alcohol ROH and more particularly the pentafluorophenyl ester;

- y representing position y with respect to the carbon atom carrying the COOH group in the radical.


17. Process according to claim 16, wherein N- α -Fmoc-x (N-y-biotin) is N- α -Fmoc-Lys (N- ϵ -biotin) or N- α -Fmoc-ornithinyl (N- ϵ -biotin).

18. Process for preparing a carboxy terminal biotinylated peptide, comprising the following steps:


- coupling of a carboxy-activated form of the intermediary product as defined above to a cleavable linker attached to the resin, for instance to obtain the following compound:




- deprotection of the α amino group of the intermediary compound, for instance by means of piperidine to obtain:



- successive addition of the subsequent amino acids AA₁.... AA_n duly protected onto



to obtain:




- deprotection of the NH₂-terminal for instance by means of piperidine,

- deprotection of the compound obtained, cleavage from the resin, extraction and purification of the peptide obtained, biotinylated at its carboxy terminal end, the steps of side chain deprotection and cleavage being liable to be performed simultaneously or separately, and particularly deprotection of the NH₂-terminal, for instance by means of piperidine,


- cleavage from the resin for instance with trifluoroacetic acid, in the presence of scavengers such as ethanedithiol, or thioanisole, or anisole, - extraction of the peptide with a solvent such as diethylether to remove most of the acid and scavengers,

- purification, such as with HPLC to obtain:



19. Process for preparing a N-terminal biotinylated peptide, comprising the following steps:

- addition of the subsequent amino acids duly protected onto the resin to give:




- deprotection of the NH_2 -terminal for instance by means of piperidine,

- addition of the intermediary product:



through its COOH onto the NH_2 -terminal to obtain:




- deprotection of the NH_2 terminal group of the compound obtained, cleavage from the resin, extraction and purification of the peptide obtained, biotinylated at its amino terminal, the steps of side chain deprotection and cleavage being liable to be performed simultaneously or separately, and particularly deprotection of the NH -terminal group of the intermediary group, for instance by means of piperidine,

- cleavage from the resin for instance with an acid such as trifluoroacetic acid, in the presence of scavengers such as ethanedithiol, thioanisole, or anisole,


- extraction of the peptide with a solvent such as diethylether to remove most the acid and scavengers,

- purification, such as with HPLC to obtain:



20. Process for preparing an internally biotinylated peptide, comprising the following steps:


- addition of successive amino acids duly protected onto the resin to give: Fmoc - AA_n AA₁ - resin,
- deprotection of the NH₂-terminal,
- addition of the intermediary product:




through its COOH onto the NH₂-terminal to obtain:



- deprotection of the α amino group of the intermediary compound, for instance by means of piperidine to obtain:



- addition of the subsequent amino acids duly protected onto the resin to give:




- deprotection of the NH₂ terminal group of the compound obtained, cleavage from the resin, extraction and purification of the peptide obtained, biotinylated at its amino-terminal, the steps of side chain deprotection and cleavage being liable to be performed simultaneously or separately, and particularly, deprotection of the NH₂ terminal group of the peptide, for instance by means of piperidine


- cleavage from the resin for instance with trifluoroacetic acid, in the presence of scavengers such as ethanedithiol, or thioanisole, or anisole,

- extraction of the peptide with a solvent such as diethylether to remove most of the acid and scavengers,

- purification, such as with HPLC to obtain:




- 21. Compound of formula:



or N- α -Fmoc-X (N-y-biotin),

wherein X represents NH - C α H - COOH



where n is at least 1 but less than 10 and is preferably between 3 and 6, one amino group being attached to the C α atom while the other being attached to carbon C γ , which is the most distal carbon in the side chain; or their esters obtained with alcohol ROH and particularly the pentafluorophenyl ester;

- y representing position y with respect to the carbon atom carrying the COOH group in the radical.

22. Process for preparing the compound according to claim 21, comprising the following steps:

- reaction of a diamino-, monocarboxylic acid previously described with fluorenylmethylsuccinimidylcarbonate or fluorenylmethyl chloroformate under conditions of carefully controlled pH to give the singly protected N- α -Fmoc derivative,

- or alternatively, use of commercially available N- α -Fmoc-protected diamino-monocarboxylic acids when the side chain amino group is provided with a protecting group which is different from the Fmoc group used to protect the α -amino group, the side chain amino group protection being liable to be selectively removed under conditions which leave the N- α -Fmoc group intact,

- purification of the mono-protected N- α -Fmoc-diamino-monocarboxylic acid derivative by selective extractions and chromatography,



- reaction of the derivative obtained with a carboxy-activated derivative of biotin, such as N-hydroxysuccinimide biotin, to obtain the (N- α -Fmoc)-(N-y-biotin) derivative which is the desired intermediary product,

- purification of the intermediary product by selective extractions, precipitations, or chromatography.

1/28

Figure 1


Method A



2/28

Figure 1 Continued


Method B




3/28

Figure 2

Method A.







Method B.







4/28

Figure 3a







5/28

Figure 3b




6/28

Figure 3c




7/28

Figure 4



8/28


Figure 5



N-terminally biotinylated TM peptide

C-terminally biotinylated TM peptide

9 / 28



— Figure 6a
HCV CORE PEPTIDES (1-13)

10/28





Figure 6a (continued)
HCV CORE PEPTIDES (1-13)

11/28




Figure 6b
HCV NS4 PEPTIDES (1-9)

12/28







Figure 6b (continued)
HCV NS4 PEPTIDES (1-9)

13/28

Figure 6c



14/28



HCV NS5 PEPTIDES (13-33)

Figure 6c (continued)

Figure 7a




Figure 7b






Figure 7c



18/28



- a: High intensity control
b: Low intensity control
c: Medium intensity control
d: Peptide XXg-1, unbiotinylated
e: Peptide XXg-2, unbiotinylated
f: Biotinylated peptide XXg-1: streptavidin complex
g: Biotinylated peptide XXg-2: streptavidin complex

Figure 8

19/28




Figure 9

20/28




Figure 10

21/28

Peptide	Sequence
HS4-n	G A I V A I K I M S G E V P S T E D I V
HS4-b	V P S I F D L V N I I P A I L S P G A L
HS4-c	A I L S P G A I V Y G V V C A A I I R R
HS4-d	V C A A I I R R H V G P G E G A V O W M
HS4-e	G E G A V O W M N R L I A F A S R G N I I

Figure 11

22/28

Peptide	Amino Acid Sequence									
Epi-152	Bio- G G - I P D R E V L Y R G G K K P D Y E P P V G G R R P O D V K F P	NS4 epitope 1				NS5 epitope 5			Core epitope 2	
Epi-33B3A	Bio- G G - W A R P D Y N P P G G O F K O K A L G L G S G V Y L L P R R G	NS5 epitope 3				NS4 epitope 3B			Core epitope 3A	
Epi-4B2A6	Bio- G G - R G R R O P I P K G G S Q H L P Y I E O S G P V V H G C P L P	Core epitope 4B				NS4 epitope 2A			NS5 epitope 6	

Figure 12

23/28




Figure 13

24/28

A.

AMINO ACID SUBSTITUTIONS AT EACH POSITION																							
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
	V				M																		
	G				A																		
	D				N																		
	R				R																		
	K				H																		
	F				S																		
	S				V																		
	H				T																		
	T				T																		
	S				N																		
	N				A																		
	A				I																		
	R				G																		
	A				M																		
	M				S																		
	I				G																		
	S				L																		
	G				V																		
	L				S																		
	I				F																		
	F				I																		
	P				I																		
	I				T																		
	P				G																		
	A				K																		
	I				Q																		
	N				I																		
	I				Q																		
	L				I																		
	I				N																		
	T				T																		

B.

2																							
4																							
16																							
64																							
192																							
768																							
4608																							
9216																							
46080																							
138240																							
414720																							
1658880																							
6635520																							
59719680																							
238878720																							
1911029760																							
1.1466179 E 10																							
No. of Variants																							

C.

6																							
48																							
192																							
1728																							
6912																							
27648																							
82944																							
248832																							
1244160																							
2488320																							
14929920																							
59719680																							
179159040																							
716636160																							
2866544640																							
5733089280																							
1.1466179 E 10																							
No. of Variants																							


D.

27648																							
13824																							
5184																							
6480																							
1440																							
2160																							
2160																							
720																							
720																							
576																							
288																							
192																							
96																							
96																							
32																							
16																							
16																							
4																							
No. of Variants																							


Figure 14

Figure 15



Mixotope Synthesis Strategy.




Cleavage and side-chain deprotection



Oxidation and dimerization




Fmoc-Ala
tBoc-Ala




Fmoc-Cys(Trt)



Fmoc-Lys(Fmoc)



Fmoc-Lys(Fmoc)



Synthesis of peptide sequence




Figure 16

27/28





Figure 17

Rabbit	Antigen
325	xxb-2 - MAP
326	
327	xxg-2 MAP
328	

FIGURE 18

Fig 18



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁵ : G01N 33/68, 33/569, 33/576 // C07K 1/00, 15/00</p>	<p>A3</p>	<p>(11) International Publication Number: WO 93/18054 (43) International Publication Date: 16 September 1993 (16.09.93)</p>
<p>(21) International Application Number: PCT/EP93/00517 (22) International Filing Date: 8 March 1993 (08.03.93) (30) Priority data: 92400598.6 6 March 1992 (06.03.92) EP (34) Countries for which the regional or international application was filed: GB et al. (71) Applicant (for all designated States except US): N.V. IN-NOGENETICS S.A. [BE/BE]; Industriepark Zwijnaarde 7, Box 4, B-9052 Ghent (BE). (72) Inventor; and (75) Inventor/Applicant (for US only): DE LEYS, Robert [US/BE]; Diepekanten 20, B-1850 Grimbergen (BE).</p>		<p>(74) Agents: GUTMANN, Ernest et al.; Ernest Gutmann-Yves Plasseraud S.A., 67, boulevard Haussmann, F-75008 Paris (FR). (81) Designated States: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, NZ, PL, PT, RO, RU, SD, SK, UA, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 17 February 1994 (17.02.94)</p>
<p>(54) Title: PROCESS FOR THE DETERMINATION OF PEPTIDES CORRESPONDING TO IMMUNOLOGICALLY IMPORTANT EPITOPES AND BIOTINYLATED PEPTIDES USED THEREIN</p> <p>(57) Abstract</p> <p>The technical problem underlying the present invention is to provide peptides corresponding to immunologically important epitopes on bacterial and viral proteins, as well as the use of said peptides in diagnostic or immunogenic compositions. The invention relates to a process for the <i>in vitro</i> determination of antibodies, wherein the peptides used are biotinylated, particularly in the form of complexes of streptavidin-biotinylated peptides or of avidin-biotinylated peptides.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TG	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 93/00517

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.Cl.5 C 07 K 1/00	G 01 N 33/68 C 07 K 15/00	G 01 N 33/569 G 01 N 33/576 //
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.Cl.5	G 01 N C 07 K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	BIOLOGICAL CHEMISTRY HOPPE-SEYLER vol. 372, no. 3, 1991, BERLIN DE pages 163 - 172 R.VON GRUENIGEN ET AL. 'Enzyme immunoassay with captured hapten. A sensitive gastrin assay with biotinylgastrin derivatives' see the whole document ---	1-3
Y	WO,A,8403506 (COMMONWEALTH SERUM LABORATORIES COMMISSION) 13 September 1984 see the whole document ---	1,2
Y	DATABASE WPI Week 9146, Derwent Publications Ltd., London, GB; AN 91-337496 & SU,A,1 612 264 (BIOORG CHEM INST) 7 December 1990 cited in the application see abstract --- -/-	1,2
<p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
03-09-1993	14. 11. 94	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	A. DE KOK	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category °	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
X	---	3,4,9, 11,13, 15,16
A	JOURNAL OF IMMUNOLOGICAL METHODS vol. 125, 1989, NEW YORK US pages 143 - 146 R.VON GRUNIGEN ET AL. 'Epitope analysis: biotinylated short peptides as inhibitors of anti-peptide antibody' see the whole document ---	1,3
A	JOURNAL OF IMMUNOLOGICAL METHODS vol. 135, 1990, NEW YORK US pages 199 - 208 K.R.ANUMULA ET AL. 'Immunologic methods for quantitative estimation of small peptides and their application to bradykinin' see the whole document ---	1,3
A	CLINICAL CHEMISTRY. vol. 37, no. 6, June 1991, WINSTON US pages 1024 - 1025 D.E.POLLET ET AL. 'Development of a screening ELISA and a confirmatory assay for hepatitis c antibodies based on synthetic peptides' abstract nr. 0547 * ---	3,5,8, 11,13
X	EP,A,0379949 (BOEHRINGER MANNHEIM GMBH) 1 August 1990 cited in the application see the whole document ---	3,4,9, 11,12, 16-21
A	EP,A,0468527 (UNITED BIOMEDICAL, INC.) 29 January 1992 cited in the application see the whole document ---	1-4,8, 11,13, 15
A	US,A,4833071 (C.Y.WANG ET AL.) 23 May 1989 cited in the application see the whole document ---	1-4,10, 14
A	EP,A,0442394 (UNITED BIOMEDICAL, INC.) 21 August 1991 cited in the application see page 7, line 55 - page 23, line 56 ---	1-4,8, 11,13, 15,16
A	EP,A,0388232 (CHIRON CORPORATION)-19 September 1990 see page 4, line 56 - page 5, line 56 see page 14, line 19 - page 16, line 35 ---	1,3,4,8, 11,13, 15,16
A	EP,A,0448095 (H.J.WOLF) 25 September 1991 cited in the application see the whole document --- -/-	3,4,9, 11,12

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	EP,A,0438332 (CLONATEC) 24 July 1991 cited in the application see the whole document ---	3,4,9, 11,12
A	EP,A,0461462 (ABBOTT LABORATORIES) 18 December 1991 see the whole document ---	3,4-9, 11-13
P,X	EP,A,0489968 (INNOGENETICS N.V.) 17 June 1992 cited in the application see the whole document ---	3,4,8, 11,13, 15,16
P,X	EP,A,0484787 (BEHRINGWERKE) 13 May 1992 cited in the application see page 3, line 43 - page 10, line 17 -----	3-9,11- 13,15

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 93/00517

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. Claims: 1-21
2. Claim : 22

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-21

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

EP 9300517
SA 72160

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 28/12/93. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A- 8403506	13-09-84	AU-B- 573574	16-06-88
		AU-A- 2542884	20-09-84
		CA-A- 1247080	20-12-88
		EP-A- 0138854	02-05-85
		JP-T- 60500673	09-05-85
		US-A- 4708871	24-11-87
EP-A- 0379949	01-08-90	DE-A- 3901857	26-07-90
		JP-A- 2233697	17-09-90
		US-A- 5001049	19-03-91
EP-A- 0468527	29-01-92	US-A- 5106726	21-04-92
		AU-B- 635124	11-03-93
		AU-A- 7439991	17-10-91
		EP-A- 0442394	21-08-91
		JP-A- 5148298	15-06-93
		JP-A- 5222094	31-08-93
US-A- 4833071	23-05-89	JP-A- 63301896	08-12-88
EP-A- 0442394	21-08-91	US-A- 5106726	21-04-92
		JP-A- 5148298	15-06-93
		AU-B- 635124	11-03-93
		AU-A- 7439991	17-10-91
		EP-A- 0468527	29-01-92
		JP-A- 5222094	31-08-93
EP-A- 0388232	19-09-90	AU-B- 640920	09-09-93
		AU-A- 5278390	22-10-90
		CA-A- 2012482	17-09-90
		JP-T- 4504715	20-08-92
		WO-A- 9011089	04-10-90
EP-A- 0448095	25-09-91	None	
EP-A- 0438332	24-07-91	FR-A- 2657016	19-07-91
		FR-A- 2657017	19-07-91
		JP-A- 4210999	03-08-92

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO.

EP 9300517

SA 72160

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 28/12/93.
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0461462	18-12-91	US-A- 5120662	09-06-92
		AU-A- 7816591	10-10-91
		CA-A- 2043689	05-12-91
		JP-A- 4232465	20-08-92
EP-A- 0489968	17-06-92	AU-A- 9068991	08-07-92
		WO-A- 9210514	25-06-92
		JP-T- 5503722	17-06-93
EP-A- 0484787	13-05-92	DE-A- 4034982	07-05-92
		DE-A- 4112743	22-10-92
		DE-A- 4120281	24-12-92
		DE-A- 4121431	07-01-93
		AU-A- 8700291	07-05-92
		CA-A- 2054798	04-05-92
		JP-A- 4330098	18-11-92